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Abstract
We have established a murine model of pneumococcal pneumonia In
order to characterise the host inflammatory response.
Intranasal infection with Streptococcus pneumoniae resulted in constant
bacterial loads within airways of susceptible mouse strains whilst the
pathogen burden increased in both the lung tissues and bloodstream. The
bacteria induced inflammation that was evident as perivascular cell
recruitment in histological sections. Mast cell granule staining indicated
that this population degranulated early in the inflammatory response,
releasing TNFa into the lung environment. Levels of TNFa and IL-I~
increased during mid infection with release of IL-6 and the anti-
inflammatory cytokine IL-IO not occurring until late infection. Kinetics of
IL-IOwere too slow to prevent inflammation causing damage to the host
tissues. The total protein levels in bronchoalveolar lavage fluid (a
marker of the integrity of the alveolar/capillary barrier) increased
significantly during the experiment.
Dose response results indicate that there is likely to be a threshold
number of bacteria required to induce this inflammatory response both in
the lungs and bloodstream.
Inoculation of bacteria into a mouse strain resistant to the above infection
resulted in bacterial clearance from both the pulmonary airways and
tissues, with few mice becoming bacteraemic. The location and timing of
the inflammatory response in this mouse strain was significantly
different. Inflammatory cell influx occurred mainly within the airways,
with perivascular areas unaffected. Mast cell degranulation occurred
rapidly following infection. TNF activity and IL-I~ levels within lung
airways were induced earlier and to a greater extent than in susceptible
mice. In contrast, the levels of TNF activity and IL-6 within lung tissues
were lower in resistant mice. Although damage to lung integrity still
occurred, this was only transient and evident during early/mid infection.
Higher endogenous IL-IO levels were implicated in the ability of resistant
mice to regulate the pulmonary inflammatory response before it could
become detrimental. Lymphocytes, previously not thought to playa role
in pneumococcal pneumonia, may be the source of regulatory IL-IO.
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Investigation of core body temperature and activity via a telemetry system
revealed that peak levels of inflammation in both resistant or susceptible
mouse strains were rapidly followed by mice becoming hypothermic.
Pneumococci were capable of entering the bloodstream of aged mice
significantly earlier than aged mice following intranasal infection. In
addition, aged mice were found to display an elevated pro-inflammatory
response to the infection. TNF activities within the airways and lung
tissues were higher in aged mice than in young animals. NO levels were
also found to increase significantly during the infection in samples from
aged mice but not from young mice.
Modulation of the host response indicated that surfactant, TNFa and NO
were all important mediators of the pulmonary host response during
pneumococcal pneumonia. Co-administration of the infectious dose in
artificial surfactant significantly reduced the pulmonary bacterial load but
did not alter overall survival.
Systemic and locally released TNFa were also implicated in the control of
pathogen burden within the lungs and in the bloodstream. Treatment of
mice with anti- TNFa antibodies significantly increased the bacterial
counts recovered in lung and blood samples. Signalling via the TNFa
p55 receptor was more important than via the p75 receptor in this respect.
Mice deficient in the iNOS enzyme were less able to control pneumococci
within the lungs following intranasal infection than wild type animals,
indicating that NO was beneficial during S. pneumoniae pulmonary
infection. Utilisation of the intravenous infection route revealed that NO
was detrimental during Gram-positive bacteraemia.
Taken together these results indicate the requirement for a rapid
inflammatory response following infection with pneumococci, but also
for tight regulation of the response in order to prevent pathology and
death.
iii
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Chapter 1
General Introduction
Chapter 1 Introduction
1.1 Streptococcus pneumoniae
Streptococcus pneumoniae (the pneumococcus) was simultaneously
identified by Pasteur and by Sternberg in 1881 (Pasteur 1881) & (Sternberg
1881). Pasteur discovered the organism in saliva from a child who had died
of rabies, while Sternberg found pneumococci in his own saliva. Each
injected saliva into rabbits and both subsequently recovered diplococci from
the blood of these animals. Two years later these bacteria were implicated in
disease when Frielander noted the association of the organism with lobar
pneumonia (Frielander 1883).
Formerly called Diplococcus pneumoniae, S. pneumoniae is a Gram-positive
encapsulated bacterium. Pneumococci are lancet shaped cocci, 0.5-1.25JlM in
diameter (McKinsey and Bisno 1980), generally present in pairs (or short
chains). The bacteria form alpha haemolytic colonies when cultured on
blood agar base with their sensitivity to the antibiotic optochin (ethyl
hydrocuprein) readily distinguishing them from other alpha-haemolytic
streptococci.
The pneumococcus is now recognised as a major human pathogen in
infancy, childhood and adult life. S. pneumoniae is capable of causing both
non-invasive disease such otitis media, as well as invasive infections such as
pneumonia, meningitis and sepsis.
1.2 Structure
The pneumococcal outer surface is comprised of 3 main parts: the capsule,
cell wall and the plasma membrane (Figure 1.1).
1.2.1Capsule
Although S. pneumoniae exists in both encapsulated and unencapsulated
forms the great majority of clinical isolates and strains of S. pneumoniae
recovered from carriage sites possess a polysaccharide capsule (Kalin 1998), of
which there are currently 90 known types (Henrichsen 1995). The majority,
if not all, of these capsular serotypes are capable of causing serious illness in
humans (Kalin 1998). There have been few reports of atypical
unencapsulated pneumococci being carried or causing infection in humans
1
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Figure 1.1 Surface of S. p n eu mo n iae in different body sites. Pneumococci vary
between a transparent phenotype (A) adapted to the nasopharynx and an
opaque phenotype (B) adapted to the bloodstream. This phase variation is
reversible and involves changes in the amount of choline in the cell wall and
the amount of several important surface proteins. These include the
protective antigen PspA, the adhesin CbpA, and the autolysin, LytA. Dark
circles represent choline. Adapted from (Tuomanen 1999)
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(Muller-Graft et al. 1999). These strains are mainly isolated from
immunocompromised individuals such as HIV-seropositive patients. Thus
the majority of unencapsulated pneumococci are only found in the
laboratory.
Capsular types were originally differentiated by the use of type specific
antiserum, the Quellung reaction. The addition of specific antiserum causes
both macroscopic agglutination and microscopically visible swelling of the
capsule (Neufeld 1902). However, when the test involves pneumococci with
small capsules the reaction can be difficult to interpret and the results
dubious. More recent methods employ fluorescent antibodies directed
against the capsule (Wicher et al. 1982).
Capsular type is classifiedby one of two classification systems: the American
assigns numbers in the chronological order of their discovery whereas the
Danish system is based on antigenic similarities. Virulent strains that cause
most outbreaks of disease were the first to be identified and thus were the
first assigned numbers by the American classification system. Accordingly,
the lower numbered serotypes are commonly isolated in human infections.
The lowest numbered serotypes such as 1 and 2 are classified identically by
both the American and Danish systems. Higher numbered serotypes in the
American system that share antigenic similarities with lower numbered
types are grouped together by the Danish system. Thus American type 48
becomes Danish 7B(as it is similar to Danish type 7A, American type 7) with
serotype 50 becoming 7C (Lee 1987). It is the Danish nomenclature for
serotypes that is now generally employed (vanDam et al. 1990).
1.2.2Capsular type 2 pneumococci
At the beginning of this century type 2 pneumococci (e.g. D39) were
associated with a high proportion of cases of both pneumonia and
bacteraemia (Austrian 1981)& (Findland and Barnes 1977). In subsequent
years, recovery of type 2 pneumococci as clinical isolates has declined to the
extent that it is almost never detected in industrialised nations (Kalin 1998).
These pneumococci do remain a problem in non-industrialised countries, in
Nigeria and Senegal they are commonly isolated (Greenwood et al. 1980). In
Papua New Guinea (an area known to have high rates of pneumococcal
2
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disease) type 2 pneumococci do not frequently colonise, but when they do
they are highly likely to cause invasive disease.
Furthermore, type 2 pneumococci are one of the serotypes most likely to
cause epidemic pneumonia or bacteraemia (Austrian 1981). Cases of
epidemic pneumonia have recently increased in the western world in a
range of settings including military camps (Musher et al. 1997), nursing
homes (Musher 1998), jails (Hoge et al. 1994) and child-care centres (Cheri an
et al. 1994). Additionally S. pneumoniae has become one of the most
common causes of bacteraemia. The pneumococcus was the third most
frequently isolated micro-organism (after Escherichia coli and Staphylococcus
aureus) from patients with severe sepsis or septic shock in a recent world-
wide study (Cohen and Abraham 1999).
The historical importance of type 2 pneumococci has led to D39 becoming a
well characterised experimental strain. Thus a wealth of genetic information
is available concerning this isolate. In addition, D39 is virulent in mice and
has frequently been employed in animal models (Canvin et al. 1995), (Rub ins
et al. 1995) & (Kadioglu et al. 2000), making it an ideal candidate for use in the
establishment and characterisation of this model of pneumococcal
pneumonIa.
1.2.3 Cell wall
The typical Gram-positive cell wall is composed mainly of peptidoglycan
(PG): glycan chains of alternating N-acetlyglucosamine and N-
acetylymuramic acid. Acidic polysaccharides termed teichoic acids are
attached to the cell wall (Figure 1.1).
The cell wall polysaccharide, a complex teichoic acid containing
phosphorylcholine residues common to all pneumococcal serotypes, is also
attached to PG (jennings et al. 1980). The phosphorylcholine residues of cell
wall polysaccharide are a recognition site for N-acetlymuramic acid-L-alanine
amidase (autolysin), an enzyme that cleaves the bond between the glycan
chain and the peptide side chain of the cell wall leading to cellular autolysis
(Paton et al. 1993), releasing cytoplasmic contents such as pneumolysin
(Section 1.3.2).
The cell wall is believed to play a significant role in instigating the
inflammatory response that occurs during pneumococcal pneumonia. The
3
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minimum cell wall component capable of initiating an inflammatory
response has now been identified as teichoic acid attached to the glycan
backbone and some small-stem peptides (Tuomanen et al. 1987).
Bybinding to pulmonary epithelia and causing separation of tight junctions,
cell wall components are likely to increase the permeability of alveolar
epithelia (Tuomanen et al. 1987). This in turn permits influx of
inflammatory cells that may be recruited via the ability of cell wall teichoic
acids to activate the alternative complement pathway (Section 1.5.3.4)
(Winkelstein and Tomasz 1978). Pro-inflammatory cytokine production
(such as TNFa. and IL-1) is also implicated in this cell recruitment. A
separate pro-inflammatory mediator released by incubation with cell wall
preparations is nitric oxide (NO) (Orman et al. 1998). As mentioned in
Section 1.5.3.5, NO is also implicated in upregulation of the inflammatory
response and is capable of causing direct damage to the lungs.
1.2.4 Plasma Membrane
The plasma membrane surrounds the cytoplasm and is composed mainly of
lipid with lipoteichoic acid and protein also present (Brock and Madigan
1991). This permeable layer is responsible for maintaining the integrity of
cytoplasmic contents.
This is also the location of the Forssman antigen (Tomasz 1981), a
lipoteichoic acid found in all pneumococci that functions as a highly specific
inhibitor of autolysin. Release of the Forssman antigen during the stationary
phase of growth leads to cell separation/ cell lysis (AlonsoDeVelasco et al.
1995).
1.2.5 Pneumococcal phase variation
Three interchangeable pneumococcal variants have been recorded: opaque,
semitransparant, and transparent (Weser et al. 1994) (see Figure 1.1 for a
diagram of transparent and opaque phenotypes). These phenotypes vary in
their suitability to different body compartments, determined by variations in
the amount of capsule expressed as well as an array of surface proteins
expressed in the cell wall (Figure 1.1). Transparent phenotypes are adapted
for survival in the nasopharynx since they are capable of adhering to the
4
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platelet activated factor receptor on epithelial cells that is upregulated during
infection (Section 1.4.2). In contrast opaque variants are unable to adhere to
this receptor but the up regulation of PspA (Section 1.3.5) and
downregulation of choline (reducing the capacity for C-reactive protein to
opsonise [Chapter 6] adapts them for survival within the bloodstream.
1.3 Virulence Factors
Pneumococci produce several factors that may be involved in the
pathogenesis of disease. These include structural components, surface
proteins and toxins (Figure 1.2). Publication of the complete DNA sequence
of S. pneumoniae by the Institute for Genomic Research in November 1997
(http://www.tigr.org/tdb) will aid the identification of novel virulence
factors by allowing comparison of sequences of known virulence factors from
other organisms with the S. pneumoniae sequence.
Virulence of pneumococci is lost with repeated passage in vitro requiring
periodic passage of the bacteria through mice for in vivo studies (Johnston
1991). This might reflect alterations in some of these virulence factors.
1.3.1 Capsule as a virulence factor
One of the oldest recognised virulence factors is the polysaccharide capsule.
Proof of the importance of the capsule to virulence was established in the
1930s. Dubos and Avery found that an enzyme obtained from a soil bacillus
could remove the serotype 3 capsular polysaccharide (Avery and Dubos 1931).
Infection of mice with bacteria treated in this way resulted in 100% survival
whilst challenge with untreated bacteria caused a fatal infection.
The role of the capsule in virulence stems from its anti-phagocytic activity
(Jonsson et al. 1985). In the nonimmune host, antibody to cell wall
constituents (ubiquitous in adults) becomes attached to the surface of the
organisms and in turn binds complement. The presence of the capsule
prevents complement factor C3b and the Fc of immunoglobulins on the
bacterial cell surface from interacting with receptors on phagocytic cells and
the organisms remain extracellular (Musher 1992). The role of the capsule in
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Figure 1.2 Schematic diagram of the main virulence factors of S. pneumoniae
including their main functions and cellular location. PMN =
polymorphonuclear leukocyte. See text for a more detailed description.
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virulence is determined not only by its size but also by its chemical
composition. Pneumococcal types 3 and 37 have similar sized capsules
although the former type is highly invasive in animal models whereas the
later is relatively avirulent (Lee et al. 1991).
Pneumococci are the prototypic extracellular pathogens with engulfment of
the organisms into a phagocytic vacuole sufficient for killing. Granulocytes
from patients suffering from chronic granulomatous disease (unable to
generate hydrogen peroxide and other microbicidal oxidants) retain anti-
pneumococcal activity (Johnston and Newman 1977). This is explained by S.
pneumoniae being catalase negative and unable to break down its own
hydrogen peroxide (Johnston 1991).
1.3.2Pneumolysin as a virulence factor
Pneumolysin is an intracellular protein belonging to the thiol-activated
toxin family (so called because they are only active in the reduced state and
reversibly lose activity on oxidation) and is only released by the pneumococci
on lysis (Boulnois et al. 1991). Pneumolysin is expressed by all pathogenic
strains of S. pneumoniae and is released in vivo as anti-pneumolysin
antibodies can be detected during infection (Kemper and Deresinki 1994)and
pneumolysin itself can be detected using fluorescent antibodies on lung
sections from infected mice (Canvin et al. 1995).
The ability of pneumolysin to act as a virulence factor is indicated by the
reduced virulence of mutant bacteria unable to produce the toxin (Berry et al.
1989). Mice infected with pneumolysin-deficient bacteria survive
significantly longer than those infected with pneumolysin-sufficient S.
pneumoniae. These bacteria are less able to survive and multiply within the
lungs and are incapable of multiplying to the same high levels in
bloodstreams as wild type pneumococci (Kadioglu et al. 2000).
This virulence factor is capable of exerting differing effects on the immune
response, depending on its concentration. At lower concentrations
(-lng/ml) pneumolysin is capable of a range of activities indicated in Table
1.1.
At higher concentrations (-10Jlg/ml) the toxin can lyse cells. The toxin is
believed to bind to cholesterol in the target cell membrane, insert into the
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Target Effect Reference
Monocytes Inhibits respiratory burst (Nandoskar et
al.1986)
Decreases anti-pneumococcal (Nandoskar et
activity al.1986)
Stimulates pro-inflammatory (Houldsworth
cytokine production et al. 1994)
Neutrophils Inhibits respiratory burst & (Paton and
migration Ferrane 1983)
Pulmonary Disrupts integrity (Rubins et al.
Epithelial cells 1993)
Inhibits cilial beating (Steinfort et al.
1989)
Pulmonary Disrupts integrity (Rubins et al.
Endothelial cells 1992)
B cells Decreases antibody production (Boulnois et al.
1991)
Peripheral blood Inhibits proliferation and (Ferrante et al.
Lymphocytes antibody production 1984)
Table 1.1 Effects of low levels of pneumolysin relevant to pneumococcal
infection.
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membrane, oligomerise and form transmembrane pores, thus disrupting
membrane integrity and causing cell lysis (Paton 1996).
These higher concentrations of pneumolysin are also implicated in the
inflammatory response that occurs during pneumococcal pneumonia.
Injection of recombinant toxin into ligated bronchi of rats induces a similar
pattern of inflammation in that area to the host response seen during
infection with virulent S. pneumoniae. The lobe becomes consolidated with
inflammatory cells and there was marked disruption to lung architecture
(Feldman et al. 1991). Furthermore, in vitro pneumolysin is capable of
stimulating the classical complement pathway (Section 1.5.3.4.1) in the
absence of pneumolysin-specific antibody, thereby instigating an
inflammatory response in the fluid layer, diverting the response away from
intact pneumococci (Paton et al. 1984). In addition, opsonisation with
human serum treated with pneumolysin significantly reduced in vitro
phagocytosis of the bacteria by neutrophils. Thus complement activation
correlates with a significant inhibition of serum opsonic activity. The
mechanism that pneumolysin utilises to exert this effect is currently
unknown but is believed to involve non-specific binding of IgG Fc by the
toxin (Mitchell et al. 1991).
As mentioned in Table 1.1,pneumolysin is capable of stimulating release of
TNFa and IL-1~, from human monocytes. Both these cytokines possess
potent pro-inflammatory activities (Section 1.6.1.1). Lower levels of TNFa,
IL-6and IFNybeing released during infection with pneumolysin deficient S.
pneumoniae mutants than wild type bacteria provides indirect evidence of
the in vivo inflammatory role played by pneumolysin (Benton et al. 1998).
Pneumolysin can also stimulate the activity of phospholipase A by
pulmonary artery endothelial cells (Rubins et al. 1994). Phospholipases
release products of the arachidonic acid pathway which have been shown to
be involved in neutrophil recruitment and activation of inflammatory cells
during pneumococcal pneumonia (Tuomanen et al. 1987). In addition,
phospholipase A is capable of degrading phospholipids in cell membranes
perhaps aiding spread of the pneumococci. Microscopic examination of cells
treated in vitro with pneumolysin has indicated that the toxin is also capable
of mediating direct damage to host cells. Disruption has so far been
identified to occur to bronchial and alveolar epithelial cells as well as
pulmonary endothelial cells (Steinfort et al. 1989), (Rubins et al. 1993)&
(Rubins et al. 1992). Pneumolysin may not act in isolation in these
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inflammatory activities, as it may also potentiate the inflammatory effects of
cell wall products. Such synergy has been previously documented for the
alpha toxin of S. aureus (Bhakdi et al. 1989).
Finally, infection with pneumococci deficient in the ability to synthesise
pneumo1ysin is known to induce significantly less pulmonary inflammation
than infection with wild-type bacteria. This laboratory has shown that
although the histopathological changes that occur within the lungs of mice
infected with pneumo1ysin deficient bacteria are similar to those occurring
during wild type infection, the kinetics are delayed and severity lessened
(Canvin et al. 1995). In addition we have recently characterised the
pulmonary cellular response during infection with pneumo1ysin deficient
bacteria (Kadiog1uet al. 2000). Following intranasal infection with 106CFU,
these pneumococci were incapable of reaching the same levels of bacterial
loads within both the lungs and bloodstreams of MF1 mice. Thus the
presence of pneumo1ysin is essential for bacterial multiplication in the
alveoli, especially within the initial 6-8h of infection. It has been previously
shown that instillation of recombinant pneumo1ysin concurrently with
pneumolysin deficient bacteria returns the pattern of bacteria growth to that
of wild-type bacteria (Rubins et al. 1995)proving that it is the loss of this one
virulence factor that is responsible for reduced pneumococcal proliferation.
In addition mice infected with pneumolysin deficient bacteria did not display
marked symptoms of infection, unlike their counterparts infected with wild-
type bacteria (Section3.2.3.1).
Our investigation of the pulmonary cell influx in response to these
infections revealed a delayed and reduced cell recruitment to the lungs of
mice inoculated with pneumolysin deficient pneumococci than infection
with wild-type bacteria. Analysis of the cell types involved indicated that
neutrophil responses were most affectedwith the redistribution of T and B
lymphocytes in and around inflamed bronchioles also delayed and reduced.
Whether these changes are due to the reduced bacterial loads within both
lungs and circulations of mice infected with pneumo1ysin deficient bacteria
acting as a poorer inflammatory stimulus, or due to pneumo1ysin directly
instigating damage by wild-type bacteria is currently unknown.
Immunisation with inactivated pneumo1ysin has been shown to offer
enhanced survival following subsequent challenge with pneumococci (Paton
et al. 1983). Survival times of mice subsequently infected with 5 x 106CPU s.
pneumoniae were increased from 2.48 days for untreated mice to 5.52 days in
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immunised animals. Although this effect is not as marked as the protection
elicited by anti-capsule antibodies, protection is not sero-type specific. This
laboratory has previously demonstrated protection against subsequent
infection with 9 different pneumococcal serotypes for mice immunised with
pneumolysin toxoid prepared from type 2 pneumococci (Alexander et al.
1994). Pneumolysin has thus been proposed as a promising antigen for use
in novel vaccines.
1.3.3Neuraminidases as virulence factors
All clinical isolates of S. pneumoniae tested produce this surface associated
enzyme capable of cleaving N-acetylneuraminic acid from glycolipids,
lipoproteins and oligosaccharides on cell surfaces or in body fluids (Camara
et al. 1994).Two separate pneumococcal neuraminidase genes, nanA and
nanB, have now been identified (Camara et al. 1994)and (Berry et al. 1996).
Production of neuraminidases may cause direct damage to the host or may
unmask potential binding sites for the organism.
Immunisation of mice with formaldehyde inactivated neuraminidase
significantly increases survival times of mice subsequently challenged with
S. pneumoniae (Lock et al. 1988), but not to the extent seen with
pneumolysin or capsular polysaccharide.
1.3.4Hyaluronidase as a virulence factor
Almost all clinical isolates secrete this enzyme which acts on hyaluronic acid,
a component of mammalian connective tissue and extracellular matrix.
Such degradation may aid bacterial spread and colonisation, as demonstrated
for hyaluronidase from other micro-organisms. In the case of Treponema
pallidum, hyaluronidase induces vascular leakage and dissemination of the
organism (Fitzgerald and Repesh 1987).
In addition, hyaluronidase may potentiate pulmonary inflammation during
pneumococcal pneumonia via complex interactions with pro-inflammatory
cytokines and chemokines. In vitro, TNFa and IL-1~ are capable of inducing
the production of hyaluronic acid by fibroblasts (Irwin et al. 1994).
Hyaluronic acid can promote further cytokine secretion by binding to CD44
on host cells. The system is further complicated by the ability of IL-1to act in
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combination with high levels of hyaluronic acid to release hyaluronidase,
thereby degrading hyaluronic acid (and surrounding connective tissue).
Breakdown products of hyaluronic acid have been shown to stimulate
chemokine expression by macrophages in vitro (McKee et al. 1996). Such
expression m vivo would induce cell recruitment, potentiating
inflammation. Furthermore, these degradation products are also capable of
elevating the phagocytosis of IgG opsonised latex beads and chemotaxis (in
response to casein) of granulocytes in vitro and in vivo (Hukansson et al.
1980).
Thus the expression of hyaluronidase by S. pneumoniae during
pneumococcal pneumonia would disrupt normal hyaluronic acid
metabolism leading to direct tissue disruption, up regulation of pro-
inflammatory cytokines and cell recruitment.
1.3.5 Pneumococcal surface protein A (PspA) as a virulence factor
PspA is a highly variable protein expressed by all medically important
pneumococcal serotypes (Crain et al. 1990) and found non-covalently
attached to the choline of the cell wall.
Mutant S. pneumoniae variants unable to produce PspA are less virulent in
systemic disease as they are more easily cleared from the bloodstream
(McDaniel et al. 1987). PspA may act by preventing the deposition of C3b
onto the surface of pneumococci. Alternatively, this virulence factor may
inhibit the formation of the alternate complement pathway C3 convertase
(Tu et al. 1999). By either method, PspA reduces the effectiveness of
complement receptor-mediated mechanisms of clearance.
More recently PspA has been identified as a lactoferrin binding protein
(Hammerschmidt et aI1999). By interacting with lactoferrin S. pneumoniae
may be able to overcome the iron deficiency of mucosal sites and progress to
cause disease.
1.3.6 Other surface proteins as virulence factors
An additional range of pneumococcal surface proteins have recently been
identified and proposed as virulence factors. One such protein is choline
binding protein A (CbpA, Figure 1.1), involved in bacterial adhesion to the
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nasopharynx (Section 1.2.5). Immunisation of mice with the same protein
but under the name PspC provides mice with protection against subsequent
intravenous challenge with either PspC producing or non-producing strains
of S. pneumoniae (Brooks-Walter et al. 1999). This cross-protection was
found to be due to the production of antibodies cross-reactive against both
PspC and PspA (the two proteins displays high homology).
Although the receptors on human cells that pneumococci adhere to have
been identified (Section 1.4.2), pneumococcal adhesins are currently
unknown. Cundell et al have found that mutations in genes identified as
peptide permeases reduced pneumococcal adherence to both of the receptors
expressed on resting lung or endothelial cells (Cundell et al. 1995). These
permeases are believed to bind and transport small peptides across the
bacterial membrane, presumably for metabolic utilisation. A homologue of
these permeases, PsaA, has been ascribed a role in pneumococcal virulence
(Talkington et al. 1996), Immunisation of mice with PsaA prior to
intravenous infection with 450 CFU type 3 pneumococci resulted in 75%
survival whilst there were no survivors in the un-immunised group. PsaA
deficient bacteria have also been constructed and shown to display attenuated
adhesion to type II pneumocytes in vitro (Berry and Paton 1996). These same
mutants were less virulent following intranasal or intraperitoneal challenge
of mice (assessed by longer survival times and higher survival rates).
More recently PsaA and three homologues, PsaB, PsaC and PsaD have been
shown to be manganese transporters (Novak et al. 1998). Mutations
upstream of the genes for these permeases reduced pneumococcal adherence
to lung epithelial cells in vitro. Rather than being directly responsible for
pneumococcal adhesion, it is now believed that these permeases act in a
regulatory capacity to alter adhesion by acting on Cbp expression (manganese
may be required for the export of Cbp).
1.4 Pneumococcal Pneumonia
1.4.1 Epidemiology of pneumococcal pneumonia
Pneumonia is the sixth leading cause of death in the United States and the
most common cause of death from an infectious disease in the non-
industrialised world (Garibaldi 1985) & (Niederman et al. 1993). Current
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estimates of mortality rates in children under the age of 5 are 2.7 million per
year (World Bank 1993).
Pneumonia is also a major cause of death in the adult population. Every
year an estimated 100,000adults between the ages of 45 and 59 die from this
infection, with 1.2 million deaths in the over 60 age group (Murray and
Lopez 1996). S. pneumoniae is believed to be responsible for most of these
deaths in the industrialised and non-industrialised worlds. Estimates
currently stand at 40-60% of cases being due to this one micro-organism
(Fang et al. 1990)& (Mulholland 1999).
One reason for the prevalence of pneumococcal pneumonia is the ubiquity
of the bacteria, they can be found colonising the nasopharynx of up to 70% of
the community (Kemper and Deresinki 1994). Such colonisation occurs early
in life with most infants colonised with pneumococci on at least one
occasion before they are 2 years old (Gray et al. 1980). Carriage of one serotype
of pneumococci does not protect against colonisation with other serotypes as
up to four serotype have been found to be carried by an individual at anyone
time (Tuomanen et al. 1995).
1.4.2Pathogenesis of pneumococcal pneumonia
Pneumococcal pneumonia is believed to occur after spread of the bacteria
from the nasopharynx to the lungs via aspiration (Musher 1992). Within the
alveoli the organisms are thought to preferentially attach to type II
pneumocytes (Cundell and Tuomanen 1994). There are two classes of
receptors expressed on resting pneumocytes: N-acetyl-D-galactosamine
linked by either ~1,3 or ~1,4 to galactose (GaINAc~1-3Gal and GaINAc~l-
4Gal) (Cundell et al. 1995). Only 0.1%of pneumococci are capable of attaching
to these receptors on resting cells (Tuomanen 1997). Activation of
pneumocytes leads to the expression of a novel receptor N-
acetlyglucosamine (GaINAc), the platelet activating factor (PAF) receptor
(Cundell et al. 1995). The appearance of this receptor results in a rapid
enhancement of pneumococcal adhesion (Tuomanen 1997).
Adherence is thought to be followed by bacterial internalisation into host cell
vacuoles via receptor-mediated endocytosis (Cundell et al. 1995)& (Talbot et
al. 1996). Pneumococci are then able to pass through these cells and gain
12
Chapter 1 Introduction
access to the bloodstream. Pneumococci may also enter the circulation via
the pulmonary draining lymph ducts.
1.4.3 Predisposing factors for pneumococcal pneumonia
Despite the high carriage rates, comparatively few individuals go on to
develop pneumococcal pneumonia. Many factors are responsible for
determining the outcome of colonisation and these can generally be
separated into physiological, non-immunological and immunological (Table
1.2).
1.4.3.1 Age as a predisposing factor for pneumococcal pneumonia
People at the extremes of age are most likely to suffer from pneumococcal
disease. The highest incidences are found in children between 18 and 24
months, infections are rarer in teenagers and young adults but increase with
middle age to peak again in individuals in their 70's and 80's (Austrian and
Gold 1964) & (Burnman et al. 1985).
This age distribution is also associated with variations in the frequency of
capsular types identified in clinical cases. Danish types 6B, 19F and 14 are
most likely to cause disease in children whereas 1,2 and 3 are more common
in adults (Leach et al. 1997).
The immature status of B cells in infants (lacking the CD40 surface antigen
required for IgG antibody production during T cell-dependent responses) is
responsible for their poor response to pneumococcal polysaccharide
(Dullforce et at. 1998). Therefore this deficiency also increases their
susceptibility to other encapsulated bacteria such as Haemophilus inJluenzae.
At present the increased incidence of pneumococcal pneumonia in the
elderly population is not understood. Environmental factors, nutritional
status and underlying infections undoubtedly playa role but the immune
response itself is also likely to be involved. Immune responses are altered in
elderly individuals with the major effects of ageing found in the cell
mediated arm of immunity. The most well known deficiency is the loss of
thymic tissue which leads to an elevated number of immature T cells within
the circulation (Simons and Reynolds 1990). The antibody response is also
known to be diminished as investigation of antibody levels 2 weeks post
immunisation with pneumococcal capsular polysaccharide detects
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Type of Factor Factor
Physiological Age of under 2 yr or over 65 yr
Male gender
Non-immunological Disruption of bronchial
epithelium (influenza, smoking)
Ethanol, narcotic intoxication
Decreased vascular perfusion (e.g.
sickle cell anaemia or congestive
heart failure)
Cold weather
Immunological Immunocompromised status for
example HIV+
Phagocytic abnormalities-
neutropenia, hyposplenia
Hypogammaglobulinemia
Specific antibody deficiency
Complement deficiency (C2, C3)
Table 1.2 Host factors that predispose individuals to pneumococcal infection
(adapted from (Johnston 1981)& (Burman et al. 1985».
~ ~C~ha~p~te~r_l~ _ulntttr~o~d~ucctt~iQ~n
significantly lower levels in elderly individuals than in young adults
(Ammann et al. 1980). Recently the reduced response of the aged population
to pneumococcal vaccination was studied in an in vitro system. By culturing
spleen cells from young and old mice with the vaccine, Garg et al discovered
that cells from young mice generated significantly more vaccine-specific
plaque-forming cells (Garg et al. 1996). The authors showed that this was not
due to elevated T-cell mediated suppression but rather the result of reduced
accessorycell function (an effect overcome by the addition of exogenous IL-
1~). It is well known that IL-1 secretion is diminished with age. Both
peritoneal macrophages and T cells from 2yr old mice possess less IL-1
activity (as assessed by the ability to induce thymocyte proliferation) than do
cells from 4 month old animals (Inamizu et al. 1985). IL-1 is capable of
stimulating B lymphocytes to proliferate, increasing antibody secretion and
inducing IL-2 production (IL-2in turn causes T lymphocyte proliferation).
Thus with reduced expression of IL-1by accessory cells (such as macrophages)
from aged individuals, a poorer response to vaccination is inevitable.
The innate immune defences also diminish with age. Phagocytosis of
zymosan opsonised yeast particles is significantly impaired in aged human
when compared to young individuals. Such phagocytic impairment is
evident in subjects in their 30s when compared to those in their 20s or teens.
This effect becomes progressively more evident and significant in subsequent
decades (Emanuelli, et al. 1986).
In contrast to these immune deficiencies, inflammatory responses are
elevated in the elderly. This effect has previously been noted in patients
suffering from pneumococcal infection (Bruunsgaard, et al. 1999). This effect
is likely to represent elevated production of inflammatory cytokines such as
TNFa and IL-6 (Foster, et al. 1992).
These results indicate that a decrease in neutrophil recruitment and activity
or reduced antibody response may be responsible for the elevated
susceptibility to pneumococcal pneumonia in aged individuals. Pathology
may be worse in this population due to overzealous inflammatory
responses, which may result from impaired regulation by lymphocytes.
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1.4.3.2 HIV status as a predisposing factor for pneumococcal pneumonia
Pneumococcal infection occurs between 5 and 17 fold more frequently in HIV
positive populations, making S. pneumoniae the most commonly isolated
respiratory pathogen in HIV positive individuals in both industrialised and
non-industrialised nations (Moore et al. 1998) & (Gilks et al. 1996).
Furthermore, the risk of bacteraemic pneumococcal pneumonia is increased
approximately 100 fold (Redd et al. 1990), with a mortality rate in AIDS
patients of 57% whereas the rate in other populations is 22-39% (Pesola and
Charles 1992).
This problem is compounded by the increased incidence of antibiotic
resistant strains of pneumococci in HIV positive patients (Paul et al. 1995).
As most antibiotic resistant strains of pneumococci are of the serotypes
covered by the present vaccine, it would suggest that the problem could be
overcome by widespread vaccination of HIV positive individuals.
Unfortunately there have been frequent reports of poor vaccine efficacy.
Rodriguez-Barradas et al found that subjects with CD4 counts below 500 are
far less likely to respond to vaccination as reflected in the low post-
vaccination total IgG titres to pneumococcal serotypes 3, 4, 6A, 8 and 23F in
these individuals (Rodriguez-Barradas et al. 1992). Furthermore HIV
seropositive individuals who respond well to vaccination may have very
low antibody levels again 12 weeks following treatment (Loeliger et al. 1995).
1.4.3.3 Gender as a predisposing factor for pneumococcal pneumonia
The incidence of pneumococcal infection in humans is greater in males than
in females, with a ratio of 2.1:1 (Burman et al. 1985). However, the reason for
such a difference is currently unknown. Male subjects do not have a higher
rate of carriage of pneumococci than females. Furthermore, male
individuals do not appear to be colonised by capsular types with higher
virulence than do females, as Scott et al found similar capsular types were
isolated from both males and females in over 7,000 cases of invasive
pneumococcal infection (Scott, et al. 1996).
Such data indicates that a defect in the male immune response increases
their susceptibility to pneumococcal infection. Indeed it is widely recognised
that in most species studied, males have weaker immune responses than
females. Gender differences in antibody levels against pneumococcal
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capsular polysaccharide have been documented with males responding less
significantly than women following vaccination (Roghmann et al. 1987).
Most data in this field of research indicates that hormonal control of the
immune response is responsible for these gender differences. By using
mouse strains that vary in their sensitivity to (but not circulating levels of)
androgen, Cohn and her laboratory have revealed that the response to
pneumococcal polysaccharides is mediated by this one hormone (Cohn 1979).
Male mice with high tissue responses (assessed by seminal vesicle growth) to
androgen displayed lower antibody levels following immunisation than did
females from the same mouse strain or males from strains with low
sensitivity.
At present the reason for androgen sensitivity mediating immune responses
is unclear. It may be that androgen mediated responses directly affect the
immune response. Alternatively the androgen response may exert its effects
via intermediaries such as cytokines. The effects of this sensitivity to
androgen on the inflammatory response during pneumococcal pneumonia
would therefore be an interesting future direction for our research to take.
1.4.3.4Other genetic factors predisposing to pneumococcal pneumonia
It has previously been noted that adoptees have a five-fold greater risk of
dying from an infectious disease if a biological parent died from the same
infection (with pneumonia accounting for 29%of the infections). The risk
was not increased if an adoptive parent died from an infection (Sorensen et
al. 1988). These facts indicate that there is a strong genetic component
determining the outcome to infectious diseases with environmental factors
playing a minor role.
Recognition of the above has led to investigation of host genetic factors
which might be responsible. A locus on mouse chromosome one, termed
Beg, Lsh or Ity, is important in controlling infections due to intracellular
organisms such as Mycobacterium spp., Listeria monocytogenes and
Salmonella typhimurium (Forget et al. 1981), (Skamene et al. 1979), and
(Plant et al. 1982). Ity encodes a natural resistance macrophage protein 1
(Nramp1) which affects the macrophage's ability to destroy ingested
intracellular parasites early in the infectious process (Vidal et al. 1993).
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Nrampl mRNA is not ubiquitously expressed but found in high levels in
phagocytic cells located within the spleen and liver. Immunofluorescence
and confocal microscopy studies have shown that Nramp1 is located in the
lysosomal compartment of phagocytes (Gruenheid et al. 1997). Upon
phagocytosis, Nramp1 is recruited to the membrane of the phagosome where
it remains during maturation to a phagosome. As of yet the exact
mechanism of Nramp1 action has not been identified, although the
identification of a separate member of the Nramp family by cross
hybridisation cDNA clones (Nramp2) may aid the discovery. Nramp2 is
highly similar to Nramp1 (78% homology) but is ubiquitously expressed
(Gruenheid et al. 1995). A role for Nramp2 as a transporter for divalent
cations has been suggested due to a mutation in Nramp2 being discovered in
the mk mouse mutant (a mouse model of iron deficiency caused by severe
defects in intestinal iron absorption) (Fleming et al. 1997). This association of
Nramp2 has led to the hypothesis that Nramp1 is also involved in divalent
cation transport. By depleting the phagosomal environment of Fe2+or other
divalent cations such as Mg2+,Zn2+or ci+, Nramp1 may remove nutrients
required for microbial growth and survival.
The human homologue NRAMP 1 has now been identified and contrary to
the murine gene is found expressed in the lungs, liver, and spleen but is
most abundant in peripheral blood neutrophils (Cellier et al. 1997).
Although the function of human Nrampl has been characterised far less
than the mouse gene, it is also associated with susceptibility to
Mycobacterium spp. (Bellamy et al. 1998).
More recently, mutations in the human IFNy receptor I have also been
identified as mediating susceptibility to infections with Mycobacteria,
(reviewed in (Abel and Dessein 1997». IFNy is a potent macrophage activator
and appears to be required for development of optimal macrophage anti-
mycobacterial activity.
In addition, currently unidentified host factors influence susceptibility to
infections due to Pseudomonas aeruginosa (Morissette et al. 1995), and
Candida albicans (Ashman and Papadimitriou 1992).
Notably missing from the above list of pathogens are extracellular bacteria.
To this date no candidate genes for resistance to such organisms have been
identified. During the 1930s it was first recognised that pathology during
pneumococcal pneumonia was dependant on the strain of mouse as well as
the capsular serotype of the bacterium, suggesting a host genetic component
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to disease susceptibility (Schiitze et al. 1936). Such findings were also
described more recently by Briles et al (Brileset al. 1986).
At present the nature of any host factor(s) involved in determining the
outcome to pneumococcal infection is unknown. For this reason we have
established models of pneumococcal pneumonia in inbred strains of mice
that are genetically resistant or susceptible to the infection with the long term
goal of identifying possible genes (Gingles et al. Manuscript in Preparation).
By infecting a range of inbred strains of mice BALB/ c were found to be
resistant and CBA/Ca mice susceptible to intranasal infection with 106CFU S.
pneumoniae. Investigation of bacterial loads following infection revealed
that BALB/ c mice were able to control the organisms within their lungs and
prevent spread to the bloodstream thereby surviving the infection. In
contrast pneumococci proliferated unchecked within the lungs and
circulation of CBA/Ca to result in a median survival time of only 27h post
challenge.
Analysis of the host cellular response to infection (by whole lung
homogenates) revealed that both the total number of leukocytes and the
number of neutrophils recruited to BALB/c lungs by 12h and 24h post
challenge were significantly higher than the levels seen in CBA/Ca mice.
This difference was also evident in histological studies with inflammatory
lesions visible earlier and to a greater extent in BALB/c lung sections than in
CBA/Ca lungs. Thus the inflammatory response is up regulated earlier and
to a greater extent in mice that are genetically resistant to pneumococcal
pneumonia. As described below, cell influx is initiated and controlled by a
range of host inflammatory mediators secreted by resident lung cells. We
have therefore hypothesised that differences in the ability of inbred strains of
mice to produce these inflammatory mediators may explain their
susceptibility/resistance to pneumococcal pneumonia. This hypothesis was
tested as part of this thesis (Chapter 5).
1.4.4Problems with control of pneumococcal pneumonia
The standard outpatient treatment for pneumococcal pneumonia in the
United Kingdom is oral administration of penicillin G for 5-7 days (Musher
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1992), with hospitalised patients being treated intravenously. In non-
industrialised nations treatment is generally with oral amoxycillin
(providing a substantially broader spectrum of coverage than required for
pneumococcal infection) with more serious cases given parenterally
administered penicillin. The efficacyof all therapeutic agents is currently
being threatened by antibiotic resistance (Goldsmith et al. 1997)& (Hart and
Kariuki 1998).
1.4.4.1 Antibiotic resistant S. pneumoniae
The first clinically significant pneumococcal strains with reduced sensitivity
to penicillin were identified in Australia and Papua New Guinea during the
1960s (Hansmann and Bullen 1967). By 1974 the incidence of penicillin
resistant pneumococci in this area was 12% (Hansmann et al. 1974)and by
1980it had reached 30%(Gratten et al. 1980).
Recent studies have identified a real problem in Western nations, some
areas of North America are currently reporting that 40% of pneumococcal
isolates are penicillin resistant (Butler and Cetron 1999). In non-
industrialised countries percentages of antibiotic resistant bacteria are
increasing even more dramatically due to unregulated use of antibiotics in
humans and animals (Hart and Kariuki 1998).
At present vancomycin is the antibiotic of last resort, with no isolates of
vancomycin resistant pneumococci reported. Recently, emergence of
vancomycin tolerance (the ability of pneumococci to survive but not grow in
the presence of antibiotics) has been detected (Novak et al. 1999). Tolerance is
generally believed to be a precursor phenotype to resistance. Thus in the
short term, strains of S. pneumoniae resistant to all appropriate antibiotics
may emerge.
1.4.4.2 Ineffective pneumococcal vaccine
Despite successful research into type-specific protection with capsular
polysaccharide preparations in the 1930sand 1940s(Lee et al. 1991),interest in
vaccines against S. pneumoniae infection was to wane quickly with the
discovery of antibiotics. The scientific community became complacent,
believing that a vaccine was now redundant, despite the fact that around 20%
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of patients over 65 years of age with pneumococcal bacteraemia die following
appropriate antibiotic treatment (Butler and Cetron 1999). Recognition of
this fact in the 1970sled to renewed interest in the development of improved
pneumococcal vaccines. In 1983a vaccine containing capsular polysaccharide
against 23 serotypes of pneumococci became available. This vaccine is
effective against those serotypes responsible for greater than 90% of cases of
pneumococcal pneumonia in the United States and Europe
(AlonsoDeVelasco et al. 1995)but less than 70%of pneumococcal infections
in Asia (Lee 1987).
The vaccine is associated with low efficacyrates due to certain groups having
poor antibody responses to polysaccharide based vaccines (White 1988).
Development of a more effective vaccine for use in infants may result from
conjugation of capsular polysaccharide to a protein carrier (e.g. H. inJIuenzae)
(Ahman et al. 1998). These work on the basis that the infant's immune
system responds to protein antigens which act as a boost for the
polysaccharide antigen (Kayhty and Eskola 1996). Phase three clinical trials
are currently being carried out with these preparations. Disadvantages still
exist in that fewer capsular serotypes can be covered (at present only 9) and
they are likely to be too expensive for use in non-industrialised countries.
1.4.5 Disease progression of pneumococcal pneumonia
In the classic description of pneumococcal pneumonia there are four
overlapping stages: engorgement, red hepatisation, grey hepatisation and
resolution.
The arrival of bacteria in the alveoli results in congestion of the alveolar
capillaries and outpouring of serous fluid. This fluid acts both as a nutrient
source and a mode of transport for the bacteria outward via the pores of
Kohn to adjacent alveoli (Harford and Hara 1950).
Further engorgement of the capillaries with erythrocytes leads to red
hepatisation when neutrophils, a few macrophages and many erythrocytes
pass from capillaries via the interstitium to fill the alveolar spaces (Loosli
and Baker 1962). Large amounts of fibrin are evident in alveolar and serosal
exudates.
Within a few hours, as exudate continues to accumulate in the alveoli,
capillaries are compressed, red cell content reduced, and leukocyte content is
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increased (McKinsey and Bisno 1980). The intravascular deposition of fibrin
causes a decline in perfusion, resulting in an appearance known as grey
hepatisation (Kline and Internitz 1915).
Pneumococci that manage to evade the immune response spread into the
interstitial lung tissues and then to the bloodstream. In immunocompetent
patients a period of several days to weeks can pass before disease progresses to
this stage, although most deaths from bacteraemic pneumococcal
pneumonia occur within the first 5 days of illness (Sato et al. 1998). In
addition, splenectomised individuals can succumb in 18-24h with no
symptoms (Musher 1992).
The cause of death in pneumococcal pneumonia remains a puzzle. Even
after antibiotic treatment has begun, with the pneumonia clearing and the
previously infected site sterile, death can still occur (Austrian and Gold 1964).
More detailed understanding of the roles played by host factors in disease
pathogenesis would be expected to help answer this question and thus aid
the search for more effective control measures.
1.4.6 Resolution of pneumococcal pneumonia
A striking finding with patients that recover fully from pneumococcal
pneumonia is that their lungs possess no permanent injuries despite the
massive inflammatory response they have endured (Catterall 1999).
Resolution is believed to occur after the appearance of anti-capsular
antibodies, which enable more efficient engulfment of the bacteria by
phagocytes. Following phagocytosis of pneumococci, neutrophils
themselves must be removed from the airways and tissues of the lungs. The
widespread belief with regard to this process is that the cells undergo necrosis
prior to their engulfment by macrophages. More recent results indicate that
neutrophils become apoptotic rather than necrotic (Haslett 1992) & (Haslett
1997). With such "programmed cell death" neutrophils retain their granule
contents and membrane integrity but no longer have the capability to secrete
contents in response to external stimuli (Haslett 1992). In addition,
macrophages that have ingested apoptotic PMN do not release pro-
inflammatory mediators. These macrophages are then cleared by
mucociliary transport (Section 1.5.1).
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Deposited fibrin acts as a provisional matrix into which fibroblasts migrate in
order to repair damaged lung interstitium (Simon and Paine 1995). Type II
epithelial cells also spread over this matrix before proliferating to repair
damaged epithelia. The inflammatory cytokines IL-1~ and TNFa (Section
1.6) have been shown to act as primers for alveolar epithelial type II cell
chemotaxis (as measured by passage through filters) when cells were pre-
incubated with these cytokines prior to addition of a type II cell chemokine
(epidermal growth factor) (Lesur et al . 1996). In contrast IL-6 was shown to
regulate the chemotaxis in a negative manner. Following fibroblast and
epithelial cell migration the fibrin scaffolding is removed by plasminogen
activators (Bertozzi et al. 1990).
Clearance of fluid, proteins and debris occurs by active transport mechanisms
(Chapter 6), lymphatic drainage and phagocytosis by macrophages.
As the alveolar walls are not destroyed during pneumococcal pneumonia
(McKinsey and Bisno 1980), the pulmonary parenchyma returns to normal
following resolution of the infection.
1.5 Protective immunity against S.pneumoniae
Inhaled air and aspirated aerosols of upper-respiratory secretions contain
high levels of viable bacteria, often as high as 108 or 109 CFU/rnl. Despite
such a constant threat from both commensal and environmental organisms,
in most cases the lungs remain free of infection. It is the responsibility of the
defence mechanisms of the respiratory tract (structural, mechanical, cellular,
and secretory) to ensure that this is the case (Figure 1.3).
1.5.1 Structural and mechanical defences against S. pneumoniae
The first line of defence against the foreign bacteria is the anatomical design
of the respiratory tract. Large particles of 10J..lmor more will be deposited in
the nasal passages due to their curved architecture. The frequent branching
of bronchi causes particles of 2J.lm-10J.lm to impact in the peripheral
conducting airways. Coughing and sneezing also act to prevent particles
passing beyond the respiratory bronchioles (Pison et al. 1994).
Only particles between 0.5J.lm and 2J.lm therefore become deposited in the
terminal respiratory units and alveoli (Nelson and Summer 1998).
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Following contact with the walls of the respiratory tract, foreign particles
become opsonised in respiratory secretions and embedded in the mucous
layer overlying the ciliated epithelium. By placing markers such as India Ink
or radio-labelled particles in the airways and measuring the distance
travelled with time, it has been estimated that the beating movement of the
ciliated epithelium continuously moves the mucous layer upwards at a rate
of 0.5-1mm/min in the small airways and 5-20mm/min in the larger airways
(Wanner 1977).
1.5.2Cellular defence mechanisms defences against S. pneumoniae
1.5.2.1Macrophages
Alveolar macrophages constitute the first line of cellular anti-bacterial
defence and are ideally situated between the lung tissue and air (Lohmann-
Matthes et al. 1994). In a normal resting animal, these cells constitute greater
than 90%of the cells of bronchoalveolar lavage fluid (Reynolds 1987).
Alveolar macrophages are believed to mainly originate from monocytes
recruited out of the bloodstream to differentiate within the alveoli. The
rapid recruitment of macrophages during acute inflammation suggests that
local proliferation of the population may also occur (Toews et al. 1979).
Additional populations of macrophages within the lungs include interstitial
and intravascular macrophages as well as dendritic cells. Interstitial
macrophages are located within the lung connective tissue and function in
both an innate immunity and an antigen presenting capacity (Lohmann-
Matthes et al. 1994). Dendritic cells can be found in low numbers within the
lung interstitium. This population have low phagocytic function and are
specialised for antigen presentation. Intravascular macrophages are evident
attached to the endothelium of pulmonary capillaries (Dehring and Wismar
1989). They are highly phagocytic (unlike monocytes) and can remove
bloodborne bacteria entering the lungs via the circulation (Warner et al.
1987),although they do not appear to play a major role in mice (Brain et al.
1999).
Alveolar macrophages are capable of engulfing bacteria rapidly following
infection. In the case of S. aureus, 80%of the bacteria are ingested within 1h
(Goldstein et al. 1974). In order to engulf bacteria macrophages express a
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range of receptors on their surface including the Fc receptors, complement
receptors and lectin receptors (Lohmann-Matthes et al. 1994).
Following phagocytosis pulmonary macrophages possess several
mechanisms of killing ingested bacteria. The phagosomes fuse with
lysosomes in the cell cytoplasm. These lysosomes contain acid hydrolases
that constitute an anaerobic killing pathway. Unlike monocytes and
neutrophils, airway macrophages do not possess much myeloperoxidase and
therefore do not utilise hypochlorous acid as an anti-microbial. They do,
however, exhibit a "respiratory burst" producing reactive oxygen
intermediates and reactive nitrogen intermediates (Poulter 1997) (Figure 1.4),
They also release free oxygen radicals, proteases and acid hydrolases into
their environment and thus may contribute to extracellular killing of
pneumococci.
In addition to their role as phagocytes, alveolar macrophages are central to
the induction of pulmonary inflammatory responses. These cells are capable
of secreting a wide range of inflammatory mediators including cytokines
(Section 1.6), nitric oxide (Section 1.5.3.5) and metabolites of the arachidonic
acid pathways. These mediators can act in both a paracrine and autocrine
manner to mediate macrophage functions such as further cytokine release,
antigen presentation and phagocytosis (Cavaillon 1994).
1.5.2.2 Polymorphonuclear leukocytes (neutrophils)
Within the healthy host the majority of neutrophils are found in the
circulation, although small numbers are present in the air spaces (less than
0.15% (Vial et al. 1984». Additional neutrophils are not recruited to the
lungs until the defences of the alveolar macrophages are overcome (Toews et
al. 1979). When required, PMN are sequestered from blood vessels (it is
estimated that 40% of the body's neutrophils are marginated within the lung
capillaries (Nelson et al. 1995) or released from the bone marrow.
Normal traffic of neutrophils is along the inner surface of blood vessels,
making contact with the endothelium. Initial tethering occurs via the L-
selectin constitutively expressed on neutrophils and the counter receptor
expressed on endothelial cells (Hogg and Walker 1995). This interaction is
not strong and is easily broken resulting in neutrophils "rolling" along the
endothelial surface. More secure attachment occurs via the E (endothelial)
24
Chapter 1 Introduction
and P (initially formed in platelets) selectin molecules on the endothelium
and their receptors on neutrophils. These interactions are assisted by
integrins on the surface of leukocytes (CDll/CD18) which interact with
immunoglobulin-like counter-receptors on the endothelium (intercellular
adhesion molecules 1&2 [rCAM-l, rCAM-2] and vascular cell adhesion
molecule 1 [VCAM-1])(Hogg and Walker 1995). Neutrophils then migrate
out of post-capillary venules at locations where three endothelial cells meet
as the tight junctions between cells are incomplete at these sites (Walker et
al. 1991). Chemotactic stimuli include complement proteins (Section 1.5.3.4)
and chemokines (Section 1.6.1.1.11).
On engulfing bacteria, neutrophils utilise both oxygen dependent and
independent anti-microbial mechanisms (Burnett 1997). The secretion of
toxic oxygen metabolites (also known as the respiratory burst) occurs after the
formation of NADPH oxidase on the surface of activated neutrophils (and
macrophages./ monocytes). This enzyme progressively adds single electrons
to O2, forming O2• which in turn can be reduced to H202, directly toxic to
micro-organisms. H202 can be reduced further to HO·, which when finally
reduced, generates H20. H202 can also be metabolised in the presence of
myeloperoxidase (MPO, found in neutrophil granules) and chloride ion to
hypochlorous acid (HOCI), which is a potent anti-microbial (Nelson and
Summer 1998),Figure 1.4.
Oxygen-independent anti-microbial systems include acid hydrolases such as
elastases, proteases which can degrade proteins in bacteria and lysozyme with
its ability to degrade cell walls (Iacquot et al. 1987). Defensins constitute
around 5% of the protein content of PMNs and are capable of creating
channels in bacterial lipid membranes, destroying permeability barriers
(Nelson and Summer 1998).
1.5.2.3 Lymphocytes.
Lymphocytes within the lungs are found as aggregates below the mucosal
layer of airways (bronchus-associated lymphoid tissue [BALT]),within the air
spaces and interstitium and in the intravascular compartment (Pabst 1997).
We and others have shown that the number of lymphocytes within lungs of
infected animals increases during pneumococcal pneumonia (Kadioglu et al.
2000) & (Bergeron et al. 1998). However, the roles of these recruited
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lymphocytes are not fully understood. Nude mice (T cell deficient) are no
more susceptible to pneumococcal infection than wild-type animals
(Winkelstein and Swift 1975)suggesting that T cells are not required for a
protective response against S. pneumoniae. Conversely, Sestini et al have
indicated that lymphocytes are involved in antibody mediated cytotoxicity
against S. pneumoniae in vitro (Sestini et al. 1987). The lymphocytes
responsible possess the phenotype of T helper cells and utilised IgA in order
to mediate their anti-bacterial activity (Sestini et al. 198~).
Lymphocytes are known to be capable of releasing a range of cytokines
(Section 1.6)that possess the ability to activate and potentiate the effects of
other cell populations. Thus the importance of lymphocytes in
pneumococcal pneumonia may be due to their regulatory capacity.
Our recent finding that pulmonary lymphocytes underwent redistribution
during pneumococcal pneumonia (Kadioglu et al. 2000)led us to investigate
the role of lymphocytes in controlling bacterial loads and contributing to
pulmonary and systemic inflammation as part of this study.
1.5.2.4 Mast cells
Mast cells are derived from CD34+progenitor cells within the bone marrow
(Kirschenbaum et al. 1991). These progenitors migrate to tissues such as the
genitourinary, gastrointestinal and respiratory tracts which are primary sites
of infection for a wide range of organisms.
The most striking feature of mast cells is the presence of 50-200 densely
packed granules within their cytoplasm (Stites et al. 1994). These granules
contain histamine, serotonin, and TNFa (Section 1.6.1.1). Mast cells are the
only cells known to store pre-formed TNFa which they quickly release
(along with newly synthesised TNFa) on activation (Gordon and Galli 1990)
& (Gordon and Galli 1991). Degranulation also releases histamine and
serotonin into the cell's environment. Each of these three substances is
capable of causing disruption to the surrounding tissue with the latter two
also known to cause vasodilation when present in high concentrations. This
effect increases blood flow to the site of infection, permitting a greater influx
of inflammatory cells (Szarek et al. 1992) & (Cushing and Cohen 1992).
Physical contact between the mast cell and bacteria is not required for mast
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cell activation as the cells can be activated at a distance by bacterial products
such as toxins (Abraham and Malaviya 1997).
In addition to TNFa., mast cells have been found to secrete a range of
cytokines such as IL-1, IL-6, IL-8, IL-10 and several chemokines (Lorentz et al.
2000) & (Mecheri and David 1997). This implicates mast cells as important
first line defences against pathogenic micro-organisms. Indeed mast cells are
able to phagocytose and kill both Gram-positive and Gram-negative bacteria.
Uptake of Gram-positive bacteria is higher and associated with far higher
TNFa. than Gram-negative organisms(Arock, Ross et al. 1998). However, the
phagocytic efficiency of these cells appears to be far less than that of
macrophages and neutrophils.
The importance of mast cells during pulmonary and systemic infections has
been highlighted by experiments carried out in mast cell deficient mice
(Malaviya et al. 1996). These animals are less able to clear invading bacteria
such as Klebsiella pneumoniae due to impaired neutrophil recruitment at
sites of infection (both systemic and local). This was shown to reflect a
reduction in TNFa levels. In addition, increasing the number of mast cells
by treating mice with c-kit ligand (also referred to as mast cell growth factor)
results in animals that are more resistant to bacterial peritonitis induced by
cecal ligation and puncture (Maurer et al. 1998).
1.5.3 Secretory pulmonary defences against S. pneumoniae
Proteins within respiratory secretions can either be produced locally within
the airway lumen or they can pass through the alveolar/capillary interface
(Stockley 1997). The degree of transudation depends on the molecular size of
the substance and the integrity of the blood-air barrier.
1.5.3.1 Surfactant
Surfactant (surface active agent) is comprised of phospholipid-rich
lipoproteins and acts to reduce the surface tension in the lungs permitting
their expansion. In addition to this physiological role, the ability of
surfactant preparations to modulate the immune response has recently been
recognised. The majority of these functions are attributed to surfactant
proteins, of which five are currently known, SP-A 1 & 2, SP-B, SP-C & SP-D.
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SP-A and SP-D are members of the collectin family of proteins which are
characterised by the presence of both a collagenous region and a lectin
domain, which mediates binding to carbohydrates on the surface of micro-
organisms. This family also contains mannose binding lectin (MBL)and two
bovine serum lectins, conglutinin and CL-43. MBL is now recognised to
activate the alternative complement system and will be discussed in more
detail in Section 1.5.3.4.3.Recent data suggest that the lung collectins (SP-A
and SP-D)are able to modulate pulmonary inflammatory responses.
SP-A is highly efficient at opsonising bacteria (including S. pneumoniae) in
order to promote their phagocytosis by alveolar macrophages. Indeed
addition of SP-A to FITC (fluorescein isothiocyanate) labelled pneumococci
in the presence of rat alveolar macrophages resulted in a higher level of
phagocytosis than IgG opsonised bacteria (Schagat et al. 1999). When both SP-
A and IgGwere present the two opsonins acted synergistically.
In vitro both SP-A and SP-D are known to act as chemoattractants for
neutrophils and macrophages, with SP-Dmore effective in this capacity than
SP-Aas higher levels of SP-Awere required to exert the same effect as lower
levels of SP-D (Madan et al. 1997)& (Wright and Youmans 1993).
Following phagocytosis, both pulmonary collectins can increase the
production of reactive oxygen species (assessed by chemiluminescence) by
either neutrophils or macrophages (van Iwaarden et al. 1990) & (van
Iwaarden et al. 1992). The effects of SP-A can be attenuated by addition of
surfactant lipids but such treatment does not affect SP-D induced production
Finally SP-A has also been shown to be capable of modulating the
pulmonary inflammatory response by altering cytokine production. This
protein can act to induce release of immunoglobulins and pro-inflammatory
cytokines such as TNFa, IL-1 and IL-6 from peripheral blood mononuclear
cells, splenocytes and alveolar macrophages (Kremlev and Phelps 1994).
Conversely, SP-Ahas also be ascribed an anti-inflammatory role in that it can
reduce TNFa activity released from LPS-stimulated alveolar macrophages in
vitro (McIntosh et al. 1996). Such differences may reflect the local
environment the inflammatory stimulus and levels of other inflammatory
mediators.
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1.5.3.2 Lysozyme
Lysozyme is a muraminidase capable of degrading bacterial cell wall
peptidoglycan. This enzyme is the major secretory enzyme of the alveolar
macrophage, accounting for approximately 25% of the protein material
released (Canto et al. 1994). Although its effects have not been widely studied
it is known to be active against S. pneumoniae (Iacquot et al. 1987). Culture
of pneumococci in media with 1000J.lg/ml final concentration of human
airway lysozyme resulted in delayed growth of the bacteria. Furthermore,
although the addition of lysozyme to a culture in early logarithmic growth
phase still permitted the bacteria to multiply, reduced viability counts were
recovered when compared to media alone cultures.
1.5.3.3 Immunoglobulins
IgA, IgG, IgD, IgE, and IgM immunoglobulins are all detectable within
respiratory secretions (Stockley 1997). Whilst a role in innate lung defence
has been identified for the initial two isotypes (upregulation of phagocytosis
by alveolar macrophages (Richards and Gauldie 1985», roles for the latter
three isotypes have not been identified. The importance of antibody
production for protection against S. pneumoniae is highlighted by the
increased susceptibility of hypogammaglobulinemic patients to
pneumococcal infections (Rosen and Janeway 1966).
1.5.3.4 Complement
Like other Gram-positive bacteria, the pneumococcus is resistant to the
bactericidal and lytic activities of complement (Kemper and Deresinki 1994).
The role of complement in S. pneumoniae infection is therefore to aid
phagocytosis of pneumococci by opsonisation.
1.5.3.4.1 The classical complement pathway
Formation of an immune complex occurs when antibodies of either IgG or
IgM class combine with an antigen (Figure 1.5) A conformational change
then occurs in the Fc portion of the antibody molecule permitting the
immune complex to bind and activate the Cl component of complement.
Activated Cl possesses the ability to activate C2 and C4 which in turn cleave
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C3 into C3a and C3b. Interaction of C3b with C2 and C4 activates the
remaining components of the cascade (Winkelstein 1981).
Activation of the classical complement system by pneumococci coated in
anti-capsular antibodies permits deposition of C3b on the outer surface of
pneumococci and is believed to playa major role in host defence against s.
pneumoniae by increasing efficacy of phagocytosis (Brown et al. 1983).
Pneumolysin is also capable of initiating the classical complement pathway
(Section 1.3.2).
1.5.3.4.2 The alternative complement pathway
The activating complex in this pathway is comprised of C3b and the cleavage
product of Factor B (Bb) which is generated by active factor D (Figure 1.5).
This C3b,Bb complex is highly efficient and cleaves C3 as for the classical
pathway (Winkelstein 1981).
As the alternative pathway does not require the presence of specific
antibodies in order to function, this pathway is probably of more importance
during early infection before type-specific antibodies are generated.
Pneumococci are capable of direct activation of the alternative pathway. By
testing a range of pneumococcal preparations in vitro, Winkelstein &
Tomasz discovered that the cell wall was responsible for depleting C3 levels
in serum and thus was activating the alternative complement pathway
(Winkel stein and Tomasz 1977). They then went on to identify cell wall
teichoic acid residues as the activating fraction (Winkelstein and Tomasz
1978).
Since C3b becomes bound to the cell wall via the alternative complement
pathway, encapsulated pneumococci are not efficiently opsonised for
phagocytosis, thus the classical complement pathway is a more effective
mechanism of host defence against S. pneumoniae (Brown et al. 1983).
1.5.3.4.3 The lectin pathway of complement activation
In 1987 it was reported that serum mannose binding lectin (MBL) possessed
the ability to activate the classical complement pathway (since sheep
erythrocytes coated in mannan were lysed by incubation in MBL depleted
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complement) (Ikeda et al. 1987). MBL has since been shown to share
structural homology with C1q.
In order to activate complement, MBL associates with mannose binding
lectin serine protease (MASP), a serine protease with the same function as
activated CIs and is found in the same fraction of human serum as MBL
when separated by sequential affinity chromatography. This cleaves both C2
and C4, generating C4b2acomplexes that possess the ability to convert C3 into
C3a and C3b (Matsushita and Fujita 1992)(Figure 1.5).
It is now generally accepted that this pathway does occur in human serum
deficient in C1qbut whether it occurs physiologically in the presence of C1q
remains a contentious issue.
1.5.3.4.4 Sources of complement proteins
Most complement components within the lung are derived from plasma
during inflammation (Stockley 1997). However, low levels of complement
proteins must be present within the lungs during health as a functioning
alternative complement pathway has been detected within the lavage fluid
of normal rats (Coonrod and Yoneda 1981). This fact may be explained by the
ability of pulmonary macrophages and epithelial cells to synthesise and
secrete C2,C4,C3, and CS (Strunk et al. 1988).
1.5.3.4.5 Effects of complement proteins
The most important complement factors in pneumococcal infection are C3
and CS. Both C3a and CSa are capable of stimulating mast cell and
neutrophil degranulation and affecting vascular permeability (Lukacs and
Ward 1996). CSaappears to be more potent than C3a in these respects and
possesses the additional ability of stimulating neutrophil migration and
degranulation. In addition to these inflammatory roles played by C3a and
CSa, it has recently been recognised that in vitro C1q can also mediate
inflammatory responses by elevating the production of pro-inflammatory
cytokines (IL-6,IL-8 and Mep-I) by human endothelial cells (van den Berg et
al.1998).
C3band CSb are able to opsonise pneumococci, as revealed by depleted C3
and CS levels in serum following incubation with the bacteria and
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agglutination and capsular swelling of opsonised bacteria following the
addition of anti-C3 serum opsonins (Shin et al. 1969).
Direct evidence of the role of CS in protection against S. pneumoniae is
highlighted by the inability of mice deficient in CS to clear the organisms,
unless exogenous CS is administered, due to impaired neutrophil
recruitment (Toews and Vial 1984). In addition, humans with complement
factor deficiency are more likely to become infected with S. pneumoniae than
are immunocompetent individuals (Newman et al. 1978).
1.5.3.5 Nitric oxide (NO)
Nitric oxide is a gaseous free radical that exhibits multiple biological
properties. The molecule was first shown to be produced by living cells in
1987 and was subsequently confirmed to be identical to the endothelium-
derived relaxing factor (Ignarro et al. 1987)& (Palmer et al. 1987).
1.5.3.5.1 NO production
NO is generated when L-arginine is oxidised to produce one molecule each
of L-citrulline and NO. This reaction is catalysed by the enzyme nitric oxide
synthase (NOS) (Ward 1997).
There are three isoforms of NOS in mammalian systems, two of which are
constitutively expressed and dependant on elevated intracellular Ca2+, eNOS
(endothelial NOS or NOS3) and nNOS (neuronal NOS, NOSI). eNOS and
nNOS are collectively referred to as cNOS (MacMicking et al. 1997). The
third isoform, iNOS (NOS2), is inducible and independent of intracellular
Ca2+. All three mammalian isoforms of NOS are thought to catalyse the
production of NO by the same biochemical pathway represented in Figure
1.4.
Stimulation of macrophages with pro-inflammatory cytokines induces NOS
production. NOS converts L-arginine into nitric oxide (NO) and L-citrulline.
NO can then react with superoxide anion (0'2) generated from another
pathway to form the highly reactive peroxynitrite anion (ONOO), which,
when protonated in an acidic environment readily forms an unstable
species, HONOO. This cleaves itself into the hydroxyl radical (HO,) and
ultimately, the formation of nitrite (NO-2) and nitrate (NO-3), which are
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quantitative indicators of the amount of NO originally formed. For
explanation of second pathway see Section 1.5.2.2.
Generally, low-output NO production sustained by the cNOSs regulates
physiologic functions of NO in the healthy host, while the high-output due
to iNOS is engaged during inflammation and infection (MacMicking et al.
1997). cNOS is responsible for producing NO for minutes at a time whilst
iNOS releases NO for as long as 5 days post stimulation (MacMicking et al.
1997).
Within the lungs, NO can be formed in epithelial cells, macrophages,
neutrophils, mast cells, smooth muscle cells, fibroblasts, and endothelial cells
(reviewed in Lukacs and Ward 1996). A given monotypic cell population can
express one, two, and perhaps all three of the isoforms of NOS. Macrophages
produce NO via both eNOS and iNOS (Miles, Bowman et al. 1998), and
lymphocytes only rarely express any NOS.
1.5.3.5.2Effects of NO
Table 1.3highlights how variable the effects of NO can be, depending on its
level of expression and the environment it is acting in (Nathan 1997). NO
has been shown to diminish lung injury (Kageyama et al. 1997) or it can
induce it (Karupiah et al. 1988). Chemotaxis of both LPS stimulated and
unstimulated human neutrophils has been shown to be attenuated in vitro
by the addition of nitric oxide synthase inhibitor (Belenky et al. 1993). This is
in direct contrast to the data presented in Table 1.3 by Kubes et al.
Despite these anti-inflammatory effects,NO is also capable of up-regulating
host defence mechanisms against micro-organisms. Growth of a range of
Gram-positive bacteria, including S. pyogenes has been shown to be inhibited
by addition of nitrite (Castellani and Niven 1955) & (Shank et al. 1962) and
NO gas in deoxygenated media hindered the growth of E. coli and L.
monocytogenes.
NO mediates its antibacterial activities via several mechanisms. Reactive
nitrogen intermediates are capable of directly damaging DNA or oxidising
proteins (Fang 1997). Nitrosylation of tyrosine residues can disrupt metabolic
pathways involving tyrosine phosphorylation preventing these pathways
from occurring, or modifying their output.
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Target Effect Reference
Mast cells Inhibit degranulation (Iikura et al. 1998)
Monocytes Increase pro-inflammatory (Eigler et al. 1993)
cytokine production
Decrease adhesion and (Bath et al. 1991)
chemotaxis
Macrophages Decrease pro-inflammatory (Thomassen et al. 1997)
cytokine production
Inhibits NF-KB activation (Raychaudhuri et al. 1999)
Neutrophils Down-regulate Adhesion & (Kubes et al. 1991)
Emigration
Decrease microbicidal (Daher et al. 1997)
activity
Endothelial cells Decrease expression of (De Caterina et al. 1995)
VCAM-1
Reduce expression of pro- (De Caterina et al. 1995)
inflammatory cytokines (IL-
6 & IL-8)
Disrupt integrity (Beckman et al. 1990)
Airway & Relaxation (Lukacs and Ward 1996)
vascular smooth
muscle
Table 1.3 Effects of nitric oxide on the immune response.
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Recently pulmonary NO production has been shown to be elevated using a
murine model of pneumococcal pneumonia (Bergeron et al. 1998). A brief
release of NO occurred within the airways of infected mice 1h post challenge.
This was followed by a sustained release in lung tissues from 24h post
challenge until the end of the experiment.
Despite such elevated NO and that fact that NO has potent anti-microbial
activities, to our knowledge there have been no previous investigations of
the role played by NO during pneumococcal pneumonia. As part of this
thesis, the production and effects of NO during pneumococcal pneumonia
were investigated in our model system via utilisation of mice deficient in
iNOS activity.
1.6 The role of cytokines in inflammation and pneumococcal
pneumonia
1.6.1Cytokines
The body requires a wide range of effector molecules to act as intercellular
mediators in the regulation of cellular function. Cytokines are one family of
such effector molecules that act within the immune response. Members
include the interleukins, tumour necrosis factors, interferons, colony
stimulating factors and chemokines (Curfs et al. 1997).
Cytokines were originally described on the basis of their functions, but are
now classified into a range of families, the numerical positioning in the
families reflecting their order of discovery.
These molecules are highly potent, often acting at femtomolar
concentrations and only requiring occupancy of around 10% of membrane
cytokine receptors in order to have an effect (Fernandez-Botran 1999).
Locally produced cytokines are believed to act in a paracrine and autocrine
manner in order to activate the inflammatory and immune response in a
beneficial manner for the host.
The interactions of cytokines with other mediators in instigation of alveolar
inflammation during pneumococcal pneumonia is depicted in Figure 1.6.
Due to the important balance between pro- and anti-inflammatory cytokines
in determining outcome to infection (Walley et al. 1996) the production of
several pro-inflammatory and one anti-inflammatory cytokine was
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characterised in this murine model of pneumococcal pneumonia. These
cytokines are by no means the only mediators involved in host response to
pneumococcal pneumonia but time prevented further investigation of this
field. A detailed description of the candidate cytokines follows.
1.6.1.1 Pro-inflammatory Cytokines
1.6.1.1.1 Tumor Necrosis Factor a (TNFa)
TNFa was initially identified as a factor in the serum of endotoxin treated
rodents, previously infected with Mycobacterium bovis strain Bacillus
Calmette-Cuerin, that caused haemorrhagic necrosis of tumours in mice
(Carswell et al. 1975). This was quickly followed by the recognition that the
same factor was responsible for the wasting syndrome cachexia (Beutler et al.
1985). Since then TNFa has been implicated in a wide range of aspects of the
inflammatory and immune responses.
1.6.1.1.2 TNFa producing cell types
The main cellular sources of TNFa are blood monocytes and tissue
macrophages (for example alveolar macrophages) (Vassalli 1992)but many
other cell types including neutrophils, mast cells, endothelial cells and NK
cells are known to synthesis TNFa. Of these cell types only mast cells are
known to pre-store TNFa and are thus capable of immediate release of the
cytokine upon activation (Gordon and Galli 1990)& (Gordon and Galli 1991)
but under certain conditions mRNA for TNFa can exist within macrophages
in an untranslated form (for example in thioglycollate-elicited murine
peritoneal macrophages) (Beutler et al. 1986). Within stimulated lungs,
TNFa is predominantly expressed by macrophages (Walley et al. 1999)
although epithelial cells may release low levels of this cytokine within
healthy lungs (Pendino et al. 1994).
1.6.1.1.3 TNFa receptors
TNFa mediates its effects on target cells via one of two cell surface receptors
named p55 (TNFRI) and p75 (TNFRII) due to their molecular weights
(Brockhaus et al. 1990).
35
Chapter 1 Introduction
In order to characterise the roles of these two receptors, TNF mutants that
either bind selectively to p55 or p75 have recently been developed.
Intravenous administration of recombinant TNFa or the p55 agonist to
primates caused the increased heart rate and drop in an arterial blood
pressure characteristic of sepsis along with increased levels of IL-6 and IL-8
(Van Zee et al. 1994). Separate investigators have also indicated that
induction of ICAM-l, E-selectin, VCAM-1, and CD44 expression on
endothelial cells are mediated via p55 (Mackay et al. 1993). p55 is therefore
believed to regulate the pro-inflammatory effects of TNFa, whilst p75 is
thought to regulate these pro-inflammatory effects by acting in an
antagonistic capacity and is also involved in TNFa's cytotoxic and apoptotic
properties (Peschon et al. 1998)& (Heller et al. 1992).
1.6.1.1.4Soluble TNFa receptors
Soluble TNFa receptors were originally identified as proteins within human
urine that could bind and inactivate TNFa (Olsson et al. 1993). These
proteins were later shown to represent soluble forms of the extracellular part
of TNFa receptors.
Soluble TNFa p55 and p75 receptors are formed by proteolytic cleavage of the
extracellular domain (Black et al. 1997)& (Moss et al. 1997), occurring in
response to several stimuli including TNFa itself (Cope et al. 1995)and cell
activation (Bemelmans et al. 1994).
Soluble p55 and p75 are thought to bind TNF competitively with their
surface bound counterparts and therefore act as antagonists, dampening
down the inflammatory response. These soluble forms may also enhance
inflammation, TNF activity has been shown to undergo spontaneous decay
(Aderka et al. 1992)but in the presence of its receptors this decay does not
occur indicating that soluble receptors can stabilise TNFa. TNFa-receptor
complexes may also act as reservoirs that slowly release bioactive TNFa and
facilitate interactions with surface bound receptors at other sites in the body.
An additional possibility is that a soluble receptor may bind to a cell which
previously did not express it, allowing it to respond to TNFa (Rose-John and
Heinrich 1994)& (Aderka et al. 1992).
36
Target Effect Reference
Monocytes Directly chemotactic (Ming et al. 1987)
Enhance monocyte cytotoxicity (Philip and Epstein
1986)
Upregulate expression of itself (Philip and Epstein
1986)
Macrophages Enhance activation and anti- (Suzuki et al. 1994)
microbial activity
Neutrophils Upregulate recruitment (Lukacs et al. 1995)
Directly chemotactic (Ming et aI. 1987)
Induce NO production (Gosselin et al. 1995)
Stimulate respiratory burst (Dusi et al. 1996)
Upregulate degranulation (Klebanoff et al. 1986)
Enhance phagocytosis (Shalaby et al. 1985)
Endothelial Upregulate adhesion molecules (Neumann et al.
Cells 1996)
Disrupt integrity (Geelen et al. 1993)
Epithelial Cells Increases expression of IL-6 (Cromwell et al. 1992)
Table 1.4 Effects of TNFa on the immune response.
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1.6.1.1.5Effects of TNFa on the immune response
TNFa is a pleiotropic cytokine acting on many aspects of the immune and
inflammatory responses. This cytokine is capable of a wide range of
inflammatory effects, some of those mediated by TNFa in vitro are described
in Table 1.4.
In addition TNFa has been shown to be required for effective in vivo host
defence against a range of micro-organisms such as K. pneumoniae,
Pneumocystis carinii and Chlamydia trachomatis (Laichalk et al. 1996), (Chen
et al. 1992a)& (Williams et al. 1990). The ability of TNFa to recruit and up-
regulate the anti-bacterial activities of inflammatory cells is the likely
explanation. However, these same effects of TNFa are implicated in the
pathology occurring during systemic inflammation as TNFa neutralisation
promotes survival during Gram-positive and Gram-negative septic shock
(Hindshaw et al. 1992)& (Fang et al. 1989).
1.6.1.1.6Interleukin 1 ut-n
The initial effects attributed to Interleukin-I were the ability to induce fever,
stimulation of the acute phase response and augmentation of lymphocyte
responses (Curfs et al. 1997). It has since been discovered that there are two
forms of IL-1,IL-1a and IL-1~,the former is cell membrane associated whilst
the latter is released from cells. IL-1 is produced by a wide range of cells
including monocytes/macrophages, neutrophils, T- and B-cells, epithelial
cells and endothelial cells (Dinarello et al. 1987)& (Warner et al. 1987). It has
been shown that IL-1~is a major product of human monocytes, constituting
1-2%of the total polyadenylated RNA following LPSstimulation (Auron et
al. 1984).
Both IL-1a and IL-1~are synthesised are precursor forms. In this form IL-1a
is fully active (Mosely et al. 1987)but is not secreted, remaining intracellular
or membrane bound until death of the cell. IL-1a can also be released from
the cells by calcium dependent membrane-associated cysteine proteases called
calpains (Kobayashi et al. 1990). In contrast, the pro-form of IL-1~is inactive
until cleaved by the intracellular IL-1~converting enzyme (ICE),a member
of the cysteine protease family called caspases (proteases that cleave after an
aspartic acid residue) (Cerretti et al. 1992). Once cleaved active IL-1~ is
secreted from the cell.
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1.6.1.1.7IL-1receptors & regulation
The effects of IL-1a and ~ are mediated through 2 IL-1 receptors, the type I
receptor IL-1RItransduces a signal whereas the type II receptor IL-1RIIbinds
IL-1but does not transduce a signal, thereby antagonising IL-1's effects (Sims
et al. 1993).
IL-1'sactivities are also regulated by a third member of the IL-1family, called
IL-1receptor antagonist (IL-1Ra). This is the naturally occurring inhibitor of
IL-1 and binds to IL-1 receptors but does not induce any intracellular
response.
Soluble forms of IL-1 type I and type II receptors are formed by proteolytic
cleavage of the membrane receptors. These are found within the circulation
of healthy humans with an increase occurring during disease (Fernandez-
Botran 1999). These soluble receptors are capable of binding IL-1 and
dampening down IL-1 responses in a dose-dependent fashion (Dinarello
1997).
1.6.1.1.8Effectsof IL-l
Despite TNFa and IL-1binding to different cellular receptors, both cytokines
have multiple overlapping and synergistic activities. Those relevant to
inflammation are summarised in Table 1.5.
Effectsof IL-1during pneumococcal infection have not been widely studied.
However, IL-1has been shown to be required for resistance to both systemic
and pulmonary infectious disease caused by a range of micro-organisms such
as P. carinii and L. monocytogenes (Havell et al. 1992)& (Chen et al. 1992b).
TNFa is known to be a potent inducer of IL-1 expression (Dinarello et al.
1986)and proof of the synergy between TNFa and IL-1 in vivo was found by
Waage et al (Waage and Espevik 1988). They found that administration of
low levels of IL-1 intravenously into mice does not result in mortality whilst
TNFa treatment alone can result in 50%mortality by 72h post injection. Co-
administration of both cytokines increased mortality to 100% in the same
time frame. Similar results have since been gathered in a rabbit system by
other investigators (Okusawa et al. 1988).
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Target Effect Reference
Neutrophils Recruitment to site of (Rogers et al. 1994)
infection
Enhance adhesion to (Belvilacqua et al. 1985)
endothelium
Monocytes Increase expression of (Dinarello et al. 1987)
itself
Enhance adhesion to (Belvilacqua et al. 1985)
endothelium
Macrophage Activation (Rogers et al. 1994)
Epithelial cells Increase expression of (Cromwell et al. 1992)
IL-6
Endothelial cells Upregulation of ICAM- (Dustin et al. 1986) &
1 expression (De Caterina et al. 1995)
Increase expression of (Warner et al. 1987)
itself
Disrupt integrity (Geelen et al. 1993)
Table 1.5 Effects of IL-1on the inflammatory response.
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1.6.1.1.9 Interleukin 6 (IL-6)
IL-6was originally cloned due to its ability to induce Bcell differentiation but
has since been recognised as a product of a wide range of other cell types
including T cells, monocytes, alveolar macrophages, neutrophils, mast cells,
endothelial cells and epithelial cells (Bifflet al. 1996). As TNFa and IL-1are
major inducers of IL-6,kinetics of IL-6 release are generally slower than those
for TNFa and IL-1production (Van Damme et al. 1987).
IL-6mediates its effectsby binding to a specific receptor called IL-6R. Only a
very short portion of IL-6Ris located within the cytoplasm of cells and this
does not transduce signals. For signal transduction the associated
glycoprotein gp130 is required (Hibi et al. 1990). The current belief is that
binding of IL-6 to IL-6R is of a low affinity but interaction with gp130
stabilises this complex. IL-6itself does not have any binding specificity for
gp130.
1.6.1.1.10 Effects of IL-6
In addition to the in vitro effects in Table 1.6,there is much proof of IL-6's
activities in vivo. IL-6 deficient mice were unable to mount an
inflammatory response to localised tissue damage generated by turpentine
injection, indicating the pro-inflammatory capacity of IL-6. In contrast,
during systemic inflammation (induced by intravenous administration of
LPS) elevated inflammation results in significantly higher TNFa levels.
Such data supports an anti-inflammatory role for IL-6 (Fattori et al. 1994). In
separate models of septic shock or endotoxaemia IL-6has been ascribed both
beneficial and detrimental roles as IL-6 neutralisation can either result in
increased or decreased mortality (Barton and Jackson 1996)& (Starnes et al.
1990). Furthermore, following systemic infection with S. pneumoniae
sustained production of IL-6has been shown to be associated with elevated
mortality in a porcine model (Ziegler-heitbrock et al. 1992).
IL-6is required for a protective response in L. monocytogenes (Dalrymple et
al. 1995)and E. coli infection (Dalrymple et al. 1996)as IL-6 deficient mice are
more susceptible to these infections than are wild type animals. In contrast
IL-6 is not required for clearance of P. carinii during pulmonary infection
(Chen et al. 1993) although it does control pulmonary inflammation (by
reducing cell influx) and attenuate antibody responses during resolution.
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Target Effect Reference
Neutrophils Induces release from (Dalrymple et al. 1995)
bone marrow
Synergises with TNFa (Mullen et al. 1995)
to increase respiratory
burst
Myeloid cells Differentiation into (Shabo et al. 1988)
macrophages
Monocytes Activation (Borish et al. 1989)
B cells Promotes maturation (Hirano et al. 1986)
& differentiation
T cells Promotes (Okada et al. 1988)
differentiation into
cytotoxic T cells
Endothelial cells Increases permeability (Maruo et al. 1992)
Hepatocytes Induces expression of (Gauldie et al. 1987)
acute phase response
proteins
Table 1.6 Effects of IL-6 on the immune response.
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It therefore seems likely that the balance between IL-6 and other mediators is
crucial in determining whether IL-6 plays an inflammatory or anti-
inflammatory role and the effect on disease outcome during pneumococcal
pneumonia.
1.6.1.1.11Chemokines
Chemokines are the class of cytokines capable of direct cellular recruitment.
There are at least four chemokine families, grouped on the basis of the
position of the first two cysteine residues.
The CXC family members appear to be more closely related to acute
inflammatory reactions and are generally characterised by their ability to
initiate neutrophil influx into the tissues. This family includes IL-8,
macrophage inflammatory protein-2 (MIP-2) and granulocyte
chemoattractant protein-2 (GCP-2).
The CC chemokines appear to be primarily chemotactic for monocytes,
lymphocytes, basophils, and eosinophils. This family contains several
related proteins, including MIP-1a, MIP-1~, and regulated upon activation
normal T expressed and secreted (RANTES).
The only known member of the C family is Lymphotactin which is released
by lymphocytes and appears to act solely on T lymphocytes (Kelner et al.
1994). Fractaline is also the sole member of a "family" of chemokines, the
CXXXC and exerts its effects on neutrophils, monocytes and T lymphocytes
(Bazan et al. 1997). In contrast to the other classes of chemokines, fractaline is
mainly produced by somatic cell lines such as endothelial cells, with little or
no expression in peripheral blood monocytes, T and B cells and NK cells.
Roles in anti-bacterial defences have been ascribed to certain cytokines. MIP-
2 is able to initiate anti-bacterial activity in vitro by increasing the ability of
neutrophils to phagocytose and kill E. coli (Standiford et al. 1996). MIP-1a is
capable of similar effects on alveolar macrophages. In addition, CC
chemokine receptor 2 deficient mice display increased susceptibility to
infection with L. monocytogenes, displaying 100%mortality by 5 days post
intravenous infection whilst all wild type animals survive (Kurihara et a 1
1997). During a pulmonary model of K. pneumoniae infection, inhibition of
MIP-2 activity results in decreased neutrophil recruitment and bacterial
clearance with an increase in mortality (Greenberger et al. 1996).
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Despite these facts, roles of chemokines in pneumococcal pneumonia have
not been investigated. Indeed effects of chemokines in vivo during other
bacterial pneumonias remain poorly understood but warrant further
investigation.
1.6.1.2 Anti-inflammatory Cytokines
1.6.1.2.1 Interleukin 10 (lL-10)
IL-10was initially described as a factor produced by Th2 cells that was capable
of inhibiting cytokine release by Th1 cells (Fiorenino et al. 1989). Production
of this cytokine has since also been detected in monocytes/macrophages,
mast cells, neutrophils, epithelial cells, and B lymphocytes (O'Garra et al.
1990)& (Moore et al. 1993).
1.6.1.2.2Effects of IL-10
Interleukin 10 is a potent anti-inflammatory cytokine with a range of
activities, summarised in Table 1.7.
IL-10is constitutively expressed by bronchial epithelial cells (Bonfield et al.
1995), placing the cytokine in an ideal location to control inflammation
within normal lungs. Indeed the fact that IL-10 knockout mice
spontaneously develop enterocolitis is further evidence of IL-10's regulatory
capacity (Kuhn et al. 1993). It is currently unknown whether IL-10deficient
mice also spontaneously develop overwhelming lung inflammation,
presumably because the enterocolitis is so severe the animals do not survive
long enough.
IL-10'sability to inhibit cytokine inhibition occurs mainly via inhibition of
gene transcription (Wang et al. 1994)since IL-10is a potent inhibitor of NF-
KBactivation in human monocytes (Wang et al. 1995). In addition IL-10can
also induce cytokine mRNA degradation (Bogdan et al. 1992)& (Kasama et
al. 1994)and increase levels of cytokine soluble receptors such as p55 and p75
(Bemelmans et al. 1993).
IL-10 is also capable of down-regulating non-cytokine inflammatory
mediators, such as NO. This effect is indirect via the ability of IL-10 to down
regulate TNFa (Oswald et al. 1992).
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Target Effect Reference
Macrophage Reduce TNFa (Zisselet al. 1996) &
production (Bogdan et al. 1991)
Inhibit Microbicidal (Oswald et a1. 1992) &
activity (Fleming and Campbell
1996)
Inhibit release of (Bogdan et al. 1991)
reactive oxygen
intermediates
Inhibit release of (Bogdan et al. 1991)
reactive nitrogen
intermediates
Inhibit apoptosis (Bingisser et al. 1996)
Mast cells Inhibit TNFa (Arock and Pretolani
production 1996)
Monocyte Enhance IL-IRa (Jenkins et al. 1994)
production
Inhibit release of TNFa (Armstrong et al. 1996)
Down-regulate ICAM-l (Willems et al. 1994)
expression
Down-regulate MHC II (de Waal malefyt et al.
expression 1991)
Neutrophils Inhibit pro- (Cassatella et al. 1993)
inflammatory cytokine
release
Promote apoptosis (Cox 1996)
Down-regulate (Kasama et al. 1994)
chemokine expression
Increase IL-IRa release (Marie et al. 1996)
in response to TNFa
Endothelial cells Suppresses NO release (Koedel et al. 1996)
Table 1.7 Effects of 11-10 on the immune response.
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Recognition of IL-10'swide array of anti-inflammatory effects has led to trials
of this cytokine as a treatment during septic shock/ endotoxaemia, with
highly variable results. Marchant et al and Gerard et al found that treatment
with IL-1D reduced levels of pro-inflammatory cytokines during
experimental endotoxaemia and was required for host survival (Marchant et
al. 1994)and (Gerard et al. 1993). Conversely Remick et al found that IL-10
treatment did not alter mortality during sepsis (Remick et al. 1997). It
appears that beneficial effects are only observed if IL-10is given either before
or very early after the inflammatory stimulant (Pajkrt et al. 1997).
1.6.1.3.Detrimental effects of cytokines
It has recently been shown that outcome of sepsis or pneumococcal
pneumonia is determined not only by the magnitude of the inflammatory
response. More critical is the balance between inflammatory and anti-
inflammatory cytokines (Walley et al. 1996)& (Mohler et al. 1998). In acute
inflammation it is hypothesised that the levels of TNFa and IL-1 produced
are higher than can be neutralised by available anti-inflammatory mediators.
Inflammation then spreads to the circulation where cytokines act in an
endocrine manner inducing endothelial damage, which leads to multiple
organ failure (due to tissue hypoperfusion) and eventually death (Molloy et
al. 1993).
The importance of cytokines to these responses is highlighted by the ability of
systemic administration of TNFa or IL-1to result in many of the symptoms
of septic shock (Okusawa et al. 1988). In addition, pathology and mortality
and can be reduced by neutralisation of these cytokines either prior to shortly
after instigation of the septic shock (Remick et al. 1990)& (Hindshaw et al.
1992).
1.6.1.4Cytokine regulation
As cytokines are highly potent molecules, capable of both beneficial and
detrimental activity, their activity is tightly regulated. Regulation occurs at
several levels, including transcriptional regulation, short half lives, soluble
cytokine receptors and anti-inflammatory cytokines.
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Nuclear factors such as NF-lCBact to upregulate transcription of cytokine
genes such as those for TNFa and IL-l. NF-lCBin turn can be down-regulated
by anti-inflammatory cytokines such as IL-10 (Wang et al. 1995).As with
promoters for pro-inflammatory cytokines, the iNOS promoter has an NF-
lCBrecognition site (Xie et al. 1994)and thus NO production can be initiated
along with that of inflammatory cytokines. However, NO can also act
upstream of NF-lCBin a regulatory capacity (Walley et al. 1999). This reduces
the amount of NF-lCBavailable for binding to the regulatory region of pro-
inflammatory cytokine genes and reduces their transcription.
The presence of UA-rich sequences in the 3' untranslated region of mRN A
transcripts leads to instability and a short half-life for TNFa transcripts
(Caput et al. 1986). Such regions are also conserved in mRNA transcripts of
other pro-inflammatory cytokines including IL-1 and IFN-y.
During sepsis, expression of cell surface TNFa receptors on circulating
monocytes and granulocytes is down regulated with a corresponding increase
in soluble receptor concentrations and an increase in IL-Ra levels (Calvano et
al. 1993). In contrast to TNFa and IL-1, there does not appear to be any
specific IL-6 antagonists in vivo. Soluble IL-6R does exist but appears to
facilitate interactions with membrane bound gp130 (Rose-John and Heinrich
1994)rather than have an antagonistic effect.
1.6.1.5Microbial factors responsible for cytokine induction
Most investigations of the roles of cytokines in infectious disease concentrate
on the effect of the cytokines in controlling the micro-organisms. Less
emphasis has been placed on the possibility that the microbes induce
cytokines in order to utilise these factors for their growth/spread or at least
have adapted in order to utilise inflammatory mediators for their benefit.
For example, IL-1 has been found to increase growth of E. coli if the bacteria
are grown in sub-optimal media such as fresh serum (Porat et al. 1991).
The mechanism by which micro-organisms utilise cytokines for their growth
is currently not understood. They may be used as simple nutrients as an
effect on proliferation only occurs when the incubation occurs in nutrient
starved conditions. This appears to be unlikely, however, as heat
inactivation or antibody treatment of the cytokine blocks the enhancement
(Denis and Porat 1995).
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In addition, interaction of organisms with cytokines may result in the
formation of mediator /bacteria complexes, capable of interacting with
cytokine receptors on the surface of lung cells. Such complexes have been
shown to occur between TNFa. and Shigella flexneri and may promote
uptake of the organism in the intestine (Luo et al. 1993). A range of bacteria
have been tested for this interaction and although Gram-negative bacteria
such as S. flexneri bind TNFa. to the highest extent, Gram-positive organisms
such as Streptococcus mitis and S. aureus are also capable of binding this
cytokine.
Cytokine induction may also prove favourable for bacteria that require cells
to be activated before expressing receptors for their attachment. As
mentioned in Section 1.4.2, S. pneumoniae may attach to 2 different
receptors on the surface of resting lung cells, but only a very low percentage
of bacteria do so. Activation of lung cells via TNFa. and IL-1 causes up-
regulation of the PAF receptor and a 200-300fold increase in pneumococcal
adherence (Cundell et al. 1995). Thus pneumococci may utilise the
inflammatory response to aid their entry to the bloodstream.
A range of pneumococcal factors have been shown to induce production of
pro-inflammatory cytokines in vitro. Heat killed pneumococci and capsular
polysaccharides are capable of stimulating in vitro release of TNFa. from
macrophages (Simpson et al. 1994). The same effect has been noted for
pneumococcal lipoteichoic acid (Keller et al. 1992). In vitro data with
monocytes have shown the induction of IL-1and IL-6following stimulation
with individual cell wall constituents of pneumococci (Riesenfeld-Orn, et al.
1989)& (Heumann et al. 1994). These factors are also capable of inducing
TNFa., but require more than 100 times the amount of cell wall to do so than
for IL-1 release.
The role of pneumolysin in induction of inflammation has already been
discussed in Section 1.3.2.
1.6.1.6Pulmonary cytokine production during pneumococcal pneumonia
Since beginning these studies several reports have been published on the
production of cytokines during murine models of pneumococcal
pneumonia. Most of publications have concentrated on single cytokines,
with the balance between pro- and anti-inflammatory cytokines poorly
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understood and results often conflicting (Takashima et al. 1997)& (van der
Poll et al. 1997a). The investigations in this thesis were therefore carried out
in order to characterise this important balance and to expand data on
cytokine interactions. The following section represents a review of the
current state of art research in this field.
The importance of pro-inflammatory cytokines in host defence against S.
pneumoniae is provided indirect support by the reduced ability of transgenic
mice with impaired NF-K:Bactivity to control type 2 pneumococcal infection
(Sha et al. 1995). As mentioned in Section 1.6.1.4,NF-K:Bis a transcription
factor capable of regulating the expression of pro-inflammatory cytokines.
NF-K:Bis composed of two subunits, p50 and p65 and mice with targeted
disruptions in the p50 subunit of NF-K:Bhave recently been produced.
Infection of these mice intraperitoneally with 100CFU type 2 S. pneumoniae
resulted in reduced survival times (24h post challenge) when compared to
wild-type mice (36-72hpost challenge) (Sha et al. 1995). Furthermore high
numbers of viable pneumococci were recovered in the blood and organs
from the transgenic mice. Thus these animals were impaired in their ability
to contain and kill the bacteria within their peritoneal cavities.
Direct evidence of the involvement of cytokines in the host response to S.
pneumoniae is provided in several recent mouse models using various
strains of immunocompetent mice. The most extensive of these was
published by Bergeron et al in 1998using a model of pneumonia initiated by
infecting female CD1 mice with 107 CFU type 3 pneumococci (Bergeron et al.
1998). This caused acute inflammation with mice dying approximately 72h
post challenge. We have since found similar histological disruption and cell
recruitment with a rapid influx of neutrophils to the lungs, initially in
perivascular areas but then spreading around infected bronchioles (Kadioglu
et al. 2000). Neutrophils were progressively replaced by monocytes and low
numbers of lymphocytes at 72h to 96h post challenge.
In the Bergeron paper, this cell influx was accompanied by rapid cytokine
release. The first cytokine to be recovered in bronchoalveolar lavage fluid
was TNFa. Significantly elevated levels were detected 1h post challenge and
these continued to increase until 12h into the experiment. By 24h post
challenge levels were returning to baseline. A similar transient production
of TNFa was evident within the lung tissues. Pulmonary IL-1a levels also
reached their peak at 12h post challenge but with slower kinetics and in
lower concentrations than TNFa. IL-1a levels remained elevated within
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lung tissues from mid infection until the end of the experiment. Airway IL-6
production was biphasic, peaking very early at 4h post challenge and again at
48h post challenge. Constant levels of this cytokine were detected within the
lung tissues from 4h until the end of the experiment.
In summary Bergeron et al found (in addition to the elevated release of NO
mentioned In Section 1.5.3.5.2) initial ineffective phagocytosis of
pneumococci leading to cytokine release in bronchoalveolar lavage fluid.
This cytokine release occurred over 4-24h as pneumococci grew in the
alveoli. Following injury to alveolar structure and bacterial access to the
bloodstream, cytokine release in the lungs was downregulated.
These kinetics of cytokine production are supported by those found in other
models of pneumococcal pneumonia. Intranasal infection with either type 3
or type 19 pneumococci resulted in rapid production of TNFa. within the
lungs (van der Poll et al. 1997a)& (Takashima et al. 1997).
Although investigation of both host pro- and anti-inflammatory responses
has not previously been carried out, van der Poll et al have characterised the
production of IL-10during pneumococcal pneumonia (van der Poll et al.
1996). They found elevated levels of IL-10from 12h post challenge but peak
production did not occur until 72h post challenge.
1.6.1.7Systemic cytokine production during pneumococcal pneumonia
Bergeron et al also investigated the systemic production of cytokines in their
model of pneumococcal pneumonia (Bergeron et al. 1998). It was found that
TNFa levels in serum increased towards the end of the experiment as
bacteria gained access to the bloodstream. IL-1a. levels increased very
transiently at 12h post challenge, at the same time point as maximum lung
levels were detected. This may indicate that systemic detection was the result
of overspill from the lungs. IL-6levels were found to increase during early
infection (4h post challenge) and again with increasing magnitude towards
the end of the experiment, correlating well with bacterial loads.
Other investigators in this field have found similar results for systemic
TNFa kinetics but have reported highly variable amounts (van der Poll et al.
1997a),supported by similar variability in human investigations (Marks et al.
1990).
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The rapidity and sustained nature of IL-6production within the circulation
has also been reported by van der Poll et al (van der Poll et al. 1997b).
Serum IFNy levels have been found to correlate well with the degree of
bacteraemia and the severity of illness (Rubins and Pomeroy 1997).
However, in these experiments mice surviving until 72h post challenge with
either serotype I, 2, 3 or 4 pneumococci possessed the lowest IFNy levels
despite elevated bacteraemia.
1.6.1.8Effects of cytokines during pneumococcal pneumonia
By altering levels of individual cytokines during the infection, either by
antibody neutralisation or utilisation of transgenic mice, it is possible to
discover the roles played by these mediators.
Systemic neutralisation of TNFa. has been found to result in elevated
bacterial loads and increased mortality following subsequent infection with
S. pneumoniae (van der Poll et al. 1997) & (Takashima et al. 1997).
Contradictory reasons for these effects of TNFa. have, however been
reported. van der Poll et al found that TNFa. neutralisation in combination
with infection with type 3 pneumococci resulted in significantly elevated
pulmonary bacterial loads but bacteraemia was unaffected. In addition, anti-
TNFa. treatment reduced IL-l~ levels but had no effect on IL-6, IL-I0 or IFN-y
levels or neutrophil recruitment to the lungs (van der Poll et al. 1997). Thus
the authors hypothesised that TNFa. was required in order to increase the
anti-bacterial activity of resident host cells during pneumococcal pneumonia
but did not recruit additional cells to the site of infection.
In contrast Takashima et al found that neutralisation of TNFa. prior to
infection with type 19 pneumococci did not affect pulmonary bacterial loads
but did significantly increase levels of bacteraemia (Takashima et al. 1997).
Furthermore significantly lower numbers of circulating neutrophils were
found following TNFa. neutralisation. This data indicates that TNFa. is
responsible for increasing circulating neutrophil numbers during
pneumococcal pneumonia and these prevent overwhelming bacteraemia.
This conflicting data prompted us to investigate what role, if any TNFa. was
exerting during our model of pneumococcal pneumonia (Chapter 4).
Although most previous research has been aimed at identifying the role of
TNFa. during pneumococcal pneumonia, the effects of other cytokine have
also been investigated. Intranasal infection of mice deficient in IL-6 results
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in a six fold increase in bacterial loads and a higher mortality rate during
pneumococcal infection (van der Poll et al. 1997b). This was evident despite
higher levels of pulmonary TNF, IL-1~ and IFNy at the end of the infection
(highlighting the importance of pro-inflammatory cytokines during early
infection but not at end-stage disease).
Interferon gamma knockout mice are significantly more susceptible to
infection with type 2 pneumococci than their wild-type counterparts with an
LDso20-fold lower (2.50 x 106 and 5.00 x 107 CFU respectively) (Rubins and
Pomeroy 1997),likely to be due to the ability of IFNy to increase neutrophil
phagocytosis.
Finally, antibody neutralisation of IL-10 2h prior to intranasal infection with
106 CPU type 3 pneumococci has been shown to result in increased
pulmonary TNFa and IFNy levels, with a corresponding six-fold decrease in
pulmonary and systemic bacterial loads and increased survival. Pre-
treatment with recombinant IL-10had the opposite effects (van der Poll et al.
1996).This indicates that overly high levels of IL-10 during pneumococcal
pneumonia reduce the levels of pro-inflammatory cytokines, permitting
greater bacterial loads and ultimately reduced host survival.
Thus there are many possible interactions and roles of inflammatory
mediators during pneumococcal pneumonia and other inflammatory
responses. Recognition of this fact led us to investigate the production of
both inflammatory (TNF, IL-1~,IL-6and NO) and anti-inflammatory (IL-10)
mediators following infection with a well characterised and utilised
laboratory strain of pneumococci. Both an outbred mouse strain
(presumably containing a wide range of genetic backgrounds) as well as in
two inbred mouse strains (differing significantly in their susceptibility to
pneumococcal pneumonia) were used. It was hypothesised that this would
characterise the balance between inflammatory and anti-inflammatory
cytokine production kinetics in a typical population. In addition it permitted
investigation of the "ideal" inflammatory response that occurs if subjects are
to control the infection. We were also able to characterise the host response
in mice that were overcome by the infection. By comparing these it was
possible to identify differences in the early response to pneumococcal
pneumonia that may be responsible for the significantly different
susceptibili ties.
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MATERIALS AND METHODS
All chemicals were purchased from Sigma-Aldrich, Dorset, UK unless
otherwise stated.
2.1 Mouse strains
The mouse strains used in these studies are listed in Table 1.
BALB/c scid mice were bred and housed in isolators within the central
research facility (CRF) at the University of Glasgow. On infection these mice
were moved into filter top cages. All other strains of mice obtained from the
Department of Immunology were bred and housed in filter top cages.
Mouse rooms were maintained at 21"C +l : TC and 55-65 % relative
humidity with 12h artificial light from 0700 to 1900h. Mice were fed pelleted
rat and mouse standard diet (B&K Universal, North Humberside, England).
Both water and food were administered on an ad libitum basis and in the
case of iNOS -/-, MF1/129, BALB/c scid and TNFa receptor deficient mice
these were irradiated
In order to allow acclimatisation, mice from commercial suppliers were kept
in the CRF for a period of at least one week prior to use.
2.2 Microbiological techniques
2.2.1 Bacterial stock preparation
Streptococcus pneumoniae D39, serotype 2, was obtained from the National
Collection of Type Cultures (NCTC 7466; Central Public Health Laboratory,
London). Bacteria were grown on Blood Agar Base Number 2 (Oxoid,
Basingstoke, UK) plus 5% (vol/vol) defibrinated horse blood (E&O
Laboratories, Bonnybridge, UK) (BAB). Stock cultures were prepared by
inoculating a sweep of 4-5 colonies into 25ml Brain-Heart Infusion broth
(BHI, Oxoid). Cultures were grown statically at 37°C overnight before 1ml
aliquots containing 15% sterile glycerol were frozen at -70°C until use. Strain
validation was carried out by confirming sensitivity to the antibiotic
Optochin (Difco, Detroit, USA). Serotype verification was performed by
checking for the presence of type specific polysaccharide capsule using anti-
type 2 capsule antiserum (Statens Seruminstitut, Copenhagen, Denmark).
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Mouse Genetic Inbred/ Age (wks) Weight Gender
Strain Background outbred (g)
MF1 a MF1 Outbred young adults 25-30 Female
8-16
aged adults 55-75 Female
52
iNOS MF1/129 Outbred 8-11 20-25 Female
knockouts d
iNOS MF1/129 Outbred 8-11 20-25 Female
controls d
CBA/caa CBA/Ca Inbred 9-12 15-20 Female
BALB/ ca,b,c BALB/c Inbred 9-12 20-25 Female
BALB/c scid BALB/c Inbred 9-12 20-25 Female
e & Male
TNFa. C57Bl/6 Inbred 11-17 25-30 Female
receptor & Male
knockouts
(p55 & p75)
f
p55 & p75 C57Bl/6 Inbred 10-16 20-25 Female
controls= & Male
Table 2.1 Mouse strains used in infection studies.
awere purchased from Harlan Olac (Bicester, UK), bwere purchased from
Charles River UK Ltd (Kent, UK), cwere obtained from CRF own stock,
dwere obtained from Professor F.Y. Liew, ewere obtained from Dr P.
Garside, fwere obtained from Dr A. Mowat, Department of Immunology,
University of Glasgow.
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2.2.2 Viable counting of Streptococcus pneumoniae
As previously described (Kadioglu et al. 2000), serial dilutions of samples
were prepared by the addition of 20~1 to 180~1 sterile PBS (Appendix) in
sterile round bottomed 96 well microtitre plates (Life Technologies, Paisley,
UK). With smaller samples (such as tail bleeds) 10~1of sample were mixed
with 90~1 PBS then 20~1 of this serially diluted as before. Lavage fluid and
lung homogenate sample dilutions were continued to 10-5with undiluted
sample also plated out. All other samples were plated out in the range of 10-1
to 10-6•
Dry BABplates were marked into 6 sectors and 3 x 20~1of each dilution were
plated on one sector. This procedure was done in duplicate and repeated for
each dilution. The plates were allowed to dry before being incubated
overnight at 37°C. Colonies were counted in the sector that had between 40-
200 colonies on each spot for the lowest dilution The following equation was
used to calculate the number of colony forming units per ml of sample:
CFU per ml = Mean number of colonies per sector x 50 x Dilution
Factor.
These methods resulted in a detection limit of 8.33 pneumococci per ml lung
sample and 83.3 pneumococci per ml of other samples.
2.2.3Growth characteristics
In order to prepare the starting culture, aliquots of stock bacteria were thawed
quickly in a water bath at 37°C and 900J.l,1of each centrifuged at 13,000rpm
(Eppendorf centrifuge 5417C) for 3min before resuspending in 900J.l,1sterile
PBS. An appropriate volume was added to 20ml BHI with 20% v tv heat
inactivated FCS (Life Technologies, Paisley, UK) to give a starting Optical
Density at 600nm of 0.04. Cultures were grown statically at 37°C and every
hour the OD6oo and a count of colony forming units was determined. From
this data the OD6oo at which the bacteria were in mid-log phase was
determined.
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2.3 In vivo techniques
2.3.1Telemetry chip implantation
Telemetry chips (Minimitter, Oregon, USA) were sterilised by immersion in
Cidex™ (johnston & Johnston Medical Limited, Skipton, UK) for 10min and
then rinsed twice in sterile distilled water.
1-2 weeks prior to bacterial challenge, mice to be implanted were lightly
anaesthetised with 2.5% v/v Halothane (Zeneca Pharmaceuticals,
Macclesfield, UK) over oxygen (1.5 L/min), administered using a calibrated
vaporiser and anaesthesia confirmed by observing no pinch reflex reaction.
The abdomen was shaved and the mouse placed on a sterile drape upon a
heat mat. The mice were then deeply anaesthetised with 3-5% v Iv
Halothane over oxygen (1.5 L/min), administered using a calibrated
vaporiser.
A sterile scalpel was used to make the initial incision in the abdomen and
the peritoneum opened with sterile scissors. The telemetry chip was placed
inside the peritoneum and the inner wound fastened using 5-0 Dexon II
suture (Cyanamid of Gt. Britain Ltd, Hampshire, UK). The outer wound was
fastened using surgical clips (Becton Dickinson). Mice were placed in a cage
warmed from below by a heat mat and left to recover for several hours before
being returned to normal housing conditions. Implanted mice were
weighed every day and their wounds inspected to ensure total recovery from
surgery. Any mice that displayed continued weight loss for three days were
fed on human baby food (Boots, Nottingham, UK) until their weight
returned to normal. One week after surgery the outer clips were removed
but the weighing continued until the end of the experiment.
Telemetry readings were gathered using the VitalView® data acquisition
system. The implanted chip captures energy from the field of radio waves
generated by the coils of an energiser/receiver box placed underneath each
individually caged animal. The powered chip emits a signal and the
frequency of this signal informs the receiver box of the core body
temperature and activity of the animal. The VitalView® software gathers
the information and presents the data for each individual animal. Data can
then be transferred into appropriate software packages for statistical
evaluation.
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2.3.2 Preparation of bacterial inoculum
Standard inoculum was prepared as previously described by this laboratory
with minor modifications (Canvin et al. 1995). 100).11of sterile PBS
containing approximately 105CFU were injected into the peritoneal cavity of
mice with an insulin syringe (F. Baker Scientific, Runcorn, UK). On
development of lethargy, mice were culled by cervical dislocation, the chest
cavity carefully opened up and a section of ribcage removed in order to
provide access to the heart. A 23 gauge needle was inserted into the right
ventricle and blood slowly collected into the attached syringe. 50).11of
infected blood was used to grow passaged bacteria in 10ml BHI statically
overnight at 37°C. Bacteria were harvested by centrifugation at 3,000 rpm for
10min (Heraeus medifuge), resuspended in fresh BHI containing 20% v/v
FCS to an A600of 0.04, and then incubated at 37°C until they reached mid-log
phase (as judged by optical density). 1ml aliquots of the suspension were
stored at -70°C, until required. After 24h at -70°C viability of the suspension
was measured by viable counting and optochin sensitivity was confirmed.
Viability was unaffected by storage at -70°C for at least 3 months.
2.3.3 Intranasal infection of mice
Aliquots of standard inoculum were rapidly thawed. A 900).11sample was
pelleted by centrifugation at 13,000rpm (Eppendorf centrifuge 5417C) and
resuspended in 900).11sterile PBS. Bacteria were diluted in sterile PBS to give
1 x 106 CFU/50).11(unless otherwise stated) and this confirmed by viable
counting (as described previously).
For experiments with heat-killed pneumococci, a preparation of bacteria was
prepared as above and then placed in a 60°C water bath for 10min. The
viable count was then re-determined.
In order to inoculate the bacteria, mice were lightly anaesthetised as described
prior to abdomen shaving in Section 2.3.1 (Kadioglu et al. 2000). Halothane
was used due to its rapid recovery time (approximately 5 min) and its ability
to depress pulmonary mucociliary clearance mechanisms, thereby aiding
infection (Forbes 1976). Once anaesthetised the animals were scruffed, with
the nose held upright, and pneumococci introduced intranasally by adding a
series of small droplets of the 50).1Linoculum in to the nostril for the mice to
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involuntarily inhale. After inoculation the mice were laid on their backs
until recovery and the viable count of the inoculum was re-determined.
To assess whether this procedure itself induced an inflammatory response,
some mice were inoculated intranasally with 50~1of PBSalone.
2.3.4Intravenous infection of mice
Mice to be infected were placed in a heated, ventilated perspex box for 5min
before bleeding. The animal was then placed in a ventilated tube and the
infectious dose as a 50JlIvolume was administered into the lateral tail vein
via an insulin syringe (Wolfensohn and Lloyd 1995). A blood sample was
then removed from a separate vein (see below) in order to determine the
initial level of bacteraemia.
2.3.5 Survival experiments
Experiments designed for survival data involved infecting groups of mice
and then monitoring them frequently between ISh (signs of illness were not
apparent prior to this time point) and 336h post challenge (or until the mice
became moribund (Toth 1997)at which point the experiment was ended).
Signs of illness were recorded on a "pain-score" system devised by the this
laboratory. This system grades the progression from normality through mild
and severe hunched stance, mild and severe piloerection and mild and
severe lethargy to the moribund state. In experiments where mice were
actively culled the time of reaching moribund was taken as the time of death.
2.3.6Tail bleeding mice
Mice to be bled were warmed as for intravenous infection. An insulin
syringe was used to remove up to 100~1of blood. Collected samples were
placed on ice until processing.
2.3.7Blood sampling for bacterial loads from sacrificed mice
At pre-chosen intervals after infection, randomly determined groups of mice
were carefully sacrificedby cervical dislocation as to ensure an intact trachea.
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The chest cavity was opened up and blood removed as for preparation of
standard inoculum (see above). The samples were kept on ice prior to viable
counting as previously described.
2.3.8 Serum sampling for cytokines
Blood samples were removed as for bacterial loads. The samples were then
left to clot for 30 min at room temperature (van der Poll et al. 1996) before
being centrifuged at 6,OOOrpm(Eppendorf centrifuge 5417C). Serum was
stored at -70°C until use.
2.3.9 Sampling lungs for bacterial loads
In order to carry out bronchoalveolar lavage, the skin and muscles above the
trachea were separated and a section of the ribcage was removed in order to
allow expansion of the lungs. Lavage was carried out in a similar manner to
that used by Van der Poll et al (van der Poll et al. 1996), the trachea was
clamped with a pair of Spencer-Wells forceps (Fisher Scientific,
Loughborough, UK) in order to prevent fluid flowing up the trachea. A 16
gauge non-pyrogenic angiocath (F. Baker Scientific) was inserted into the
trachea and lavage was carried out with 2 x 1ml volumes of PBS. The usual
recovery volume was 1.25 - 1.50 ml per mouse. For CBA/ca mice, the
smaller lung size meant 2 x 0.75ml volumes of PBS were used. This
generated between 0.80 - 1.00 ml lavage fluid per mouse. A small aliquot of
this fluid was placed on ice for bacterial counts prior to snap freezing the
remainder for cytokine analysis (see below).
The lavaged lungs were then removed and placed in 5ml sterile PBS with
homogenisation carried out using a glass handheld tissue homogeniser
(Jencons, Leighton Buzzard, UK). The viable count for the recovered lavage
fluid and lung homogenates were then determined as previously.
In order to investigate the contribution of bloodborne pneumococci to lung
bacterial loads, perfusion of blood from the lung tissues was carried out in
one experiment. This involved rupturing the left atrium prior to insertion
of a syringe containing Sml non-pyrogenic saline into the right ventricle.
The syringe contents were slowly injected into the heart and the resulting
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fluid was allowed to drain from the left ventricle. The perfused lungs were
then rapidly removed as previously described.
2.3.10Alveolar cell recovery
For BALB/c cell recovery experiments lavage was carried out during late
afternoon in order to prevent firm adherence by erythrocytes in addition to
airway cells. Lavage volume was increased to 5 x 1ml aliquots of non-
pyrogenic saline (Baxter Healthcare Ltd Norfolk, UK), resulting in 4.0 -
4.25ml fluid recovered per mouse. For CBA/Ca cell sampling, 5 x 0.75ml
volumes were instilled this gave 3.0-3.25mlper animal. In order to prevent
cell adherence to the collection tube, the recovered fluid was kept on ice at all
times.
2.3.11Sampling lungs for cytokines
Bronchoalveolar lavage was carried out as above but in this case the fluid
was collected into a sterile cryotube (Sarstedt, Leicester, UK) before
immersion in liquid nitrogen. Following lavage, the lungs were removed
and wrapped in aluminium foil and also snap-frozen in liquid nitrogen.
Both bronchoalveolar lavage fluid and whole lavaged lung samples were
stored at -70°Cuntil further processing.
2.3.12Processing of lung samples for cytokines
On thawing, the whole lungs were weighed and then homogenised as
previously. Following the protocol by van der Poll et al (van der Poll et al.
1996),homogenates were centrifuged at 1600gfor 30min at 4°C to remove cell
debris. The cell-free supernatants were then centrifuged at 5000g (Sigma
4K15centrifuge) for 30 min at 4°C after which the supernatants were filter
sterilised (0.2J.lM,Gelman Sciences,Northampton, UK) and stored at -70°C.
Once thawed, lavage fluid samples were centrifuged at 13,000 rpm
(Eppendorf centrifuge 5417C)for 3 min in order to remove any cells present
before cytokine determination was carried out
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2.3.13Sampling of lungs for histological analysis
Mice chosen for histological analysis were carefully culled and the ribcage
opened, trachea clamped and a catheter inserted as above. The lungs were
then inflated with 1ml (CBA/Ca mouse lungs were fixed with 0.75ml) formal
saline (Appendix) in order to improve clarity of histologic lesions (Wood Jr
1940). The lungs were removed intact and placed in 5ml formal saline in a
plastic bijoux. A piece of tissue paper was then placed at the top of the fluid
in order to ensure that the lungs remained submerged at all times.
Following 48h in fixative, the heart and trachea were removed.
2.4Histological techniques
2.4.1Basic histological analysis
After two weeks in preservative lungs were removed, embedded in paraffin
and blocked utilising standard histological protocols by either Ms J. Hope or
Miss C. Macleod at the Glasgow Dental Hospital and School or by the
Glasgow veterinary pathology department.
Lung blocks were sectioned at 5~m prior to staining with haematoxylin and
1% eosin.
Histopathology was scored blind using Table 2.2 (adapted from (Bergeron et
al. 1998)):
2.4.2Mast cell staining
Mast cell staining was performed by Miss Y. Paterson at the University of
Glasgow. The lung sections were initially warmed to 56 QCfor 1hr followed
by 2 x 5min washes in Histoclear (National Diagnostics, Georgia, USA) and 2
x 5min washes in 100%ethanol. The sections were then rinsed in each of the
following for 2min, 90%ethanol, 70%ethanol, 50% ethanol and finally tap
water. The slides were then left in 0.5 % Toluidine blue (National
Diagnostics, Appendix) for 24h before being rinsed in 0.7N hydrochloric acid
and stained in 0.5% safranine 0 (Appendix) for 10min. Background
counterstain was removed by rapid submersion in each of 70% ethanol, 90%
ethanol, 2 x 100%ethanol and finally Histoclear for Imin. Slides were then
mounted with Histomount and left to set.
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Parameter Score Interpretation
Inflamma tory 0 No neutrophils, lymphocytes, or
Cells eosinophils in alveoli and lung tissue;
normal amount of alveolar macrophages
1 Slight increase in the number of any
inflammatory cell population
2 Recruitment of a large number of
inflammatory cells
Haemorrhage 0 No erythrocytes in alveoli
1 Few erythrocytes in alveoli
2 Numerous erythrocytes
Oedema 0 Absent
1 Minimal swelling of tissue interstitium
2 Widespread swelling of tissue
interstitium
Tissue injury 0 Absent
1 Minimal modification in alveolar
architecture
2 Widespread disorganisation of lung
tissue, including epithelial hyperplasia
Table 2.2 Scoring grid for histopathologic examination of lung tissue.
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2.4.3 Immunohistochemistry
Immunohistochemistry was carried out by Miss C. MacLeod at the Glasgow
Dental Hospital and School, utilising the following procedure. Lung sections
were deparafinised in xylene and rehydrated and graded through ethanol
(99% and 95%) before being washed with distilled water and then treated
with 3% hydrogen peroxide in methanol for 15min.
The sections were again washed with distilled water before being
microwaved three times in 0.1M EDTA for 5 min. Sections were allowed to
cool to room temperature and then washed in PBS for 5 minutes. Blocking
serum was prepared by adding three drops of rabbit serum to 10ml PBS,200JlI
of blocker were added to each slide followed by an incubation at room
temperature for 20min.
Blocking serum was replaced by primary antibody diluted in PBS/blocking
serum to a pre-determined optimal titration (see below), this was left
overnight at 4°C or for 1-2h at room temperature. The slides were then
washed in PBS/ 0.01% Tween (v/v) for 5min and in PBS alone for an
additional 5min.
A biotinylated anti-mouse IgG (Vectastain, Vector Laboratories,
Peterborough, UK)was prepared by adding 1 drop to 10ml rabbit serum/PBS
(prepared as above). 200JlI of prepared antibody were placed on each slide
and incubated for 30min at room temperature.
An alkaline phosphatase/anti phosphatase HRP complex (Vectastain A/B
mix, Vector Laboratories) was prepared according to manufacturers
instructions by the addition of 2 drops solution A and 2 drops solution B to
5ml PBSwith a 30min incubation at room temperature prior to use. Sections
were washed twice in PBS/ Tween for 5min and once in PBS for 5min before
addition of 200JlI A/B mix and an additional incubation at room
temperature for 30min.
A further 2 x 5min washes in PBS/Tween were followed by a single wash in
PBS alone for 5 min before the addition of 200JlI developing solution.
Developer (Fast Red TR Napthol AS Mix) was prepared by dissolving one
Tris buffer tablet in 10ml distilled water before dissolving one Fast Red TR
Napthol AS tablet. This was left on slides for 15-30min at room temperature,
or until a signal was detected.
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Sections were then washed twice in distilled water before being counter
stained in Haematoxylin for 10min and mounted with Aquamount (Merck
Ltd, Leicestershire, UK)
The optimal titrations of primary antibodies were as follows:
Rat anti mouse IL-IO monoclonal (Endogen Cat. No. MM-OIO-S, TCS
biologicals, UK) 1/100 dilution. This antibody is of the JES-2A5clone specific
for mouse IL-IO.
Rat anti-mouse TNFa. monoclonal (Serotec Ltd, Oxford, UK Cat. No.
MCA1487)1/50 dilution. This antibody is of the MP6-XT3clone specific for
murine TNFa..
Rat anti-mouse PMN (Serotec Cat No. MCA7719) 1/100 dilution. This
antibody of the 7/4 clone recognises a polymorphic 40kD antigen expressed by
polymorphonuclear cell, but absent on macrophages.
2.5 Immunological techniques
In each assay samples were run either in duplicate or triplicate, as stated in
the method. Actual measurements were determined by comparing the
mean sample absorbance to the standard curve.
2.5.1Detection of TNFa.by Quantikine™ ELISAkit from R&D Systems
Following the protocol supplied with the kit, the required number of wells
were placed in the plate frame and SOIlIof assay diluent RD1Wadded to each
well. The standard curve was prepared by reconstitution of the mouse INF-
o. standard with calibrator diluent RD5T to give a standards with
concentrations of 1500-23.44pg/ml. Unused standard was aliquoted into
single use volumes and frozen at -70°C until required. The batch specific
control was resuspended as directed in distilled water and excess stored as
single use aliquots frozen at -70°C. 50111of standard, control or undulate
sample were added to the wells in duplicate with calibrator diluent serving
as the zero standard. Well contents were mixed by gentle tapping and the
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plate was covered with an adhesive strip and incubated at room temperature
for 2hrs.
Wells were then emptied and washed for a total of S washes using diluted
wash buffer. The anti-mouse TNF-a conjugate was diluted in conjugate
diluent and 100J.lIadded to each well, the plate was covered with a fresh
adhesive strip and incubated at room temperature for 2hrs.
The wash step was repeated prior to addition of 100J.lIof substrate (prepared
by mixing equal volumes of colour reagents A and B) to each well and the
plate incubated in the dark for 30min to allow the colour change to occur.
Colour development was stopped by the addition of 100111stop solution to
each well. The A4S0 nm was read with correction at AS70 using a Dynatech
MRX ELISA reader with Biolinx 2.21™ software.
2.5.2 Detection of IL-lP by Quantikine™ ELISA kit from R&D Systems
Following the protocol supplied with the kit. The required number of wells
were placed in the plate frame and SOIlIof assay diluent RD1-14 added to each
well. IL-1P standard curve was prepared by reconstitution of the mouse IL-1P
standard with calibrator diluent RDST to give a standards with
concentrations of SOO-7.5pg/ml. The remainder of the standard was
aliquoted into single use volumes and frozen at -70°C until required. A
batch specific control was resuspended as directed in distilled water and
unused control stored as single use aliquots at -70°C. Lavage fluid were
diluted 1 in 2 and lung homogenates 1 in 4 in calibrator diluent before the
addition of SOIlI of standard, control or sample in duplicate to the wells.
Calibrator diluent served as the zero standard. The plate was tapped gently to
mix the well contents and covered with an adhesive strip and incubated at
room temperature for 2 hrs.
The wells were emptied and washed for a total of S washes using diluted
wash buffer. An anti-mouse IL-1P conjugate was diluted in conjugate
diluent and lOOll1added to each well before covering the plate with a fresh
adhesive strip and incubating it at room temperature for 2 hrs.
The wells were then emptied and washed as above. Substrate was prepared
(by mixing equal volumes of colour reagents A and B), and 100J.lIadded to
each well and the plate incubated in the dark for 30min to allow the colour
change to occur. Colour development was stopped by the addition of lOOJ.lI
59
Chapter 2 Materials and Methods
stop solution to each well. The A4sonm was read with correction at AS70
using an MRXELISAreader.
2.5.3 Detection of IL-6by ELISA
A sandwich ELISAwas performed to detect IL-6 in samples. Plastic flat-
bottomed 96-well maxisorb™ plates (Life Technologies) were coated with
50111per well of a 2.0Ilg/ml preparation of the purified anti-mouse mAb to
IL-6 (Pharmingen Cat No.1807lD, Becton Dickinson) in coating buffer
(Appendix), sealed with cling-film to prevent evaporation and incubated
overnight at 4°C.
Wells were then emptied and unbound areas blocked by the addition of
200lliblocking buffer (Appendix) at room temperature for 2h.
Blocking buffer was removed from all wells and the plates were washed 3
times with PBS/0.05% polyoxyethylenesorbitan monolaurate (Tween 20).
The recombinant murine IL-6standards (Pharmingen Cat No. 19251V) were
prepared in blocking buffer/Tween (Appendix) in the range of 10U/ml - 0.04
U/ml. Lavage fluids were diluted 1 in 2 and lung homogenates 1 in 4 in
blocking buffer /Tween prior to the addition of lOOll1of standard or sample in
duplicate. Plates were then incubated at room temperature for 2h or for l6h
at 4°C.
Plates were washed 4 times with wash buffer and lOOll1of a 1.01lg/ml
solution of biotinylated anti-mouse mAb to IL-6 (Pharmingen Cat
No.18082D)was added, followed by a 1h incubation at room temperature.
Following 4 washes with wash buffer, lOOll1streptavidin-HRP (1/2000 dil of
Genzyme Cat No. 80-3546-03)was added for 30min at room temperature.
After 5 washes with wash buffer, specifically bound IL-6was visualised with
lOOll1of ELISA substrate (Appendix). Plates were incubated in the dark at
room temperature for 30min and the reaction stopped by addition of 100111
1M H2S04, A4s0was determined by reading the plates on an MRX ELISA
plate reader with correction set at As7o.
2.5.4 Detection of IL-tOby ELISA
Plastic flat-bottomed 96-well maxisorb™ plates (Life Technologies) were
coated with 100111per well of a 4.0Ilg/ml preparation of the purified anti-
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mouse mAb to IL-10 (Genzyme, Kent, UK Cat No. 80-4858-02) in coating
buffer (Appendix), sealed with cling-film and incubated overnight at 4°C.
Plates were washed 3 times with PBS/0.05% Tween 20 and unbound areas
blocked with 250111blocking buffer (Appendix) at 37°C for 2h.
The recombinant murine IL-10 standards (1600-0pg/ml, Genzyme, Cat No.
80-4857-02)were prepared in standard diluent (Appendix). Blocking buffer
was removed from all wells before addition of lOOll1of standard in duplicate.
50111of standard diluent were added the remaining wells before addition of
50111sample (resulting in a 1 in 2 dilution) in duplicate and plates incubated
at 37°C for 2h. From this point on all solutions were made up in standard
diluent.
Plates were washed 4 times with wash buffer and lOOll1of a 0.2Ilg/ml
solution of biotinylated anti-mouse mAb to IL-10 (Genzyme Cat No. 80-4862-
02) was added, followed by a 1h incubation at 37°C.
Following 4 washes with wash buffer, 100111streptavidin-HRP (1/2000 dil of
Genzyme Cat No. 80-3546-03)was added for 30min at 37°C.
After 5 washes with wash buffer, specifically bound IL-10was visualised with
100111of ELISA substrate (Appendix). Plates were incubated in the dark at
room temperature for 30min and the reaction stopped by addition of lOOll1
1M H2S04. A4s0was determined by reading the plates on an MRX ELISA
plate reader with correction set at As7o.
2.5.5 Nitric oxide determination
Nitric Oxide (NO) has a half-life of only milliseconds before being oxidised to
nitrite (N02-) and nitrate N03-). Both N02- and N03- are more stable forms
and can be measured in serum as an indication of NO production. Nitrate
levels in samples were determined using the conversion assay described by
Moncada (Moncada et al. 1991). The degree of conversion was assessed by the
Greiss reaction (Migliorini et al. 1991).
Standards of both N02- and N03- were prepared in the range 400llM to
6.251lMby diluting a O.lM stock solution of NaN02 and NaN03 respectively
in distilled water. 30111of standard, sample or blank (dH20 ) were added to
the wells of a flat bottomed 96 well micro titre plate (Life Technologies) in
duplicate and then 30111of conversion buffer (Appendix) added. Plates were
incubated at 37°C for 2h and then 60111of Greiss solution (Appendix) was
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added. After 10min at room temperature the plate was read in an MRX
ELISAplate reader at 540nm. NO levels were determined from the nitrite
standard curve with the nitrate standard curve utilised to ensure proper
conversion had taken place.
2.5.6 Total protein determination
Total protein measurements were determined via the Bradford assay
(Bradford 1976). Standard curves were prepared by the dilution of a 2mg/ml
stock solution of BSA in PBS giving a range from 1500llg/ml - 62.5Jlg/ml.
10111of sample, standard or PBS (blank) were added to the wells of a flat
bottomed 96well plate. 200Jllof Bradford's reagent were then added to each
well and the plate incubated at room temperature for 10 min. Colour
development was determined at 570nm on an MRX ELISA plate reader.
Total protein levels within the samples were calculated by comparison to the
standard curve.
2.6Tissue culture methods
2.6.1 Standard passage of L929 cells
The L929 mouse connective tissue cell line was purchased from the
European Collection of Animal Cell Cultures (ECACC,No. 85011425). Once
flasks reached confluency the flasks were left one more day before removing
the growth media (RPMI 1640 plus 10% heat inactivated FCS, 50 IV/ml
penicillin and 50Jlg/ml streptomycin) and washing the cells by the addition
of 10ml sterile PBS. On removal of this, 1ml trypsin/EDT A (Life
Technologies) was added, the cells coated and excess discarded. The flasks
were incubated at 37°C and 5% CO2until the monolayer began to lift from
the flask (usually 5-10min) The cells were the resuspended in 10ml fresh
media. 2ml of the resulting suspension were used to inoculate 18ml of fresh
media. The caps were loosely closed and the flasks incubated at 37°Cand 5%
CO2,
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2.6.2 Cryopreservation of mammalian cells
Once the cells became confluent the cells were trypsinised (as described
above) and resuspended in freeze media (normal medium with 10% v Iv
DMSO). The cells were aliquoted into 1ml volumes in sterile cryotubes and
frozen to -70°C at a rate of 1°C/min by placing them in a box surrounded
with isopropanol (Mr Prosty'P' Fisher Scientific) in a -70°C freezer. Cells
were then transferred to a liquid nitrogen store.
2.6.3 Recovery of cells from liquid nitrogen storage
A vial of cells was removed from liquid nitrogen storage and defrosted
quickly at 37°C by immersion in a water bath after loosening off the lid. The
tube was the swabbed with 80% industrial methylated spirits to ensure
sterility. The cells were resuspended in 10ml growth medium and pelleted
by centrifugation at 1000rpm (Sigma 4K1S centrifuge) for 10min. The
supernatant was discarded and the pellet resuspended in Sml growth
medium, transferred to a (25 cm-) flask and incubated at 37°C and 5% CO2,
2.6.4 TNF bioassay
A TNF bioassay was developed and optimised from a method routinely run
at AstraZeneca pharmaceuticals, and published cytotoxicity assays (Levesque
et al. 1995) and (Coote and Arain 1995). This assay was based upon the ability
of TNF to cause cytotoxicity on fibroblast cells. Cell death was assessed by the
inability of cell mitochondria to breakdown MTT (3-[4,S-Dimethylthiazol-
2y1]-2-S, diphenyltetrazolium bromide) into a formazan product.
During late afternoon (in order prevent target cells from proliferating to an
unusable level before the addition of samples), flasks were trypsinised as
above and viable cells counted using SOOIlItrypan blue, 300lli media and
200111cells. This was left for 5min before counting the cells in an improved
Neubauer chamber. The number of cells was adjusted to 3x10s/ml in media
and 200lli of this suspension was added to each well of a flat bottomed 96
well tissue culture plate.
Following an overnight incubation at 37°C and 5% COz,the media was
removed from all wells and replaced by 50111of a 20llg/ml solution of
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Actinomycin D in PBS (to prevent L929 multiplication in wells without TNF
activity). The TNFa standard was diluted 1/3 in media giving a range of
concentrations from 2500 V/ml to 0.014 V/ml. Samples were subjected to 3 x
1/3 dilutions in media as well as being tested undiluted (for serum, the
volumes recovered meant that samples were already diluted 1/15 before
being tested in this assay). 25J,1Lof TNFa standard or sample was then added
in triplicate to the appropriate wells with 25J,11of media were added in
triplicate to separate wells as a 0% kill control.
The plates were returned to 37°C and 5% CO2 for an overnight incubation.
Cell viability was then indicated by the addition of 100J,11of 1mg/ml MTT
with a 4h incubation.
After removal of the media, the formazan product of MTT was solubilised by
the addition of 100J,11of dimethyl-sulphoxide/0.04N hydrochloric acid and
gently tapping the plates.
The AS40was then read with correction set at A630in an MRX ELISA plate
reader. A logarithmic standard curve was used to determine the activity of
the samples by the 50% kill method. This involved determining the TNFa
standard activity that was capable of killing 50% of the cells per well. The
corresponding absorbance was then compared to the diluted samples. This
gives a dilution factor that was used to determine the actual TNFa activity of
the sample (Thorpe et al. 1992).
2.6.5 In vitro airway cell stimulation assays
Cells recovered as in Section 2.3.10were washed by centrifugation at 1000rpm
(Sigma 4K15 centrifuge) and 4°C for 5min. The pellet was resuspended in
500J,11RPMI 1640 culture medium used in TNFa bioassay. Cell viability was
measured as above and the number adjusted to 2.0 x 105cells/ml. 100J,11of
this cell suspension were plated per well in a flat bottomed 96 well micro titre
plate. Cells were incubated overnight in 37°C and 5% CO2 before being
washed twice with 100J,11sterile PBS. Adherent cells were then stimulated
with LPS, purified pneumolysin or heat killed pneumococci.
LPS (from E. coli 0127:B8)was utilised at a range of concentrations from
50,000ng/ml - 0.0005ng/ml or media alone for 24h. The supernatant fluid
was sampled and TNFa total protein and activity measured as above. This
incubation period has previously been shown to be sufficient for TNFa
production to occur (Houldsworth et al. 1994).
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Recombinant pneumolysin protein was obtained from Ms J. Search, Division
of Infection & Immunity. This protein was known to possess biological
activity as it was haemolytic for red blood cells. The concentrations of
pneumolysin utilised as stimulants were 100ng/ml, 1ng/ml, 10pg/ml or
3pg/ml which were previously shown to be capable of stimulating TNFa and
IL-1~ production by human monocytes (Houldsworth et al. 1994).
Supernatant fluids from pneumolysin stimulated cells were only assayed for
TNFa by ELISA due to unpublished observations that pneumolysin is
cytotoxicfor L929cells.
For heat killed pneumococci stimulation experiments the number of bacteria
used were either 106 , 105 or 104 CPU. These numbers of heat killed
pneumococci have been shown to be capable of releasing IL-1~from human
monocytes (Riesenfeld-Orn et al. 1989). With heat killed bacterial
stimulation, supernatant fluid was centrifuged at 13,000rpm (Eppendorf 5417
centrifuge) for 3min in order to remove bacteria from samples prior to
detection of TNFby bioassay or ELISA.
In a preliminary experiment 106 CFU heat killed pneumococci were
combined with 1ng/ml pneumolysin.
2.7 Immune modulation techniques
2.7.1 Effect of exogenous surfactant on pneumonia
Artificial lung expanding compound (ALEC,Britannia Pharmaceuticals Ltd,
Surrey, UK) was re-suspended in non-pyrogenic saline to a concentration
41.67mg/ml. This was shaken gently and left at 4°C for 30min to allow the
viscosity to settle before experiments were carried out. The initial in vitro
7
experiment involved preparing a suspension of approximately 2.0 x10
CFU/ml and investigating viability over time.
This was followed by investigation of bacterial growth in vitro in BHI
supplemented with 5% (v/v) ALEC(Rubins et al. 1996). An equal volume of
non-pyrogenic saline was added to BHI as a control. Viable bacteria were
counted hourly until control cultures were seen to pass through each stage in
a typical growth curve. Absorbance readings could not be obtained for the
cultures containing ALECdue to the opacity of a 5%ALECsolution.
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In vivo investigations involved intranasal administration of SOJlI ALEC
6
either 2h prior to challenge with 10 CFU S. pneumoniae, at the same time as
the bacteria, 2h after pneumococci, or alone with bacterial loads at 24h and
overall survival determined.
2.7.2 Anti TNFa antibody modulation
Affinity-purified neutralising anti- TNFa polyclonal antibody (R & D
Systems) was re-suspended in sterile non pyrogenic saline to a concentration
of 200llg/ml. The amount of antibody required to neutralise the level of
TNFa produced in vivo during pneumococcal pneumonia was determined
using the TNF bioassay. TNFa standard was prepared at the highest activity
detected in lavage fluids or per total animal during pneumococcal
pneumonia and the level of antibody required to neutralise this activity
calculated. Accordingly, 40llg of antibody was given intraperitoneally to
groups of S mice at 2h prior to infection with 1 x 106 CFU S. pneumoniae.
The negative control was 40llg Goat IgG (as the anti- TNF-a antibody was a
goat anti-mouse IgG antibody) and 200lli anti-pneumococcal type 2 capsule
antiserum (diluted 1 in 200 in sterile non-pyrogenic saline) provided the
positive control. In the case of survival times an additional control set
consisted of an untreated group of mice.
Animals were monitored until 24h after infection when they were sacrificed
and bacterial loads determined in lavage fluid, lung homogenates and blood.
Aliquots of lavage fluid were also snap frozen for cytokine analysis.
Neutralisation of airway TNFa was achieved by intranasal administration of
lOllg anti- TNFa antibody, lOllg Goat IgG, or SOIlI anti-type 2 capsule
antiserum 2h prior to infection with 1 x 106 CFU S. pneumoniae. Samples
were taken at 24h post challenge as for the intraperitoneal modulation route.
2.7.3 Effect of SNAP on S. pneumoniae growth in vitro
The effect of NO on the growth and viability of S. pneumoniae in vitro was
determined using s-nitroso-acetyl penicillamine (SNAP, Calbiochem,
Nottingham, UK), a NO donor (Kaplan et al. 1996). SNAP was freshly
prepared in BHI and filter sterilised to give a range of concentrations from
200-2SIlM. These preparations were incubated at 37°C for 24h, with 1ml
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samples removed and frozen at -70°C at several time points. Total nitrite
was determined in these samples using the Greiss reaction. From this
experiment the concentration of SNAP required to induce a rapid and easily
detectable production of NO was determined.
S. pneumoniae was obtained from vials of standard inoculum and was
therefore in mid log phase of growth. This preparation was added to BHI
containing 200liMSNAP to give a bacterial load of around Sx104du/ml. S.
pneumoniae was also incubated in controls (BHI alone, D-penicillamine [to
control for SNAP] and sodium nitrite [to control for nitrite production]), both
at the same concentrations as SNAP. The cultures were incubated at 37°C
and growth of the bacteria was measured each hour by optical density at
600nm and by viable counting. Culture samples were stored at -70°Cprior to
nitrite levels being determined by Greiss reaction as previously.
2.8 Statistical analysis
Results are expressed as geometric mean +/ - 1 SEMunless otherwise stated.
Comparisons of survival times following infection and core body
temperatures were carried out using non-parametric Mann Whitney U
analysis with P<O.OSor P<O.Olconsidered statistically significant for all
analyses (Wardlaw 1997). If a value of greater than 0.05was obtained, this is
not mentioned in the text. Levels of inflammatory mediators were also
compared by Mann Whitney U analysis with a Bonferroni correction for
multiple analyses.
Comparisons of bacterial load data from time course experiments were
compared using one way analysis of variance (ANOVA) with Scheffe's post
hoc test. Where samples contained fewer CFU/ml than the lower detection
limit for the viable counting assay (Log 1.92)they were ascribed a value just
below the detection limit (Log 1.91)in order to prevent artificial reduction of
the geometric mean. Comparisons between mouse strains or treatment
groups were carried out using multiple unpaired student t tests with a
Bonferroni correction for multiple analyses.
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Chapter 3 Results Inflammation in MFl mice
3.1 INTRODUCTION
A murine model of pneumococcal pneumonia has been used to study the
pathogenesis of the infection. This model is based on that described by
Canvin et al (Canvin et al. 1995)and involves respiratory challenge of 9 week
old adult MF1mice. An acute infection is initiated, resulting in bacteraemic
pneumococcal pneumonia within 48h.
Previous investigations utilising this model have concentrated on roles
played by the bacteria during the infection (Kadioglu et al. 2000). This chapter
characterises the host inflammatory response to the inoculated pneumococci.
The effect of reducing the infectious dose on the inflammatory response was
characterised in order to determine whether there was a threshold number
of bacteria required to induce the inflammatory response. In addition the
possibility that the magnitude of the host response correlates with the
infectious dose was investigated.
Epidemiological studies have shown age to be a very important factor in
determining outcome after pneumococcal pneumonia. Infants under 2 years
of age and elderly individuals older than 65 years have the greatest infection
rates and the poorest outcome to infection (Burman et al. 1985). Immune
alterations responsible for increased susceptibility in infants are better
understood than those in the elderly population. The murine model of
pneumococcal pneumonia was therefore utilised in order to determine
whether there was also an age bias in mice and whether an altered
inflammatory response could account for such an effect (Bruunsgaard et al.
1999)and Section 1.4.3.1.
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3.2 RESULTS
3.2.1 Growth characteristics of D39
In vivo experiments were carried out with pneumococci that were in mid
log phase, requiring the growth characteristics of D39 to be investigated.
Figure 3.1 shows the growth curve for S. pneumoniae in serum broth with
lag phase, logarithmic phase, stationary phase and then decline evident.
Logarithmic growth is associated with a doubling time of approximately 25
min. Mid-log phase of growth occurs at an OD6oo of approximately 0.600.
3.2.2 Viability of D39 on ice
As S. pneumoniae is known to be a labile bacterium (Jonsson et al. 1986)&
(Johnston 1991)viability of the challenge dose on ice was investigated.
Viability of S. pneumoniae prepared in PBS and kept on ice drops with time
(Figure 3.2). The greatest decrease occurs within the initial 20min with a
more gradual loss of viability occurring in the following 40min, suggesting
that the decline in viability is levelling off. All animal inoculations were
therefore performed within this 40min window.
3.2.3 Intranasal infection
During the initial18h post intranasal infection with D39,MF1mice displayed
normal behaviour (Figure 3.3 A) and are highly alert. There then followed
progression through a range of clinical indications of pneumococcal
infection. The primary observation was a hunched stance (Figure 3.3 B) as
animals walked or stood still. The next clinical sign of pneumococcal
pneumonia displayed byMPl mice is piloerection. The hairs covering the
back of the mouse in Figure 3.3 C are standing on end. This mouse is no
longer interested in its surroundings and is displaying a marked hunched
appearance. All further clinical signs of illness are manifested in the
movement of the mice and cannot thus be displayed in a figure. Mice
become more lethargic in their movement before finally becoming
unwilling to move (moribund (Toth 1997)). Animals reaching this stage
were sacrificed.
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Figure 3.1 Growth characteristics of S. pneumoniae in BHI + 20% v Iv heat-
inactivated fetal calf serum. These results represent four bacterial suspensions
grown on two separate occasions.
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Figure 3.2 Viability of S. pneumoniae resuspended in PBS and kept on ice.
n=3, *, P<0.01 and +, P<0.05 reduced viability when compared to Omin results.
Figure 3.3 Clinical signs of pneumococcal pneumonia displayed
by MF1 mice following infection with 106 CFU S. pneumoniae.
A= healthy mouse, B= mouse displaying early signs of infection
with a hunched stance, and C= mouse with piloerection during
mid/late infection.
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Development of these signs of illness was followed by a "pain-score" system
developed by this laboratory (Section 2.3.5). This involved frequent
recording of the severity of each of the above signs throughout the
experiments, in order to monitor disease progression.
3.2.3.1 Survival & signs of illness following intranasal infection
Mice succumbed to the infection rapidly after intranasal challenge with 106
CFU S. pneumoniae (Figure 3.4). The onset of signs of infection occurred at
around 18h into the experiment with a hunched appearance being the most
common clinical observation. The earliest time of death recorded was 26h
post challenge, followed by a steady decline in the percentage survival un til
118h after infection. In seven experiments only two mice (out of 53)
survived the infection. Statistical comparison of the survival times gained
in the 7 separate experiments revealed no significant differences, showing
the reproducibility of the model.
3.2.3.2Telemetry following intranasal infection
The "pain-score" monitoring system is not ideal as it does not permit
continual monitoring, e.g. during the night. In addition, it is difficult to
utilise pain-score data in a quantitative method. For these reasons a
telemetry system was employed. This permitted constant monitoring of core
body temperature (Teo) and activity of mice throughout the infection.
Previous investigations have shown telemetry systems to yield reliable data,
comparable to conventional methods of disease monitoring such as rectal
probes (without the constant distress to the experimental animals) (Dilsaver
et al. 1992).
In this set of experiments mice were infected at 08:00h on 12/08/98
(month/ day/year) with telemetry readings taken for 12h prior to infection.
Although a cyclical alteration could be seen in the temperature of sham
infected mice, no significant alteration in core body temperature was found
(Figure 3.5). In addition, activity counts for sham infected animals remained
high during the experiment (Figure 3.6). Periods of no activity occurred
infrequently and with short duration.
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Figure 3.4 Survival of female adult MF1 mice after intranasal challenge with
9.76 x 105CFU S. pneumoniae. n= 53 from 7 experiments.
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Figure 3.5 Core body temperature (QC)of an MFl mouse sham infected with PBS.
Vertical line represents time of "infection".
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Figure 3.6 Activity score (arbitrary units) of an MFl mouse sham infected with PBS.
Vertical line represents time of "infection".
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Figure 3.7 Core body temperature (QC)of an MF1 mouse infected with 106 CFU
S. pneumoniae. Vertical line represents time of infection.
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Figure 3.8 Activity score (arbitrary units) of an MF1 mouse infected with 106 CFU
S. pneumoniae. Vertical line represents time of infection.
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During the initial 24h of the experiment core body temperature in S.
pneumoniae infected animals was not seen to alter significantly from
controls and a similar cyclicalalteration of Teo as seen in PBS treated mice
was documented (Figure 3.7). The circadian rhythm of infected animals then
became less pronounced and mild, transient hypothermia developed in 8/20
implanted MF1 animals succumbing to the infection, Teo in infected mice
then partially returned to baseline before the animals went on to develop
marked hypothermia. The other 12 animals displayed only one period of
marked hypothermia. Core body temperature dropped to ambient room
temperature, over a period of around 6h with time of death around 09:00h
on 12/08/98.
At the initiation of hypothermia clinical symptoms of infected mice were
found to be moderate with hunched appearance, piloerection and mild
lethargy. When ambient room temperature was reached signs of infection
had progressed to the stage that mice were deemed moribund.
Activity records show that MF1mice are highly active during the initial 30h
of the experiment (Figure 3.8). Concurrently with the development of mild
hypothermia activity scores were reduced. High activity counts were
recorded less frequently as the end stages of disease were reached and Tco
dropped below 34°C.
3.2.3.3 Bacteriology in the pulmonary air spaces following intranasal
infection
Counts of viable pneumococci within pulmonary air spaces did not alter
significantly from time Ohvalues during the infection (Figure 3.9).
3.2.3.4Bacteriology in the lung tissues following intranasal infection
Bacterial loads recovered from lung tissues increase immediately 0n
inoculation although a period of greater than 12h appears to be required
before the bacteria become fully acclimatised to their new environment
(Figure 3.10). Following this time the counts increased significantly towards
the later stages of the infection with a mean doubling time of 2h whilst in
logarithmic growth. By the end of the disease, as many as 107 CPU were
found associated with each ml of lung homogenate.
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Figure 3.9 Bacterial loads within the airways of MF1 mice following intranasal
infection with 9.75 x 105 CFU S. pneumoniae. n=14-24.
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intranasal infection with 9.75 x 105CFU S. pneumoniae. n=5-9, ", P<O.Ol,+,
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3.2.3.5Systemic bacteriology following intranasal infection
S. pneumoniae was able to enter the bloodstreams of 6 of the 7 infected mice
by 12hpost challenge (6 of the 17were bacteraemic at this time) [Table3.1]. By
18h into the experiment only one mouse did not have detectable
pneumococci in the bloodstream. Once in the circulation pneumococcal
counts increased until the end of the infection when greater than 107CFU
were cultured from each ml of blood. The mean doubling time of
bloodborne bacteria was 1.4h (slightly more rapid than the 2h seen within
lung tissues).
3.2.3.6Bacteriology in perfused lung tissues following intranasal infection
As such high bacterial counts are present in the blood of infected mice and
the lungs contain a high proportion of this blood it was a possibility that the
elevated bacterial counts seen in the lung tissues was due to blood-borne and
not tissue associated pneumococci. Blood was therefore perfused from
selected lungs prior to removal and homogenisation. Bacterial loads
recovered from these lung homogenates were not significantly different
from those detected in unperfused lungs (Figure 3.11) at all times
investigated. Therefore the increase in bacterial numbers seen in the lung
homogenates is not solely due to blood-borne bacteria.
3.2.3.7Histology following intranasal infection
Histological investigation revealed the development of acute inflammation
within the lungs following intranasal infection with 1.02 x 106 CPU S.
pneumoniae (Figure 3.12). The pattern of inflammation shows that
bronchopneumonia has developed. As little as 6h into the infection some
areas of lung tissue were already displaying oedema. In addition, increased
numbers of neutrophils could be seen within the blood vessels. These cells
were found both among erythrocytes in the middle of the blood vessels and
in association with the endothelium. By the 12h time point areas of oedema
were more common between the normally closely associated blood vessels
and bronchioles and a slightly higher number of inflammatory cells could be
found in these areas. By 24h these perivascular areas contained appreciable
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numbers of infiltrating cells. Microscopic examination of the nuclei of these
cells identified them as mainly being neutrophils. The lesions grew in size
through 36h until 48h post challenge when the areas were masses of
inflammatory cells. Only low levels of haemorrhage (as determined by
presence of erythrocytes in alveoli) could be detected at any time post
challenge.
Utilisation of a scoring grid for histopathologic examination of lung tissue
adapted from that used by Bergeron et al (Bergeron et al. 1998), (Section
2.3.13), permitted a numerical value to be associated with lung
histopathology. Results of this analysis are presented in Table 3.2.
Histopathologic scores increased slightly immediately following infection
and continued to increase until 12h post challenge when a significantly
higher score was obtained than at time Oh (P<0.01). The level of
inflammation then remained constant for 12h prior to increasing at 36h and
48h post challenge, also significantly higher than time Ohscores.
3.2.3.8 Mast cell detection following intranasal infection
Mast cells were differentiated within lung tissues by virtue of their
characteristic granules. This stain is not intense and is not readily
reproduced by photography, for this reason data is presented in Table 3.3.
Mast cells were detected in the lungs of untreated MFl mice, of PBS sham
infected mice and of MF1 mice immediately following intranasal infection
with 106 CFU S. pneumoniae. Immediately following infection cells
containing granules were present in high numbers and were mainly located
around blood vessels. 6h into the experiment, the majority were associated
with blood vessels but were also scattered around lung interstitium. By 12h
into the experiment most cells had degranulated (or migrated out of the
lungs) as fewer positive staining cells were evident, however this was not a
statistically significant reduction (indeed the number of granule containing
cells did not alter significantly from time Oh values throughout the
experiment). At 24h post challenge they were again present in slightly
higher numbers, with the number of granule containing cells remaining
constant until the end of the experiment. Mast cells were never found
within the foci of inflammation but were located in the immediate
surrounding areas of lung.
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3.2.3.9 Production of inflammatory mediators following intranasal infection
Recent investigations have highlighted the important balance that exists
between pro- and anti-inflammatory markers during infection (Walley et al.
1996) & (Mohler et al. 1998). Contrary to absolute amounts of such
mediators, their levels in relation to each other and the kinetics of their
production are more important in determining outcome. In order to
investigate whether this balance is altered during pneumococcal pneumonia,
the biological mediator NO and the cytokines TNFa, IL-1~, IL-6 and IL-10
were selected for investigation. The former four are believed to act in a pro-
inflammatory manner (Section 1.6.1.1) whilst IL-10 is a potent anti-
inflammatory mediator (Section 1.6.1.2) (although IL-6 can also act in this
manner in certain circumstances). Such characterisation of baseline levels
was also required prior to modulation experiments (Section 4.2.2).
Total protein levels within lavage fluid of mice can be used as an indicator of
the permeability of the alveolar/capillary barrier (Rubins et al. 1995).
Disruption to this barrier during the course of infection, either by bacteria
moving out of the lungs into the bloodstream or by recruitment of effector
cells in the opposite direction, increases the level of total protein as serum
proteins enter the airways.
Components of the pneumococcal cell wall have been shown to induce
production of inflammatory cytokines both in vitro and in vivo
(Section1.6.1.5). In vivo inflammation was therefore investigated following
instillation of heat killed pneumococci in order to assess the ability of the cell
wall of D39 to promote inflammation in this model of pneumococcal
pneumonia. TNF activity and IL-10, NO and total protein levels were
selected as markers of the pro-inflammatory / anti-inflammatory balance.
3.2.3.9.1 Production of inflammatory mediators in the pulmonary air spaces
following intranasal infection
TNF activity was undetectable within airways of mice immediately following
infection (Figure 3.13 A). Levels became detectable during the mid and late
stages of infection. TNF activity rapidly increased between 12h and 18h post
challenge and equally rapidly decreased by the 24h time point (significantly
reduced in comparison to 18h P<O.Ol). A second, smaller peak in activity
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Figure 3.13 Production of pro-inflammatory mediators within the airways of
MFI mice following intranasal infection with 9.75 x 105 CFU S. pneumoniae.
A= TNF activity n=II-21, B= TNFa. protein levels n=5-7, C= IL-l~ Levels n=5,
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Figure 3.14 Production of inflammatory mediators within the airways of MF1
mice following intranasal infection with 9.75 x 105 CFU S. pneumoniae. A= IL-
10 levels n=6-12, B= NO levels n=11-14, and C= Total protein content n=6-14, "',
P<O.Ol higher when compared to time Oh values.
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occurred 30h post challenge, again transient in nature but a significant
increase comparison to 24h results (P<0.05).
Similar kinetics were evident for TNFa protein levels although in this case
ISh samples were not taken (Figure 3.13B). Peak levels were thus recorded
at 24h post challenge with production decreased at 36h.
IL-l~ levels had already increased by 6h following infection, with this trend
continuing until ISh post challenge (Figure 3.13 C). At this time maximal
levels of this cytokine were detected. A gradual decline in IL-l~ levels then
occurred towards the end of the experiment although a significant decrease
from this peak production was not evident until 36h post challenge (P<0.05
when ISh and 36h results are compared).
Detection of IL-6increased from early during the infection with high levels
detected during mid infection (Figure 3.13D). Most IL-6was detected during
the final ISh of the experiment. As with TNF, IL-6 release may be occurring
in two waves, perhaps explained by direct IL-6 induction by TNF although
the decrease in IL-6 levels at 24h post challenge is not significant when
compared to ISh results.
Interleukin 10was present in appreciable levels within the airways of mice
from the time of infection (Figure 3.14 A). Such levels remained constant
until after the 12h time point. IL-IOproduction then increased slowly with
peak amounts detected 30h into the experiment. High levels of IL-IOwere
not sustained as only 6h later they had returned to baseline.
Nitric oxide was investigated for its effects on epithelial and endothelial
disruption in other models of disease (Section 1.5.3.5.2). As with the other
pro-inflammatory mediators, low levels of NO were found within the
airways of mice at the time of infection (Figure 3.14B). These levels did not
increase significantly from baseline values during the experiment.
Disruption to the alveolar/capillary barrier, as measured by protein leakage,
occurred rapidly after instillation of the bacteria (Figure 3.14C). By 6h post
challenge protein levels in lavage fluids were already elevated and by a
further 6h significantly higher levels of protein were detected than
immediately following infection. These levels continued to increase almost
unchecked until the end of the infection.
Heat killed pneumococci were incapable of causing the release of detectable
TNF activity within the air spaces of mice (data not shown). A similar lack
of effect was noted on NO levels.
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Inoculation of heat killed bacteria did not significantly increase lavage fluid
IL-10 levels during the experiment. These facts indicate that mild
inflammation, undetected by the above assays may still have occurred.
Further evidence is found with the increase in lavage fluid total protein
levels that occurred at the end of the experiment (P<O.Ol).
Methods employed to initiate infections were not shown to initiate
inflammation. The airways from PBS sham infected mice did not possess
detectable TNF activity, nor did they contain significantly elevated NO, IL-10
levels or total protein (data not shown).
3.2.3.9.2Production of inflammatory mediators in the lung tissues following
intranasal infection
TNF activity was detected in low amounts during the first 12h of infection.
This was followed by a rapid and significant increase at 18h post challenge of
a similar magnitude to that seen in the lung airways (Figure 3.15 A). TNF
activity levels remained significantly elevated for the remainder of the
experiment.
Detection of TNFa protein was not possible within the lung tissues of
infected mice until after 12h (Figure 3.15B). Following this time (again a 18h
time point was not carried out), there was a significant increase in its
detection. Heightened TNFa levels were sustained until after the final time
studied.
Significantly elevated IL-1~levels were detected within lung tissues rapidly
after infection (Figure 3.15 C). By 18h post challenge they were at their
highest detected level. After this time they decreasing slowly towards the
end of the infection although they remained elevated in comparison to time
Ohvalues.
IL-6 production did not increase significantly until after 12h into the
experiment (Figure 3.15D). Maximum levels were not detected until 30h
post challenge with production not sustained but rather decreasing with
time. The capacity of lung tissues to release this cytokine, as well as TNF and
IL-l~, is significantly higher than that found within the pulmonary airways
(Figures 3.15& 3.15).
IL-10 levels within the lung tissues increase from after 6h into the
experiment until after the 30h time point. Elevated levels of this cytokine
within the tissues significant at the level of P=0.028were found 30h post
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Figure 3.15 Production of inflammatory mediators within the lung tissues of
MF1 mice following intranasal infection with 9.75 CPU x 105 S. pneumoniae.
A= TNF activity n=5-17, B= TNFa. protein n=5-7, C= IL-1~ levels n=5, D= IL-6
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challenge. This elevation was of a far smaller magnitude than that seen in
the airways although more IL-10was found in association with the lung
tissues than in the airways (Figure 3.15E and Figure 3.14A).
TNF activity remained undetectable within the lung tissues of all mice
inoculated with heat killed pneumococci (data not shown). However,
homogenate IL-10levels increased significantly at 6h (P<0.05)and 24h post
challenge (P<0.01)when compared to time Ohvalues.
Lung tissues from PBS sham infected animals did not contain detectable
levels of TNF activity although lung tissue IL-10levels were elevated at 6h
and 12h post challenge (P<0.05)(data not shown).
Similar kinetics of TNF production were gathered using the TNF bioassay
and the ELISA. However, the higher levels of variation evident with the
ELISAresulted in all further TNF measurements in this thesis being carried
out by bioassay
3.2.3.9.3Systemic TNF activity following intranasal infection
TNF activity was undetectable within the circulation of mice until 24h post
challenge (Figure 3.16). Following this time detection of TNF activity was
highly variable within serum from infected mice. High levels of activity
were found in serum from mice which were highly bacteraemic at 24h and
30h post challenge. Since the majority of mice did not possess systemic TNF
activity a high level of variability was associated with the mean activity
levels at 24h and 30h post challenge. This resulted in no statistical
significance when these time points were compared to baseline.
This highly variable detection of TNF within serum from infected mice was
found to be directly related to their level of bacteraemia. Comparison of all
MF1 mice infected with S. pneumoniae and investigated for systemic TNF
activity led to the discovery that only one mouse with a level of bacteraemia
lower than 2.88x 107CPU/rnl possessed such activity, whilst all 12mice with
higher bacteraemia had systemic TNF levels.
In table 3.4, all young MFl infected in the experiments described in this
chapter and sampled after 24h post challenge are separated into two groups
on the basis of the magnitude of their bacteraemia. All mice in the high
bacteraemia group (greater than 2.88x 107CFUIml) possessed systemic TNF
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Figure 3.16 TNF activity within serum of MF1 mice following intranasal
infection with 9.75 x 105CFU S. pneumoniae. n=6-16.
Group description Mean bacterialload Mean TNF activity
(CFU/ml) +/- SEM (U/mt) +/- SEM
Mice with level of
bacteraemia higher than 8.00+1- 0.20 718.30 +1- 201.41
log 7.46 CFU/ml n=12 *
Mice with level of
bacteraemia lower than 3.75+1-0.22 2.97+I-2.97
log 7.46CFU/ml n=75
Table 3.4 TNF activity levels in MF1 mice with levels of bacteraemia higher
than or lower than log 7.46 CFUIml following intranasal infection with 9.75 x
105CFU S. pneumoniae. n=12-75, *, P<O.Ol higher when compared to low
bacteraemia group.
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activity whilst only one mouse in the lower group did so. Furthermore, the
mean level of TNF activity in the high bacteraemia group is significantly
higher than that displayed in the low bacteraemia group (P<O.OOOl). This
data indicates that there is a threshold number of pneumococci required in
the bloodstream of an outbred population before high levels of systemic TNF
activity are released and that this threshold is approximately 2.88 x 107
CFU/ml.
This fact also explains why no TNF was detected in mice prior to 24h post
challenge and after 30h post challenge in Figure 3.13, as none of the mice in
these groups had more than 2.88 x 107 CFU pneumococci/ml of blood.
TNF activity was not detected in serum from mice either inoculated with
PBS or heat killed pneumococci (data not shown).
3.2.3.10 Immunohistochemistry following intranasal infection
Histological analysis was only capable of describing the kinetics and gross
characteristics of pulmonary inflammation during pneumococcal
pneumonia. Immunohistochemistry was thus employed in order to better
define the roles played by certain cell populations.
Immunohistochemistry revealed that TNFa and IL-10 are expressed in low
levels within the alveoli of untreated animals and mice immediately after
infection, a finding previously reported by other investigators (Pendino et al.
1994) & (Bonfield et al. 1995). The location and nuclear morphology of the
cells responsible implicates alveolar macrophages and bronchial epithelial
cells.
Early during infection TNFa positive cells were detected both within the
alveoli and bronchial epithelium with granular cells also frequently staining
positively. Following inflammatory cell recruitment (24h-36h post challenge)
most of the lung associated TNFa, as detected by immunohistochemistry,
was located in these areas of cell influx (Figure 3.17 A). Both cell associated
and secreted TNFa was detected.
IL-10 expressing cells were present in low numbers within alveoli and
bronchial epithelium until 24h post challenge. Following this time, as with
TNFa, IL-IO could mainly be detected within areas of inflammation and was
present as both a cell bound and secreted form (3.17 B). However, during late
infection IL-IO staining was more widespread and more intense than TNFa,
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Figure 3.17 Immunohistochemistry on sections of lung from a mouse 36h post
challenge with 1.01 x 106CFU S. pneumoniae (x 200 magnification).
Figure 3.17A Immunohistochemical detection of TNFa. A consolidated area
around a bloodvessel (BV)is shown. A signal for TNFa is detected both in the
alveoli (A) and the foci of inflammation. In the areas of cell influx both cell
associated (C) and secreted (5) forms of TNFa can be seen.
Figure 3.17Bshows immunohistochemical detection of IL-10 in a serial section
of the same lung. A stronger signal can be seen for IL-10 with more cells
staining pink than are seen for TNFa in Figure 3.17A. Again both cell
associated (C) and secreted (5) IL-10can be detected. Alveolar cells are also
expressing this anti-inflammatory cytokine, as are bronchial epithelial cells
(BE).
Identification of the majority of recruited inflammatory cells has been carried
out with immunohistochemical staining for a neutrophil marker in the same
section (Figure 3.17C). Most of the cells in the area of consolidation (CO) are
staining positive for this marker. In addition to areas of consolidation,
neutrophils are also evident marginating through the endothelium of the
bloodvessel (M).
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with bronchial epithelial and alveolar cells releasing the anti-inflammatory
cytokine but not TNFa.
Both TNFa and IL-10were found within the same areas of inflammatory foci
during end infection. This fact may be explained if the initial cells to become
stimulated had already expressed TNFa and were now synthesising IL-10
whilst newly recruited cells would still at the producing TNFa stage.
Light microscopy identified most of the recruited inflammatory cells as being
neutrophils, an identification supported by immunohistochemical staining
with a neutrophil marker (3.17C).
3.2.4 Dose response
In each of the subsections associated with the effect of lowering the infectious
dose, data for 106CFUhave been discussed elsewhere in this chapter and will
not be reiterated.
3.2.4.1Signs of infection & survival following intranasal infection with
reduced doses of S. pneumoniae
Reducing the challenge dose from 106 CFU to 105CFU was sufficient to
significantly increase survival times (P<O.Ol) [Figure 3.18]. Mice inoculated
with 105CFU started to display clinical symptoms 24h into the experiment
but did not begin to succumb of infection until 48h post challenge. No
further mice succumbed to the infection after 121h into the experiment.
An infectious dose of 104 CFU increased survival times even more
significantly (P<O.Ol when compared to 106 CFU). Mice displaying signs of
illness following infection with 104 CFU developed them with similar
kinetics as with the other doses and all deaths occurred by 74h.
However, these statistics do not take into account the fact that many of the
mice challenged with lower infectious doses survived the infection. In order
to account for this fact it is necessary to separate the groups into those that
resist the infection and those that succumb.
Table 3.5 shows that reducing the infectious dose from 106 CFU to 105CFU
significantly increases the survival times of MF1mice that do succumb to the
infection. The variability associated with resistance/susceptibility with this
dose prevents its use as a less acute model of infection.
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Figure 3.18 Survival of MF1 mice following inoculation of 9.76 x 105
CFU, 9.95 x 104 CFU, or 1.02 x 104 CFU S. p n eu mo n ia e. n= 10-53, *, P<O.Ol
longer survival times when compared to 106mice.
Infectious Dose No. of animals that Mean survival time
succumb (h)
106 51/53 53.38
105 7/12 70.57 *
104 2/10 60.00
Table 3.5 Survival times of MF1 mice following inoculation of 9.76 x 105
CFU, 9.95 x 104 CFU, or 1.02 x 104 CFU S. p n eumo n.iae that succumb to
pneumococcal pneumonia. *, P<0.05 longer when compared to 106 CFU
group.
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Mice inoculated with 104 CFU also had longer mean survival times than
those infected with 106 CFU. However, the small group size prevents
statistical significance.
Analysis of the following data from the dose response experiments revealed
a marked intra-group variation in outcome following intranasal challenge
with either 105or 104 CFU S. pneumoniae. As the infectious dose was
reduced the proportion of mice that did not succumb to the infection but
rather were resistant, increased. This led to the data being analysed by
additional procedures. The mean data are presented (as above for 106 CFU
dose) in order to allow the overall kinetics of inflammation to be compared
between infectious doses. The bacteraemia results were then separated into 2
groups on the basis of whether the mice appeared to resist the infection and
not develop bacteraemia, or succumbed. Production of inflammatory
mediators was also investigated in a similar manner with the infectious dose
groups separated on the basis of an elevated response in comparison to
baseline data. All mice that did respond in this manner from 6h post
inoculation of reduced doses were put in one group whilst those that did not
respond were placed in another group. This permitted analysis of whether
mice challenged with reduced doses of pneumococci displaying a host
response did so to a similar extent as mice infected with 106 CFU S.
pneumoniae. This method of analysis could not be performed elsewhere in
this thesis due to small group sizes in either the responding (for example
BALB/c bacteraemia, Section 5.2.1.5) or non-responding (MF1/129 non-
bacteraemic animals Section 4.2.4.2.3)groups.
3.2.4.2Bacteriology following intranasal infection with reduced doses of S.
pneumoniae
Lung tissues samples were utilised for the analysis of production of
inflammatory mediators. Bacteriological profiles could therefore only be
investigated in lavage fluid and blood samples from mice infected with
reduced doses of S. pneumoniae.
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3.2.4.2.1Bacterial loads within pulmonary air spaces following intranasal
infection with reduced doses of S. pneumoniae
The number of viable bacteria found associated with the lung airways on
challenge with 105CFUwas around ten fold lower than that recovered from
lungs of mice challenged with 106CFU (Figure 3.19). This in tum was higher
than that discovered in airways of mice given 104CFU.
Bacterial loads within the airways of mice inoculated with 105CFU contained
similar numbers of viable pneumococci at all times studied. All of the 57
mice in the 105CPU group were found to have viable pneumococci wi thin
their airways during the experiment. A slight increase in bacterial load
occurred during late infection and at 36h there were similar numbers of
bacteria within the airways of mice given either 106 CFU or 105 CFU S.
pneumoniae (prior to this point there were significantly lower bacterial
loads within lungs of mice infected with 105CFU than with the higher dose
[P<O.Ol]).
Bacterial viability within airways of mice challenged with 104 CFU D39
dropped immediately on instillation. This trend continued towards the later
time points with fewer than 104 CFU/rnl found in all mice but one
throughout the experiment. However, very few (7/54) mice inoculated with
104CFU S. pneumoniae had undetectable bacteria within their lungs during
the experiment. At all times bacterial loads within airways of mice infected
with 104 CFU pneumococci were significantly lower than those in airways of
mice infected with 106CFU (P<O.Ol) and only at 24h were the levels in the 104
CFU group not significantly lower than in the 105CFU animals, at all other
times a P value of P<O.Ol was found.
3.2.4.2.2Systemic bacterial loads following intranasal infection with reduced
doses of S. pneumoniae
Grouping all mice inoculated with the various infectious doses permitted
development of bacteraemia in these groups to be used as a marker of disease
progression (Table 3.6).
Viable pneumococci were not detected within the bloodstream of any mice
until 12h post challenge. At this time similar numbers and levels of positive
cultures were found in each of the groups (Table 3.6).
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Figure 3.19 Bacterial loads within the airways of MFI mice following
inoculation of either 9.75 x 105, 9.56 X 104 or 9.55 x 103 CFU S.
pneumoniae. n=8-24, red asterisk denotes P<O.Ollower bacterial load in
105CFU group and blue asterisk denotes P<O.Ol lower bacterial load in
the 104 CFU group, when compared to the 106 CFU group.
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The mean data from the 105 group revealed that bacteria were able to
continue to increase in number with significantly more colony forming
units detected 36h and 48h post challenge when compared to time Oh
(P<O.Ol). At 24h post challenge the level in the 105CFU was significantly
lower than that in the 106CFU group (P<O.Ol)but by 36h post challenge both
groups of mice had a reached levels that were not significantly different.
The rate of increase in pneumococcal numbers within the circulation of mice
inoculated with 105 CFU was slightly slower than that in the group
challenged with 106 CFU (mean doubling time of 2.2h versus 1.4h for 106
CFU).
In mice inoculated with 104CFU, mean levels of bacteraemia did not increase
above the level of approximately 102CFU/rnl with no significant alteration
from the time Oh levels. Bacteria in the bloodstreams of mice in this group
had a slow doubling time of 12.6h.
From 24h post challenge onwards, mice inoculated with 104 CFU had
significantly fewer viable pneumococci within their bloodstreams than mice
infected with 106CFU (P<0.01). Only at 36h and 48h post challenge were the
levels of bacteraemia in the 104CFU group reduced in comparison to the 105
CFU group (P<0.05at 36h and P<O.Olat 48h).
As with the survival data, these overall data do not account for many of the
mice remaining free of bacteraemia during the experiment. In order to
investigate whether mice that succumbed to the disease after infection with
reduced doses did so to comparable levels as the mice infected with 106CFU
D39 it is necessary to divide the data. In Table 3.7 mice that did not develop
bacteraemia are removed, leaving only those that did. All three infectious
doses resulted in similar levels of bacteraemia at 12h into the experiment
although the highest number of mice with positive blood cultures were
infected with 106CFU.
Infection with 104CFU did not result in high levels of bacteraemia in most
mice, only one animal in this group had a very high level (7.70, occurring
36h post challenge). Statistically fewer pneumococci were present in blood
from these than in mice infected with 106CFU at 24h (P<O.Ol)and 36h post
challenge (P<0.05). The mean doubling time for D39within the circulation
of this batch of mice was 4h with no significant alteration in viable counts
detected on comparison to time Oh.
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Chapter 3 Results Inflammation in MFl mice,
Reducing the infectious dose to 105CPU reduced the level of bacteraemia in
comparison to the 106 CFU group at 24h post challenge and 36h post
challenge (P<0.05). Furthermore, the rate of development of bacteraemia
was slower with this reduced dose as it took until 36h for the magnitude of
bacteraemia to reach that displayed by the 106 CFU group at 30h post
challenge. Significantly higher bacterial loads were found in bacteraemic
mice infected with 106 CPU by 18h post challenge (P<0.05) and 24h post
challenge (P<O.Ol)whilst to took until 36h for the level to change
significantly following inoculation with 105CPU (P<O.Olat 36h in the 105
CFU group).The mean doubling time for pneumococci in the bloodstream of
mice inoculated with 105CFUwas 1.43h.
Thus spread of pneumococci into the circulation is reduced when a low dose
of 104 CFU is administered. However, lowering the infectious dose to 105
CFU does not reduce the level of bacteraemia associated with pneumococcal
pneumonia but does marginally slow down its development (this may be
due to a slightly lower number of D39gaining access to bloodstream at 12h in
this group).
3.2.4.3Histology following intranasal infection with a reduced dose of S.
pneumoniae
Histological examination of lung tissues compared mice inoculated with 105
CFU S. pneumoniae to those of mice infected with 106CPU. Lung histology
was not determined following infection with 104 CPU due to the highly
variable nature of infection following this dose. A similar pattern of event
occurred within the lungs of mice inoculated with 105CFU as with 106CFU,
areas of oedema between blood vessels and airways were the earliest sign,
followed by slight haemorrhage and cell influx. More significant cell influx
then occurred until large areas of the lungs were consolidated with
inflammatory cells (data not shown).
The same histopathology scoring system as in Section 3.2.3.4was utilised in
order to give this inflammation an arbitrary score in order to permit
comparisons between the two doses (Table3.8).
Histopathology was slower to develop within lungs of mice inoculated with
105CPU S. pneumoniae despite two sections displaying mild inflammation
immediately following infection. In addition, lower inflammatory scores
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were detected within lung tissues of mice inoculated with 105CFU when
compared to those infected with 106CFU pneumococci. Inflammatory scores
for the 106CFU dose were significantly increased by 12h post challenge, but a
similar effect was not evident in the 105CFU group until48h post challenge.
As with the bacteriology data in Section 3.2.4.2,in order to better detect any
histopathology in mice inoculated with 105CFU it is necessary to separate the
animals into those that did display inflammation and those that did not,
Table 3.9.
Inflammatory scores from lungs of mice that did respond with lung
pathology following infection with 105CFU were lower than those that
responded following infection with 106CFU. Furthermore, infection with
the reduced dose required a longer period of time before marked
inflammation became evident. These results indicate that although a
similar pattern of lung pathology occurs following infection with 105CFU as
with 106 CFU these events require longer in the reduced dose group.
3.2.4.4Production of inflammatory mediators within pulmonary air spaces
following intranasal infection with a reduced dose of S. pneumoniae
Only one lavage fluid sample from the 54 tested in the 105CFU challenged
group showed measurable TNF activity (Figure 3.20A). This occurred at 36h
post challenge with 2.89U/rnl detected. This mouse had the highest level of
viable pneumococci within its airways with log 5.60CFU/rnl,
Mice challenged intranasally with 104CFU S. pneumoniae did not produce
detectable TNF within their airways during this experiment. This is in
agreement with none of these mice having high numbers of viable bacteria
in their airways.
Production of IL-6within the lavage fluids of mice inoculated with 105CFU
was delayed in comparison to that in the 106CFU group (Figure 3.20B) with
significantly lower levels at 12h post challenge (P<0.05). Elevated IL-6levels
in the former group did not occur until 24h post challenge and even then
levels were low and only present in (2/8) mice, significance was not obtained
until36h post challenge (P<O.Ol)but this was maintained until the end of the
experiment.
Reducing the dose to 104CFU greatly reduced the amount of IL-6 produced
during the infection with no significant production discovered. Very few
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Figure 3.20 Levels of inflammatory mediators within the airways of MF1 mice
following inoculation of 9.75 x 105CPU, 9.58 x 104 CFU, or 9.55 x 103 CFU S.
pneumoniae. A= TNF activity, n=9-21, B= IL-6 levels, n=5-11, C= lL-10 levels,
n=6-12, D= NO levels, n=8-14, and E= total protein level, n=8-23. Red asterisk
denotes P<O.Oldifferent in 105CFU group and blue asterisk denotes P<O.Ol
different in the 104 CFU group when compared to the 106 CFU group. Red cross
indicates P<0.05 different in 105CPU group and blue cross represents P<0.05
different in 104 CFU group when compared to 106 CPU group. 0, no samples
were tested from reduced doses at 18h and 30h post challenge.
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(2/56) mice in the lowest dose group had detectable levels of IL-6 during the
infection and only one of these had high levels (4.56 U/ml). From 12h
onwards the 104 CFU group had significantly lower levels of IL-6 associated
with their airways than did the 106CFU group (P<0.05).
Lavage fluid from mice inoculated with 104 CPU contained similar levels of
IL-10 at the time of infection as did the 106 CFU control group (3.20 C).
Detection of this anti-inflammatory cytokine did not alter significantly
during the experiment in this group of mice.
The highest amounts of IL-10 associated with the group of mice inoculated
with 105CPU D39 were found at the time of infection although these were
not significantly higher than levels found in the other two groups. From
that time onwards the IL-10 levels decreased, although not significantly so,
until the end of the experiment.
Similar levels of NO were found associated with lavage fluid from mice
inoculated with 105CFU as with 106CFU at the time of infection (Figure 3.20
D). A significant decrease in detectable NO in the 105CPU group occurred
after 12h into the experiment when compared to time Oh results (P<0.05) and
this was sustained until 24h. At these same time levels in the 105CPU group
were significantly reduced in comparison to those in the 106 CFU group
(P<O.Ol).By the penultimate time studied NO levels in the airways of mice
inoculated with 105CFU had returned to those originally detected.
Infection with 104 CPU resulted in lower levels of NO being detected
throughout the experiment when compared to the other doses. At the time
of infection these levels were significantly lower than levels found in the
other groups (P<O.Ol). A significant, but transient, elevation did occur in the
amount of NO that was recovered during mid infection (P<0.05) but even
following this increase, levels were lower than those seen at the time of
infection with the other doses.
Lavage fluids recovered from mice inoculated with 105 or 104 CFU S.
pneumoniae contained significantly higher amounts of protein at the time
of infection than did the 106CPU group [P<0.05] (Figure 3.20 E). Levels in the
105CPU group remained constant during the initial 6h of the infection after
which they increased slightly, but not significantly, towards the end of the
experiment.
Protein levels in mice inoculated with 104 CFU also increased slightly during
mid infection. This increase occurred to a reduced extent than in the higher
doses and had disappeared by the end of the experiment.
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3.2.4.5Production of inflammatory mediators within lung tissues following
intranasal infection with a reduced dose of S. pneumoniae
Elevated TNF activity levels were detected in the lung tissues of mice
inoculated with 105CFU S. pneumoniae but not until 24h post challenge
(Figure 3.21A) resulting in significantly lower levels at 12h post challenge
compared to 106 CFU group (P<O.OS).At this time similar levels of TNF
activity were found as detected in the 106CPU group at 12h post challenge.
By36h post challenge TNF activity in the group of animals inoculated with
105CFUwas significantly elevated in comparison to time Ohvalues (P<O.OS)
but by 48h post challenge significance was no longer obtained.
No TNF activity was found in lung tissues of mice inoculated with 104CFU
D39 until mid/late infection when very low levels of activity were detected.
Most mice (49/53) inoculated with this dose of S. pneumoniae did not
respond by inducing detectable TNF activity. Thus significantly reduced TNF
activity was detected in this group than in the 106CPU group (P<0.05at 12h
and P<O.Olat 24h).
IL-6 production was induced less rapidly and to a lower extent within the
lung tissues of mice inoculated with 105CPU than those infected with 106
CFU (Figure 3.21B). No mice responded with elevated IL-6levels until 24h
post challenge when 6/9 mice did so to significantly elevate IL-6levels above
baseline (P<O.OS). Similarly significant levels continued to be detected
throughout the remainder of the experiment.
Inoculation of 104CPU did not result in significant IL-6 induction with only
(3/54) mice inoculated with this dose of S. pneumoniae had elevated IL-6
levels in their lung tissues giving a P value of <0.05when results from the
104CFU group were compared to the 106CFU group at 24h post challenge.
Similar levels of IL-10 were detected within lung tissues from all mice
immediately following infection with S. pneumoniae (Figure 3.21 C).
Production of IL-10 was only increased slightly (but not significantly)
following infection with 105CFU and this occurred at 36h post challenge.
Elevated IL-10 levels were not found within the lung tissues of mice
inoculated with 104 CPU S. pneumoniae. Thus these data suggest that the
only infectious dose capable of altering IL-10levels within lung tissues is 106
CPUD39.
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Figure 3.21 Levels of inflammatory mediators within the lung tissue of
MF1 mice following inoculation of 9.75 x 105CFU, 9.58 x 104 CFU, or 9.55
x 103CFU S.pneumoniae. A= TNF activity levels, n=5-9, B= 1L-6levels,
n=5-9, C= IL-10 levels,5-10. Blue asterisk denotes P<O.Ol different in the
104 CFU group when compared to the 106 CFU group. Red cross indicates
P<0.05 different in 105 CFU group and blue cross represents P<0.05
different in 104 CFU group when compared to 106 CFU group. 0, no
samples were tested from reduced doses at I8h and 30h post challenge.
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3.2.4.6Production of inflammatory mediators in mice that display a host
response following inoculation of reduced doses of S. pneumoniae
In order to determine whether mice inoculated with reduced doses of S.
pneumoniae were capable of releasing similar levels of inflammatory
mediators as the 106 CFU group, mice were separated into responding and
non-responding phenotypes as described in Section 3.2.4.1.
Reducing the challenge dose significantly reduced the number of mice that
responded to infection by increasing TNF activity (Table 3.10). A lower level
of TNF was also found in the single mouse that released detectable TNF
following infection with 105 CFU S.pneumoniae. The low group size
prevents statistical analysis.
Although the number of mice responding to infection by releasing higher
levels of TNF activity in lung airways was reduced in a dose dependent
manner, the levels expressed by mice responding to the inoculated bacteria
were not significantly different between the 104 and 106 groups. The
possibility that similarly high bacterial loads were present in the lung tissues
of mice that increased TNF activity cannot be excluded. Numbers of viable
pneumococci within lung homogenates could not be investigated in these
experiments. Indeed, elevated bacteraemia levels in many of the 105CFU
inoculated mice at later time points suggests that lung tissue bacterial loads
would be increased (due to correlation of systemic/lung tissues bacterial
loads mentioned earlier). This fact would explain why lung tissues from
mice in this group had significantly higher TNF activity levels than the 106
CFU group (P<0.05).
As with TNF, the number of mice responding to pneumococcal pneumonia
by increasing their IL-6 levels within lung airways and tissues increased in a
dose related manner (Table 3.11). In this case however mice inoculated with
reduced doses of S. pneumoniae responding with elevated airway IL-6levels
did so to a similar extent as the 106 CFU group. Within the lung tissues,
however, only mice inoculated with the two higher doses were capable of
releasing high levels of this pro-inflammatory cytokine. Levels of IL-6
released by the 104 CFU group were significantly lower than those in the
other two groups (P<O.Ol).
A 100 fold reduction in infectious dose significantly reduced the level of NO
released by mice responding to the infection [P<O.Ol] (Table 3.12). This might
be explained by the reduced bacterial loads within these samples. Mice in the
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Infectious Dose Sample No. responding Mean Level +/-
SEM (U/ml)
104 Lavage fluid 0/46 ND
105 Lavage fluid 1/45 2.89
106 Lavage fluid 44/68 18.99+/ - 3.59
104 Lung 4/44 11.21+/- 8.27
homogenate
105 Lung 11/46 35.34+/ - 7.95
homogenate +
106 Lung 31/43 16.48+/ - 2.51
homogenate
Table 3.10 TNF activities within lung samples from MF1 mice responding with
elevated production of this mediator after inoculation of either 9.75 x 105,9.56 X
104 or 9.55 x 103 CFU S. pneumoniae. ND= none detected, +, P<0.05 higher
when compared to 106 CPU group.
Infectious Dose Sample No. responding Mean Level +/-
SEM (U/ml)
104 Lavage fluid 2/47 2.37+/-0.17
105 Lavage fluid 16/47 3.16 +/- 0.86
106 Lavage fluid 27/30 2.64 +/ - 0.47
104 Lung 9/45 1.34+/ - 0.80
homogenate II-
105 Lung 26/44 5.84 +/ - 1.06
homogenate
106 Lung 25/30 6.11 +/-1.25
homogenate
Table 3.11 IL-6 levels within lung samples from MF1 mice responding with
elevated production of this mediator after inoculation of either 9.75 x 105, 9.56
X 104 or 9.55 x 103 CFU S. pneumoniae. *, P<0.01 reduced when compared to
other infectious doses.
Infectious Dose No. responding Mean Level +/- SEM
(J.lM)
104 9/46 3.84 +/ - 0.21
*
105 12/47 8.47+/ - 1.39
106 12/62 9.56 +/-1.34
Table 3.12 NO levels within lung samples from MF1 mice responding with
elevated production of this mediator after inoculation of either 9.75 x 105,9.56 X
104 or 9.55 x 103 CPU S. pneumoniae. ", P<O.Ol reduced when compared to 106
CFU group.
Infectious Dose No. responding Mean Level +/- SEM
(ug/ml)
104 30/46 203.12+/ - 13.00
105 27/47 243.04+/-11.18
106 56/65 247.44+/-16.42
Table 3.13 Total protein levels within MF1 lung samples from mice responding
with elevated production of this mediator after inoculation of either 9.75 x 105,
9.56 X 104or 9.55 x 103 CFU S. pneumoniae.
Infectious Dose Sample No. responding Mean Level +1-
SEM (pg/ml)
104 Lavage fluid 24/44 54.17 +/- 2.77
l!-
105 Lavage fluid 4/45 82.83 +/ - 14.23
106 Lavage fluid 41/49 69.63 -r- 6.92
104 Lung 12/41 1900.58 +/ - 72.52
homogenate
105 Lung 19/43 2018.26 +/- 49.66
homogenate
106 Lung 23/30 2098.19 +t- 94.81
homogenate
Table 3.14 IL-10 levels within MF1 lung samples from mice responding with
elevated production of this mediator after infection with either 9.75 x 105,9.56 X
104 or 9.55 x 103 CFU S. pneumoniae. *, P<O.Ol reduced when compared to 106
CFU group.
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106 and 105CFU groups were equally capable of releasing NO within their
airways.
Reducing the infectious doses did not significantly reduce the total protein
levels associated with lung airways during pneumococcal pneumonia (Table
3.13). This suggests that similar levels of disruption occurred to the
alveolar / capillary barrier in mice succumbing to the infection in each of the
groups.
Few mice in the 105CFU group responded to infection by increasing lavage
fluid IL-10 levels above that seen immediately after infection (Table 3.14).
This may be explained by the unusually high IL-10 levels seen at time Oh.
Those mice that did respond in this manner did so to a similar level as the
106CFU group.
Although half of the mice challenged with 104 CFU S. pneumoniae
upregulated their airway IL-10 levels following infection, the magnitude of
elevation was significantly lower than that seen in the 106 CFU group
(P<O.Ol).
This dose dependency was absent from lung homogenate IL-10 levels as mice
in all three groups were equally capable of up-regulating tissue levels of this
anti-inflammatory cytokine.
Thus although the overall data for IL-10 (Figure 3.17 C) suggested that only a
very high infectious dose was capable of altering lung tissue IL-10 levels,
Table 3.14 shows that this is not the case. All three infectious doses are
capable of releasing similar levels of IL-10.
3.2.4.7 Systemic inflammation following intranasal inoculation of reduced
doses of S. pneumoniae
Serum TNF activities were also measured in the dose response samples in
order to further explore the possibility of a threshold number of
pneumococci required for initiation of systemic inflammation.
Mice inoculated with any of the doses of S. pneumoniae were capable of
releasing systemic levels of TNF activity (Figure 3.22). The highest levels
were found in mice inoculated with 105 CFU and occurred at 36h post
challenge, 6h later than that seen in the 106 CFU group. At 36h post
challenge of the mice inoculated with 105CFU had detectable TNF activity
within their circulations with levels ranging from 68U/ml to 2400U/ml. At
this same time point, one mouse inoculated with 104 CFU had detectable
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Figure 3.22 TNF activity within serum from MFl mice following
intranasal infection with either 9.75 x 105, 9.58 X 104, or 9.55 x 103 CFU S.
pneumoniae. n=6-16.
Dose No. responding TNF activity (mean
+/- SEM)
104 1/38 1400
105 7/40 782.10 +/ - 325.86
106 5/59 393.56 +/ - 148.95
Table 3.15 TNF activity within serum samples from MFI mice
responding with elevated production of this mediator after infection
with either 9.75 x 105,9.56 X 104 or 9.55 x 103 CFU S. p n eumo niae.
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TNF activity in its circulation, the only mouse to do so in this group
throughout the experiment.
By separating these mice into responders and non responders, as with
pulmonary TNF activities, it is possible to better understand the effects of
dose on systemic inflammation.
Reducing the infectious dose to 104CFU significantly reduced the number of
mice with detectable systemic TNF (Table 3.15). Only one mouse in this
group possessed such activity, although its serum did contain a very high
level.
Mice in the 105 CFU group displayed the greatest signs of systemic
inflammation, the largest number of positive mice and the highest activity
levels. Systemic inflammation also occurred in mice in the 106CFU group,
but in fewer animals and to a reduced extent to that in the 105CFU group.
All of these findings directly relate to the level of bacteraemia in these
groups, with low levels in the 104CFU group, higher in the 106 CFU group
and the highest in the 105 CFU category. See Table 3.4 for further
investigation of TNF activity/level of bacteraemia relationship.
3.2.5Effect of age on response to intranasal infection
In order to investigate the effects of ageing on host response to S.
pneumoniae, 52 week old MF1 mice were infected with 106 CFU and their
survival times, bacterial loads and inflammatory response compared to
young mice.
3.2.5.1Survival and signs of illness following intranasal infection of aged
and young mice
By 24h into the experiment 13/15 aged mice displayed symptoms of illness.
At this time, a hunched appearance was the most common although one
mouse was lethargic. Some mice passed rapidly through the range of signs
of illness with 2 mice culled at 28h post challenge whilst others progressed
slowly through the infection. One mouse apparently recovered from the
illness with symptoms disappearing after 92h and surviving until the end of
the experiment at 336h.
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Figure 3.23 Survival of aged and young MF1 mice following intranasal
infection with either 1.01 x 106 CFU (aged mice) or 9.76 x 105 CFU (young
controls) s. pneumoniae. n=11-53.
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Figure 3.24 Bacterial loads within the airways of aged and young MF1
mice following intranasal infection with either 1.06 x 106 (aged mice) or
9.75 x 105CFU (young controls) S. pneumoniae. n=4-28.
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Despite 5 aged mice dying within 36h, the overall survival times of these
mice were not significantly different from those of young mice (Figure 3.23).
3.2.5.2 Bacteriology following intranasal infection of aged and young mice
At the time of conducting these experiments a technical problem had arisen
with the bacterial preparations used in infections. This resulted in higher
counts recovered within the lungs immediately following intranasal
infection than were previously (and since) found. However, comparisons of
the trends between groups are still possible.
3.2.5.2.1 Bacteriology in the pulmonary air spaces following intranasal
infection of aged and young mice
Bacterial loads within the airways of aged mice were higher at all points than
young controls (Figure 3.24). No significant alteration in bacterial loads was
detected in either group during the infection.
3.2.5.2.2 Bacteriology in the lung tissues following intranasal infection of
aged and young mice
Numbers of viable pneumococci associated with lung tissues of aged mice
increased throughout the experiment (Figure 3.25). As with young mice, the
initial increase was slow in occurring and required around 12h
acclimatisation before the number of viable bacteria increased rapidly to
reach a level of approximately 106CPU/ ml of lung tissue by the end of the
experiment. The level of variation associated with aged mouse lung tissue
bacterial loads resulted in this increase being insignificant.
3.2.5.2.3 Systemic bacteriology following intranasal infection of aged and
young mice
Bacteraemia developed earlier in aged mice than in young controls following
intranasal infection with S. pneumoniae (Table 3.16). By 6h post challenge
all aged mice had culturable pneumococci within their circulations a
significant increase (P<0.05),whilst none of the young controls had detectable
bacteraemia. Blood counts continued to increase rapidly in the aged group
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Figure 3.25 Bacterial loads within the lung tissues of aged and young
MF1 mice following intranasal infection with either 1.06 x 106 (aged
mice) or 9.75 x 105CFU (young controls) S. p n eu mo n iae. n=4-11.
Time post Aged mice Young mice P value
challenge (h) bacterial load (log bacterial load (log
CFU/ml) CFU/ml)
0 ND NO P>0.999
6 2.460 +/ - 0.269 NO P<O.Ol
12 3.702 +t- 0.416 2.414 +/- 0.213 P<0.05
24 6.853 +/ - 1.116 5.315 +/ - 0.316 P>0.05 (NS)
30 7.900 +/- 0.274 5.801 +/ - 0.347 P<O.Ol
Table 3.16 Bacterial loads (mean +/ - SEM) within the bloodstreams of
aged and young MF1 mice following intranasal infection with either 1.06
x 106 (aged mice) or 9.75 x 105CFU (young controls) S. p n e u mo n ia e.. n=4-
26. ND= below detection limit of viable count assay «log 1.92 CFU / ml),
NS= not significantly different.
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until the end of the experiment (at 30h post challenge). By this time around
108CFUwere present per ml of blood. Similar kinetics of increasing bacterial
viability were found in the circulation of young mice, the mean doubling
time for 039 in young mice was l.4h and in aged mice 1.3h. There was a
delay in bacterial loads becoming significantly increased (not until 12h post
challenge), with counts lagging behind by a factor of 1 log until 30h post
challenge when a 2 log difference was evident.
3.2.5.3Histology following intranasal infection of aged and young mice
Due to the rapid progression through symptoms of illness, and the short
survival times of some aged mice, all time courses carried out with aged
mice were finished at 30h post challenge instead of 36h.
Lung sections sampled immediately following infection displayed minor
signs of inflammation in "healthy" aged mice There was evidence of slight
inflammatory cell influx and disruption to alveolar architecture. By 6h post
challenge, sections from aged mice displayed marked neutrophil recruitment
especially around blood vessels (both marginating through endothelium and
already located with surrounding lung tissue [Figure 3.26]). Histopathology
then followed a similar pattern in aged mice as that described for young mice
in Section 3.2.3.7with aged animals displaying more rapid kinetics (Table
3.17).
3.2.5.4 Production of inflammatory mediators in the pulmonary airways
following intranasal infection of aged and young mice
Upregulation of TNF activity occurred earlier and to a significantly greater
extent in the airways of aged mice when compared to young animals (Figure
3.27A). At 6h, 12h and 24h post challenge significantly higher TNF levels
were found in aged mouse samples than in young samples (P<O.Ol). In both
sets of mice TNF activity was transient with lower levels found at the later
time points.
NO levels were significantly lower in the airways of aged mice immediately
following intranasal infection with S. pneumoniae (P<O.Ol,Figure 3.27 B).
Levels of NO did increase in lavage fluid towards later time points but it was
not until peak production that levels reached those normally found in
young mice.
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Figure 3.26 A
Figure 3.26 B
Figure 3.26 Comparison of cell influx to the lungs of aged and young mice
early after intranasal infection with 106 CFU S. pneumoniae. A major
bloodvessel (BV) and bronchiole (B) is evident in each section.
A) Histological section of lung from an 9 week old MF1 mouse 6h post
infection with 106 CFU S. pneumoniae stained with haematoxylin and eosin.
Minor inflammatory cell presence is evident both inside a major bloodvessel
and in the surrounding tissue (x200 magnification).
B) Histological section of lung from a 52 week old MFl mouse 6h post infection
with 106 CFU S. pneumoniae. There is marked inflammatory cell influx in the
tissues surrounding the major blood vessel (C) and marginating through the
endothelium (M) (x20 magnification).
Mouse Time post challenge (h)
age 0 6 12 24 30 36 48
9wks 0.00 1.83 3.75 3.50 ------- 5.67 5.00
52wks 2.00 4.00 6.00 5.00 8.00 ------ -------
Table 3.17 Histopathologic score for lung tissue from 9 or 52 week old MFI
mice following intranasal infection with 1.01x 106CFU S. pneumoniae. n=1-3
mice per time point. SEMhave been omitted from the 9wk group as there are
no SEM for aged mice samples. At most times only one aged mouse was
sampled and at the others the two mice had the same histopathology score.
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Figure 3.27 Production of inflammatory mediators within the airways of
aged and young MFI mice following intranasal infection with 9.75 x 105
(young mice) or 1.06 x 106 (aged mice) CFU S. pneumoniae. A= TNF
activity n=4-21, B= NO levels n=4-12, and C= Total protein content, n=8-
14. 0= no samples for aged mice at 18h post challenge. *, P<O.Olhigher
for aged mice samples when compared to young mouse samples. +I
P<0.05 higher for young mouse samples when compared to aged mouse
samples
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A high level of disruption occurred to lung integrity of aged mice during the
infection (Figure 3.27 C). Protein levels increased steadily and highly
significantly from 6h post challenge indicating that damage occurred to the
alveolar / capillary barrier early during the experiment. At each time point
investigated, lavage fluid from aged mice contained significantly higher
levels of total protein than in lavage fluid from young mice (P<O.Ol).
Preliminary data gathered for IL-IO suggests that age did not have an effect on
production of IL-IO during pneumococcal pneumonia. Similar levels were
found in samples from aged and young animals (data not shown).
3.2.5.5 Production of inflammatory mediators in the lung tissues following
intranasal infection of aged and young mice
Elevated levels of TNF activity were evident within the lungs of aged mice
from 6h post with significantly elevated levels present at l2h and 24h post
challenge (Figure 3.28). Lung tissues from aged mice contained significantly
higher levels of TNF activity at l2h and 24h post challenge than did young
mice (P<O.Ol at l2h and P<O.05 at 24h). By 30h post challenge however, the
relationship was reversed with more TNF activity associated with young
mouse lung tissues (P<D.D5).
Preliminary data recovered for IL-ID within these same samples indicates
that production of this cytokine was no different in aged mice than in young
mice during pneumococcal pneumonia (data not shown).
3.2.5.6 Systemic production of inflammatory mediators following intranasal
infection of aged and young mice
Only 4 aged mice had detectable levels of TNF levels in their serum during
infection. One mouse mice displayed low levels of systemic TNF activity at
24h with two doing so at 3Dh post challenge. These results are not
significantly different from those obtained with young mice (Figure 3.16).
3.2.5.7 Immunohistochemistry following intranasal infection of aged and
young mice
As with young mice, TNF and IL-IO could be detected at low levels within
lungs immediately following infection, mainly within bronchial epithelial
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Figure 3.2S TNF activity levels within the lung tissues of aged and
young MF1 mice following intranasal infection with either 1.06 x 106
CFU (aged mice) or 9.75 x 105CFU (young mice) S. p n eumo ni ae. n= 4-17,
*, P<O.Olhigher for aged mouse samples when compared to those from
young mice, +, P<0.05 different for young mouse samples when
compared to aged mouse samples. 0= no samples for aged mice at ISh
post challenge.
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cells. Similar results were obtained 6h post challenge. At 12h post challenge
TNFa was mainly located in areas of cell influx with lower expression in the
bronchial epithelium. At 24h post challenge there were high levels of TNF
present throughout the lungs. At 30h post challenge TNF was only found
associated with areas of inflammatory cell influx and even then was present
at very low levels. As with young mice, both cell-attached and secreted
forms of TNFa were present although secreted constituted the majority
(Figure 3.29B). A histological section is included as Figure 3.29Aas a point of
reference.
From 12h onwards IL-I0 expression was mainly found at sites of cell influx.
This anti-inflammatory cytokine was detected in similar areas to TNFa at the
end of the infection but a stronger signal was detected suggesting more IL-IO
was present that TNFa (Figure 3.29C).
As with young mice, neutrophils constituted the majority of recruited cells
to the lungs of aged animals (Figure 3.29D).
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3.3 SUMMARY
This chapter describes the characterisation of the acute inflammatory
response that occurs following intranasal infection of MF1 mice with 106
CFU S. pneumoniae.
Such mice rapidly succumb to the infection with a median survival time of
47h post challenge.
The number of viable pneumococci found within the pulmonary air spaces
did not alter greatly during infection, whilst the number of pneumococci
associated with the lung tissues and bloodstream increased significantly.
There was a significant correlation between the bacterial loads in lung tissues
and bloodstreams (P<0.05),i.e. as the number of bacteria associated with lung
tissues increased so did the level of bacteraemia.
The bacteria induced inflammation that was evident in histological sections.
From 24h post challenge, disruption to the normal lung architecture was
evident throughout the lobes. The majority of inflammatory lesions evident
within infected lungs were perivascular, a pattern of disease previously
reported by this laboratory (Canvin et al. 1995) and others (Branch and
Stillman 1924). Candidate cell types involved in this inflammation are
neutrophils which were rapidly recruited in large numbers and mast cells
which appeared to release their granular contents.
One of these granule contents was likely to have been TNF. Pulmonary
activity of this pro-inflammatory cytokine did increase during mid infection.
Kinetics suggested two waves of production, one at 18h and one at 30h post
challenge. The early peak may have been released by resident pulmonary
cells with recruited cells responsible for the later peak.
IL-1~ levels detected within bronchoalveolar lavage fluid also increased
during mid infection. Peak IL-6 and IL-10 production was delayed in
comparison, although IL-6 production displayed similar trends to TNF
activity. Kinetics of production of all inflammatory mediators were similar
in the tissues and air spaces. NO could only be detected within lung airways,
with no significant increase in production evident during the infection.
The protein content of these lavage fluids increased from early in the
experiment indicating that damage did occur to the integrity of the
alveolar/ capillary barrier rapidly after instillation of the pneumococci.
Infected mice became severely hypothermic at the end of the infection, with
kinetics closely following elevated production of several inflammatory
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mediators, suggesting that one of these might have been the stimulus for the
decline in Teo-
PBS sham infection did not induce TNF activity in lung airways or tissues,
suggesting that the inflammation was due to the bacteria and not due to the
procedures involved. Sham infected mice did display a very transient
increase in the production of IL-10,which may constitute an attempt to down
regulate any detrimental inflammation directed against a harmless liquid.
Disruption to lung integrity was also detected in these mice.
TNF activity was not detected in either the pulmonary airways or tissues of
mice challenged with heat killed bacteria. This indicates that live
pneumococci are required for activating this arm of the inflammatory
response. IL-10levels were elevated in these mice as was the protein content
of lavage fluids. These findings suggest that inflammation not mediated by
TNFa. is occurring within lungs of mice inoculated with heat killed S.
pneumoniae. IL-l~ may be a likely replacement for TNFa. in such situations
(Riesenfeld-Orn et al. 1989).
Reducing the infectious dose decreased overall mortality associated with
pneumococcal pneumonia. In addition, mean data indicate that the kinetics
of the host response following inoculation of a reduced dose of S.
pneumoniae are delayed in comparison to those evident following infection
with 106CFU.
By separating mice into responding and non-responding phenotypes it was
possible to investigate whether similar responses resulted with reduced
challenge doses. Results showed that an infectious dose of 105 CFU
significantly lengthened the survival times of mice during the infection.
However, in respect of bacterial loads and inflammatory mediator
production, mice that were overcome by 105CFU responded in a similar
manner, but more slowly than those infected with the control dose of 106
CFU. Reducing the challenge dose even further to 104 CFU resulted in a
marked difference in not only response kinetics but also the magnitude of
several components. Even in mice responding with elevated lung tissue IL-
6, airway NO or IL-10 release, levels were significantly reduced in
comparison to the other doses. Such a phenomenon indicates that there
may be a threshold number of bacteria required to induce pulmonary
inflammation. Inoculation of 104 CFU does not result in bacterial loads that
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reach this threshold and the host response is diminished. With higher doses
the threshold is reached and mice succumbing to the infection all respond in
a similar manner, albeit with slower kinetics in the 105CFU group (a longer
period of time may be required for pneumococci to reach the threshold).
Data from Tables 3.10, 3.12 and 3.14 indicate that the threshold number of
pneumococci may be higher within the airways than in the lung tissues. No
TNF activity at all was observed in the lavage fluid from animals inoculated
with 104 CFU. There was also significantly reduced NO levels and IL-10
levels (suggesting that there was a lower general pro-inflammatory stimulus
for IL-10production) whilst levels in lung tissues were generally no different
from the other doses. Such a hypothesis supports the idea that the host
would not benefit from inflammation caused by low numbers of non-
pathogenic organisms encountered in the airways during everyday life.
Rather, high levels of inflammation would only be beneficial if the bacteria
became associated with the lung tissues.
The pulmonary threshold hypothesis is also supported by the inability to
detect systemic TNF activity in mice with a level of bacteraemia lower than
2.88x 107CFU/rnl, Thus a systemic threshold number of bacteria must be
reached before the cytokine cascade is initiated.
Bacteraemia was found to develop earlier in aged mice than in young
controls following intranasal infection with S. pneumoniae. Cytokine
analysis in the aged mice revealed a heightened production of TNF during
the infection, reduced NO levels and greatly elevated disruption to lung
tissues.
Significant inflammatory cell recruitment around major blood vessels in
aged mice lung sections occurred by 6h post challenge. Marked disruption to
lung tissues was evident from 12h post challenge until the end of the
experiment. These results indicate that an overzealous inflammatory
response occurs in aged mice during pneumococcal infection.
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4.1 INTRODUCTION
In an attempt to define the mechanism of inflammation in response to
pneumococci we decided to investigate the roles played by selected
components of the host system. An overview of the factors is given before a
detailed description of the results.
One of the first lines of non-specific defence is surfactant (Section 1.5.3.1).
Surfactant is a substance capable of lowering the surface tension in the lungs
and is produced by type II pneumocytes within the alveoli (Dobbs 1989).
Surfactant contains 20% protein and 80-90% lipid by weight and of this,
around 80%is phosholipid (Dobbs 1989).
Surfactant replacement therapies were originally designed to aid lung
function in pre-term infants (Shapiro 1998). We have employed the
synthetic surfactant preparation called artificial lung expanding compound
(ALEC) (Bangham et al. 1979)in attempts to modulate the disease process in
this model of pneumococcal pneumonia. This preparation is comprised of a
mixture of 70% phosphatidylcholine (the major phospholipid of natural
surfactant) and 30% phosphatidylglycerol and has been shown to function
well in a surface tension regulating capacity (Morley 1987), although its
effects on the immune system during disease is unknown. As this is used
clinically it is of interest to determine whether it confers any protection to
infectious disease in neonates.
The majority of host defence functions of surfactant are attributed to
surfactant proteins. The possibility that surfactant phospholipids can have
effects on host defence during pneumococcal pneumonia has therefore not
been extensively studied.
ALECwas thus employed as a convenient method of elucidating the roles of
surfactant phospholipids in immunity to infectious disease.
The first transgenic mice were successfully generated in 1980 (Gordon,
Scangos et al. 1980). Transgenic animals have since become a standard
method of investigating the effects of an individual mediator during
infection (van der Poll et al. 1997a& b), (Decken et al. 1998)(Deckert-Schluter
et al. 1998)& (McInnes et al. 1998) and inflammation (Kuhn et al. 1993),
(Peschon et al. 1998).
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These animals have advantages over antibody neutralisation of mediators
due to assurance of complete removal of the cytokine of interest.
Additionally, substances used to manipulate one cytokine are likely to have
unknown effects on others.
One disadvantage of cytokine "knockout" mice is that they do not permit
investigation of selective depletion of a cytokine within one body
compartment, e.g. the lungs. For this reason, antibody neutralisation of
cytokines still has a role to play in elucidating the effects of cytokines during
infections.
As described elsewhere in this thesis (Chapter 1) TNFa is known to playa
major role in host defence during infections caused by pneumococci and
other organisms. Antibody neutralisation of TNFa during disease has
revealed roles for this cytokine in the recruitment of inflammatory cells to
the site of infection thereby reducing bacterial loads, preventing
development of bacteraemia and improving survival rates (Britton et al.
1998), (Chen et al. 1992a), (Gosselin et al. 1995), (Laichalk et al. 1996),
(Takashima et al. 1997),(van der Poll et al. 1997a),and (Williams et al. 1990).
For this reason TNF was selected as a target to modulate the immune
response during pneumococcal pneumonia. Neutralising antibodies and
TNF receptor deficient mice were both used.
TNFa 's activities are mediated via two structurally related receptors, p55
and p75, named due to their molecular masses (Brockhaus et al. 1990)
(Section 1.6.1.1.4). These receptors can be found as cell surface bound on
most cell types, or as free soluble receptor after proteolytic cleavage of the
extracellular domain (Black et al. 1997)& (Moss et al. 1997). TNFa's more
classic functions such as up-regulation of adhesion molecules and increased
phagocyte anti-microbial activity (Le. inflammatory effects) are mediated
through p55. p75 is thought to be responsible for TNFa's cytotoxic and
apoptotic responses and down regulation of TNFa's inflammatory reactions
(Peschon et al. 1998). In certain situations, however, p75 can act to enhance
p55 mediated responses (Weiss et al. 1997).
Mice deficient in either or both TNF receptors have now been described. p55-
/- mice display heightened susceptibility to a range of infections including
intracellular micro-organisms (Everest et al. 1998), (Castanos-Velez et al.
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1998)& (Garcia et al. 1995),fungi (Steinshamn et al. 1996)and systemic S.
pneumoniae infection (O'Brien et al. 1999).
In general p75-/- mice do not display heightened susceptibility to infectious
disease (Deckert-Schluter et al. 1998).
Infections in humans and experimental animals are often associated with
significant increases in systemic and local NO production (Bergeron et al.
1998). NO production by the inducible NO synthase isoform (iNOS) is
stimulated by pro-inflammatory cytokines such as TNFa. and IL-1~,as well as
by microbial products such as lipoteichoic acid (Fang 1997).
Literature concerning the anti-microbial activities of NO mainly concerns
intracellular organisms such as Chlamydia (Igietseme et al. 1998) and
Mycobacteria (Nozaki et al. 1997). Roles for NO in controlling infections due
to extracellular bacteria is much less well understood with limited literature
available (Kaplan et al. 1996)& (Tsai et al. 1997),although a recent report does
implicate NO in cell recruitment during pneumococcal pneumonia
(Bergeron et al. 1998).
As with anti-cytokine antibodies, most of the pharmacological inhibitors of
iNOS also have an effect on cNOS and all have activities that are unrelated
to the ability to down-regulate iNOS (MacMicking et al. 1997). Thus, use of
genetically engineered mice unable to produce iNOS was a more appropriate
method of discovering the roles exclusive to iNOS during infection.
Viable and fertile genetically engineered mice deficient in iNOS (iNOS-/ -)
were originally produced by Wei et al (Wei et al. 1995). Peritoneal
macrophages from these mice completely lack expression of iNOS but not of
cNOS following LPS stimulation.
Survival of iNOS-/ - mice is markedly diminished upon infection with
bacteria such as L. monocytogenes, and the protozoan Leishmania major, in
comparison to wild-type mice of comparable genetic background
(MacMicking et al. 1995)and (Wei et al. 1995).Where examined, decreased
survival correlated with major increases in microbial burden in the affected
organs. In contrast these mice are more resistant to endotoxic shock than are
wild-type mice.
Experiments were thus carried out in an attempt to discover whether iNOS
depletion has any effects in pneumococcal pneumonia and the resulting
local inflammation.
99
Clwpter 4 Results Modulation Q,f response
4.2 RESULTS
4.2.1 Artificial lung expanding compound (ALEC)
4.2.1.1 Effect of ALEC on infectious dose in vitro
Prior to using ALEC in the in vivo model, it was necessary to assess any
effects of preparation of the infectious dose in ALEC in order to ensure that
the intended viable doses of S. pneumoniae would be administered.
Viability of s. pneumoniae D39 was not altered significantly by incubation in
ALEC (Figure 4.1). Bacterial survival drops similarly in both treatment
groups from initial preparation until the end of the experiment. Although
the rate of decline in viability does appear to be slightly greater for the ALEC
preparation than that for PBS alone, at no time are the numbers of viable
bacteria significantly different.
4.2.1.2 Effect of ALEC on bacterial loads in vivo
An in vivo experiment was carried out in order to measure any effects of
ALEC on bacterial loads during pneumococcal pneumonia. ALEC was
administered in several regimes, either 2h before, 2h after, at the same time
as the bacteria, or alone.
Administration of ALEC either 2h prior to or 2h post introduction of the
bacteria had no effect on lung associated bacterial loads 24h post challenge
(Figure 4.2). Inoculation of pneumococci concurrently with ALEC reduced
the number of viable bacteria that could be recovered 24h into the
experiment. In this group, approximately 2 log fewer CFU were recoverable
per ml of homogenate, a significant reduction in viability when compared to
no ALEC group (P<O.Ol).
The possibility that reduced bacterial loads were due to the viscosity of the
bacterial ALEC preparation hampering infection of the mice was
investigated. Sacrifice of 5 mice directly after challenge revealed that the
mean log bacteria count associated with each lung was 5.61 +1- 0.21. This
level is not lower than total lung associated counts recovered from other
experiments (not involving ALEC) where bronchoalveolar lavage fluid
counts and lung homogenate counts were gathered (4.84 +1- 0.08). This
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Figure 4.1 Viability of D39 when suspended In ALEC or PBS. n=4 for PBS
suspensions and n=3 for ALEC preparations.
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Figure 4.2 Bacterial loads within the lungs of mice 24h after undergoing
various ALEC treatment regimes in connection with intranasal administration
of either 1.06 x 106 (groups A,B, and D) or 9.40 x 105 (Group C) CFU S.
pneumoniae. A= ALEC 2h prior to infection, B= no ALEC, C= pneumococci in
ALEC, D= ALEC 2h post challenge, E= no pneumococci. n=8 for each group. *
P<0.0110wer when compared to no ALEC group.
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suggests that the lowered bacterial loads 24h following intranasal infection
with D39 in ALECwas not a consequence of impaired bacterial inoculation.
4.2.1.3Effect of ALECon pneumococcal growth in vitro
The ability of ALECto prevent growth of pneumococci was investigated by
culture of S. pneumoniae in BHI plus 5%ALEC or 5% non-pyrogenic saline.
Growth of D39 in 5% surfactant was not inhibited in comparison to that in
BHI plus 5% saline (Figure 4.3).Both cultures had the same mean doubling
time (approximately 25min) and reached similar maximum viability levels
Sh post inoculation. Bacteria grown in 5%ALEC displayed an earlier decline
phase at the end of growth and by the final time point the number of viable
bacteria within the 5% ALEC preparations was lower than those in the
controls, but not significantly so.
4.2.1.4 Effect of ALEC treatment on survival during pneumococcal
pneumonia
As co-administration of ALECand S. pneumoniae reduced bacterial loads
24h post challenge, it was a possibility that this would lead to an alteration in
survival times. Development of signs of illness in mice administered S.
pneumoniae in ALECwas delayed in comparison to those in the D39 alone
group. Clinical signs of illness were not apparent in the former group until
36h post challenge with 9/10 mice at this time displaying symptoms. Mice
infected with D39 in PBS displayed signs of illness from lS-24h post
challenge. Symptoms of mice in the ALECtreated group reached the same
severity as mice infected with D39alone after 36h. All mice then progressed
through illness at a similar rate to control animals. Despite the earlier
appearance of clinical symptoms, ALEC treated mice did not survive
significantly longer than mice given bacteria in PBS (Figure 4.4).
Results thus suggest that co-administration of pneumococci in ALEC initially
reduced bacterial viability in comparison to control animals. This reduction
was associated with a delayed appearance of signs of illness but no overall
effect on survival.
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Figure 4.3 Viable counts of D39 grown in BHI alone or in BHI plus 5% ALEC
(v/v). n= 3 for both cultures.
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Figure 4.4 Survival of MFI mice following intranasal infection with 9.76 x 105
(D39 alone) or 9.60 x 105 (D39 plus ALEC) CFU S. p neu mo ni a e alone or in
combination with ALEC. n=10-53.
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4.2.2Antibody neutralisation of TNFa
Previous investigations of TNFa's role in pneumococcal pneumonia have
indicated that this cytokine is required for a protective response (Takashima
et al. 1997) & (van der Poll et al. 1997a). These studies did not identify
interactions of TNF with other inflammatory mediators (e.g. IL-lO).
Furthermore, no previous investigations have been carried out into the
ability of local neutralisation within the lungs to alter the response to
pneumococcal pneumonia. In the studies reported here mice were treated
either systemically or locally with anti- TNFa antibody sampled at 24h post
challenge and samples investigated for cytokine levels.
4.2.2.1 Systemic neutralisation
Neutralisation of TNF activity was carried out using a goat polyclonal
antibody against mouse TNFa. In vitro, 40J.lgof this antibody were capable of
neutralising SOU TNF activity. This level of TNF activity is equivalent to
the total activity (lavage fluid plus lung homogenate and serum) detected at
peak levels of TNF activity within the lungs (lSh post challenge). 40J.lgof
antibody were thus administered intraperitoneally to mice 2h prior to
intranasal infection with 106 CFU D39. The effect of this treatment on
bacterial loads 24h after bacterial inoculation was then investigated.
In order to determine interactions of TNFa with other inflammatory
mediators during pneumococcal pneumonia, levels of IL-10, NO and total
protein were also measured within the bronchoalveolar lavage fluid
recovered from these mice.
4.2.2.1.1 Effect of systemic TNFa neutralisation on bacteriology
Significantly fewer viable pneumococci were recovered from lung airways
(P<0.05) and tissues (P<0.01) from mice pre-treated with anti-capsule anti
serum than with no treatment (Table 4.1). This treatment also prevented
development of detectable bacteraemia in all but one mouse (P<0.01). Such
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Bacterial Load! treatment
No treatment Anti-type 2 GoatIgG Anti TN Fa
capsule
Lavage fluid 4.24 +I : 0.16 3.38 -r- 0.12 3.76 + / - 0.21 4.49 +/ - 0.35
Lung 5.42+/-0.18 3.05 +/- 0.11 4.77 +/- 0.20 6.40 +/ - 0.35
homogenate *
Blood 5.22 +/ -0.34 0.48 +/ - 0.48 5.51 +/ - 0.60 7.47 +/ - 0.65
Table 4.1 Effect of systemic administration of neutralising anti- TNFa antibody
on bacterial loads within pulmonary airways, lung tissues and circulation 24h
post infection with 1.02 x 106 CFU S. pneumoniae. n= 5-24 mice, *, P<O.Ol
higher for anti-TNFa treatment when compared to goat IgG treatment.
Mediator level! treatment
None Anti-capsule GoatIgG Anti-TNFa
TNF activity 9.45 +/- 3.31 6.43 +/ - 2.26 6.17 +/-1.87 5.38 +/ - 2.34
(V/ml)
IL-10 level 60.57 +/-10.88 73.50 +/ - 2.42 41.50 +/- 5.97 69.00 +/- 4.11
(pg/ml)
NO level 5.69 +/ - 0.77 5.22 +/ - 0.85 4.17 +/-1.35 6.33 +/-1.13
(J.lM)
Total protein 221.72 +/- 28.83 231.14 +/-11.65 263.60 +/- 47.39 309.69 +/ - 54.88
(J.lg/ml)
Table 4.2 Levels of inflammatory mediators within bronchoalveolar lavage
fluid recovered 24h post challenge with 1.02 x 106 CFU S. pneumoniae from
untreated controls or mice treated intraperitoneally with anti-capsule anti
serum, anti-TNFa antibody, or Goat IgG. n=5-24.
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findings are in agreement with the type specific protective effects of anti-
capsule previously reported (MacLeod et al. 1945).
Bacterial loads within lung tissues recovered from Goat IgG treated animals
were lower than those normally found with no modulation of the immune
response (P<O.Ol). In the setting of this experiment, Goat IgG treatment
constitutes a more appropriate control than no treatment at all (in order to
control for any non-specific effects of IgG treatment and to account for the
treatment procedure itself inducing alterations). Systemic neutralisation of
TNF activity results in higher bacterial loads within each site investigated
when compared to Goat IgG treated mice and the untreated group. Anti-
TNFa treatment resulted in less than I log of an increase in viable bacteria
associated with pulmonary airways when compared to Goat IgG treated
control mice. In lung tissues and bloodstreams TNFa neutralisation lead to
an almost 2 log increase in associated bacteria (P<O.Olfor lung tissues and
P=0.058 in blood).
4.2.2.1.2 Effect of systemic TNFa neutralisation on the production of
inflammatory mediators
Lavage fluid TNF levels in the three treatment groups were not statistically
different from those in untreated mice (Table 4.2). Anti- TNFa treatment
neutralised 100% of TNF activity within the airways of two mice but high
levels of activity were recorded in lavage fluid from the remaining 3 mice.
IL-10 levels were similar in untreated mice or in those mice treated with
anti-capsular anti serum or with anti- TNFa. In addition anti- TNFa
treatment did not significantly alter NO levels from those in Goat IgG
treatment group or untreated animals.
The total protein content of lavage fluid recovered from untreated control
animals were similar to those levels detected in anti-capsule anti serum or
Goat IgG treated mice. Higher levels were found within the lungs of anti-
TNFa treated mice, but this difference was not significant. The highest
levels were found in lavage fluids that contained the most TNF activity.
Systemic TNF activity could only be detected in one mouse given anti- TNF
antibody and in one mouse given Goat IgG. Both of these Mice had levels of
bacteraemia greater than log 7.5 CFUIml.
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4.2.2.2 Effect of local neutralisation of TNFa
After successfully indicating that systemic levels of TNFa do playa role in
controlling pneumococcal viability, modulation of pulmonary TNF was
attempted.
10Jlg anti-TNFa antibody were found to neutralise the peak levels of TNFa
activity produced normally within the airways following intranasal
challenge with 106 CFU. Intranasal delivery of this amount of antibody 2h
prior to infection with 1 x 106 CFU S. pneumoniae was thus carried out, with
bacterial loads investigated 24h later.
As with systemic modulation, it was of interest to determine levels of other
inflammatory mediators during the infection. The aim was to investigate
local interactions of TNFa within the lungs.
4.2.2.2.1 Effect of local TNFa neutralisation on bacteriology
In contrast to the ability of systemic anti-capsule antiserum to significantly
reduce pneumococcal viability, local administration did not have an effect
on bacterial loads in any body compartment when compared to either non-
treated or IgG treated animals.
Neutralisation of TN Fa within the airways results in significantly higher
bacterial loads in both the air spaces and lung tissues when compared to the
other three groups (Table 4.3) [P<O.Ol for air spaces and P<0.05 for lung
tissues when compared to Goat IgG group and P<O.Ol for air spaces when
compared to no treatment group]. Bacteraemia levels were also higher in
anti- TNFa treated mice, although this difference was not significant when
compared to goat IgG treated animals.
4.2.2.2.2 Effect of local TNFa neutralisation on the production of
inflammatory mediators
TNF activity was undetectable within lavage fluid from all mice treated with
anti-capsule anti serum, anti- TNFa antibody or goat IgG (Table 4.4).
Comparison of these levels to those associated with the no treatment group
did not result in a statistically significant difference due to the variability in
TNF activity in the latter group.
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Bacterial Load! treatment
No treatment Anti-type 2 GoatIgG Anti TNFa
capsule
Lavage fluid 4.24+/- 0.16 4.02+/ - 0.24 4.42+/- 0.19 5.74+/- 0.03
*
Lung 5.42+/-0.18 5.31+/- 0.23 5.04+/ - 0.27 6.03+/ - 0.37
homogenate +
Blood 5.22+ / -0.34 5.99+/ - 0.60 6.02+ / - 0.37 6.62 + / - 0.45
Table 4.3 Effect of neutralisation of pulmonary airway TNFa activity on
bacterial loads within pulmonary airways and tissues and circulation 24h post
challenge with 1.01 x 106CFU S. pneumoniae. n= 5-24, +, P<0.05 and *, P<O.Ol
for anti-TNFa treatment when compared to goat IgG treatment.
Mediator level! treatment
None Anti-capsule GoatIgG Anti-TNFa
TNF activity 9.45+/-3.31 0.00 0.00 0.00
(U/ml)
IL-10 level 60.57 +/ - 10.88 61.00+/-16.27 47.50 +/ - 6.96 48.50 +/ - 6.59
(pg/ml)
NO level 5.69 +/- 0.77 3.89 +/ - 0.36 5.28 +/-1.45 4.67 +/ - 1.50
(flM)
Total protein 221.72 + / - 28.83 229.57 +/-15.70 179.08 +/- 20.54 221.86 +/ - 44.50
(flg/ml)
Table 4.4 Levels of inflammatory mediators within bronchoalveolar lavage
fluid recovered 24h post challenge with 1.01 x 106 CFU S. pneumoniae from
untreated controls or mice treated locally with anti-capsule anti serum, anti-
TNFa antibody, or Goat IgG. n=5-24
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IL-10 levels were not significantly different in any of the groups of mice,
although lower levels of IL-10 were found in airways of animals treated with
either TNFa antibody or goat IgG.
Similar levels of NO and total protein were found in samples recovered
from all mice during this experiment with no statistical difference between
any treatment groups.
No mice were found to have detectable levels of TNF activity within their
circula tions.
4.2.3 Pneumococcal pneumonia in TNFa receptor -/- mice
Following demonstration that systemic TNFa neutralisation was capable
significantly altering pneumococcal viability following respiratory infection
with S. pneumoniae, it was decided to investigate TNFa's role further.
Utilisation of TNFa receptor deficient mice permitted the effect of an
inability to mediate TNFa's functions on overall survival to be determined.
Further analysis of TNFa's effects on bacterial loads were possible at multiple
time points. These experiments also enabled the roles of TNFa's two
receptors to be investigated independently during pneumococcal
pneumonia.
4.2.3.1 Signs of illness and survival of TNFa receptor -1- mice
Despite all control mice surviving the infection (Figure 4.S), almost all
infected animals displayed clinical signs of illness during the experiment. In
the case of the CS7Bl/6 controls these were of mild nature, with a slight
hunched appearance from around 36h post challenge. By 72h post challenge
all mice had returned to normal behaviour.
p7S-/- mice also displayed a hunched appearance during the experiment. In
this case it occurred at lS-24h into the experiment and the symptoms were
gone by 72h post challenge.
In addition to displaying transient signs of infection, all p7S-/- and CS7Bl/6
mice survived the infection (mean survival time >336h), making them
more resistant than MFl (Figure 3.4) and CBA/Ca mice (Figure S.l).
pSS-/ - mice were hunched in appearance from around 24h post challenge. In
all but 2 of the pSS-/- mice, symptoms were not displayed in the order
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Figure 4.5 Survival of p55-/ -, p75-/ - or wildtype C57Bl/6 mice following
intranasal infection with 1.01 x 106 CFU S. p n e u mo n ia e. n=10, *, P<O.Ol shorter
survival times for p55-/ - when compared to p75-/ - and C57Bl/6 mice.
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Figure 4.6 Bacterial loads within the lung airways of p55-/ - and C57BI/6 mice
following intranasal infection with 1.01 x 106 CFU S. p n eu moniae. n=3-7, *,
P=O.Olhigher bacterial load in p55- / - airways than in C57Bl/ 6 airways.
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normally seen in susceptible mice, rather mice proceeded from mild signs of
illness to being moribund in a matter of approximately 6h. There was no
evidence of piloerection or lethargy in these animals.
p55-/- deficient mice were susceptible to the infection, with 100% mortality
by 89h into the experiment (median survival time 63h). Statistical
comparison of survival times of each group of mice revealed that p55-/-
mice survived for significantly shorter periods following intranasal infection
with 106 CFU S. pneumoniae than did both p75-/- and C57Bl/6 mice (P<
0.01).
4.2.3.2 Bacteriology in TNFa receptor -/- mice
As p75-/ - mice were no more susceptible to pneumococcal pneumonia than
C57Bl/6 controls, further experiments were mainly carried out in p55-/- and
C57Bl/ 6 mice.
Bacterial loads were only investigated in p75-/- mice at 24h post challenge.
At this time bacterial loads in lavage fluid (4.35+/- 0.22 CFU/ml), lung tissues
(3.15+/- 0.22CFU/ml) or blood (0.66+/- 0.43 CFU/ml) from p75-/- mice were
no different from those in C57B1/6 mice 24h into the experiment.
4.2.3.2.1Bacteriology in pulmonary air spaces of TNFa receptor -/- mice
The numbers of viable pneumococci within the lung airways of p55-/- mice
did not alter significantly during the infection (Figure 4.6). Approximately
105CFU were recovered per ml of lavage fluid at each time point.
During early infection there were similar numbers of bacteria within the
airways of C57Bl/6 mice as in p55-/- mice. A decrease in pneumococcal
viability then occurred within C57Bl/6 airways so that 30h post challenge just
over 103CFU were recovered per ml of lavage fluid. Comparison of the two
mouse strains revealed higher numbers of pneumococci within p55-/-
airways at 24h (significant at the level of P=0.026) and at 30h (P=O.Ol)than in
C57Bl/ 6 controls.
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4.2.3.2.2 Bacteriology in lung tissues of TN Fa receptor -/- mice
At I2h post challenge both strains of mice have similar numbers of
pneumococci associated with their lung tissues (Figure 4.7). The numbers
then increased slowly within p55-/-lungs during the next I2h, with a rapid
increase in recoverable pneumococci occurring during the final 6h studied.
By 30h post challenge a statistically significant increase in pneumococcal
viability over that at I2h was found (P<O.OI).
Pneumococcal viability in C57BI/6 lungs did not alter between the 12h and
24h time points. A rapid increase in their number did occur during the final
6h with a statistically significant increase compared to levels at 12h by 30h in
the experiment (P<O.OI).Significantly lower numbers of viable pneumococci
were still found associated with these lung tissues than in p55-/- mice
(P<0.05at 24h and P<O.OIat 30h).
4.2.3.2.3 Systemic bacteriology in TNFa receptor -/- mice
At I2h post challenge the two strains of mice had similarly low levels of
pneumococci in their bloodstreams (Figure 4.8). Numbers of viable bacteria
then increased rapidly in p55-/ - mice until the end of the experiment when a
significantly higher number of pneumococci were cultured in the samples
(P<O.OI).In C57Bl/6 mice, pneumococci were controlled during the next I2h
with recoverable numbers not increasing until after the 24h time point
(P<O.OIat 30h).
From I8h onwards significantly higher numbers of pneumococci were
cultured from p55- blood than from C57BI/6 samples (P<O.OI)
4.2.3.3 Production of inflammatory mediators within airways of TNFa
receptor -/- mice
Production of inflammatory markers was investigated at 24h post challenge.
This single time point was selected as the low numbers of samples currently
recovered at the other times would result in ineffective statistical
comparisons.
At this time TNF activity could not be detected within lavage fluid from
C57Bl/6 or p55-/ - mice (Table4.5). At 24h post challenge lavage fluids from 3
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Figure 4.7 Bacterial loads within the lung tissues of p55-/ - and C57BI/6 mice
following intranasal infection with 1.01 x 106 CFU S. pneumoniae. n=3-6, +,
P<O.05 and *, P<O.Ol higher for p55-/ -lungs than for C57BI/6 samples.
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Figure 4.8 Bacterial loads within the blood of p55- / - and C57BI/6 mice
following intranasal infection with 1.01 x 106 CFU S. p neu moni ae. n=4-18, *,
P<O.Ol higher for p55-/- samples than for C57Bl/6.
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out of the 5 p75-/- mice possessed detectable TNF activity but these results
were not significantly different from the other groups although they do agree
with the p75 receptor acting as a TNF scavenger (Peschon et al. 1998)during
pneumococcal pneumonia.
Similar levels of IL-10 were found in p55-/- and p75-/- mice. Control
C57Bl/6 samples only contained around a third of this amount, but this
difference was not significant.
NO production was significantly lower in both TNF receptor deficient mouse
strains during mid infection when compared to C57Bl/6 controls (P<0.05).
The lowest levels were found in p55-/- mice with slightly higher levels in
p75-/-.
Similar levels of disruption to the alveolar/capillary barrier occurred to in
both p75-/ - and C57Bl/6 mice. These mice had around double the amount of
protein associated with their lavage fluids than did p55-/ - mice. The
difference between p55-/ - and p75-/ - micewas not significant but comparison
of protein levels in p55-/ - lavage fluids with those from C57Bl/6 mice
revealed that mice with the ability to signal through the p55 TNF receptor
had significantly more pulmonary disruption during the infection (P<0.05).
Inflammation appeared to be contained within the lungs as no TNF activity
could be detected within serum from any mice during the experiment.
During pneumococcal pneumonia in p55-/ - mice there appears to be slightly
higher IL-10levels but decreased NO and lung integrity. Signalling through
the p55 TNFa. receptor appears to upregulate inflammation within the lungs
and mediates disruption to the alveolar/capillary barrier permitting influx of
serum proteins.
4.2.4 Pneumococcal pneumonia in iNOS -/- mice
In a recent report NO was implicated in monocyte recruitment during
pneumococcal pneumonia with overzealous production involved in
pathology (Bergeron et al. 1998). These experiments to be described were
carried out in order to determine if this was the case for this model of
pneumococcal pneumonia, and to also investigate interactions of NO with
other inflammatory mediators. Mice unable to produce NO via the
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Lavage fluid
marker Mouse Strain
pSS-/- p7S-/- CS7BI/6
TNF activity 0.00 U/ml 4.98 U 1m1 +1- 3.64 O.OOU/ml
(U /ml)
NO level (11M) 2.72 11M+1- 0.56 4.00 11M+1- 0.53 5.39I1M+I - 0.20
+ +
IL-10 level 36.00 pgl ml +1- 9.35 34.80 pg/ml +1-16.42 12.60 pgl ml +1- 6.63
(pg/ml)
Total protein 128.2811g1ml +1- 32.83 278.71l1g/m1 +1-56.80 2475711g/ml +1-19.31
content (11~/ ml) +
Table 4.5 Levels of inflammatory markers within the lavage fluid from TNFa
receptor deficient or control mice at 24h post intranasal challenge with 1.01 x
106 CFU S. pneumoniae. n=5, +, P<0.05 lower for p55-/ - mice than for p75-/-
and C57Bl! 6 mice.
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Figure 4.9 Survival of iNOS-/-, iNOS +/- and wildtype MF1/129 mice
following intranasal challenge with 1.05 x 106 CFU S. pneumoniae. n=9-10.
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inducible nitric oxide synthase pathway were infected and their response
characterised. The role of NO in Gram-positive septic shock was also
investigated.
4.2.4.1 Signs of illness and survival of iNOS .t: mice following intranasal
challenge
Development of symptoms in control MF1/129 mice was highly variable. At
the same time as 1 mouse was moribund (24h post challenge) 2 other mice
that did succumb to the infection later were still completely normal.
Additionally, the speed that MF1/129 mice passed through the range of
clinical indications was also not uniform.
Symptoms in the heterozygous iNOS+ / - group tended to occur by 24h post
challenge with a hunched stance being the most common. In general these
mice passed slowly through the range of symptoms.
iNOS-/- mice displayed piloerection from 24h into the experiment, although
at this time one mouse had already succumbed to the illness. iNOS-/- mice
developed the most severe signs of illness of the three mouse strains. This
occurred shortly after intranasal infection with all iNOS-/ - mice succumbing
to the illness by 101h.
Although there appeared to be a shift to lower survival times for iNOS-/-
mice, statistical analysis revealed no significant difference between any of the
mouse strains (Figure 4.9).
As iNOS+ / - mice displayed similar survival times and symptom progression
to MF1/129 mice, subsequent studies were only performed on iNOS-/- and
the wild type MF1/129 strain
4.2.4.2 Bacteriology in iNOS -/- mice following intranasal challenge
Although survival times were not significantly different between iNOS
deficient and normal mice, there still remained a possibility that NO was
playing a subtle role in host defence. In order to investigate that hypothesis,
the size and location of bacterial loads following intranasal infection were
determined.
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Figure 4.10 Bacterial loads within the airways of iNOS- / - and control MFl/ 129
mice following intranasal infection with 1.03 x 106 CFU S. pneumoniae. n= 5-
10, *, P<O.Ol higher for iNOS-/ - than for MF1/ 129 samples.
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Figure 4.11 Bacterial loads within the lung tissues of iNOS- / - and control
MF1/129 mice following intranasal infection with 1.03 x 106 CFU S.
pneumoniae. rt= 5-10, *, P<O.Ol higher for iNOS-/- than for MF1/129 samples.
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4.2.4.2.1Bacteriology in the pulmonary air spaces of iNOS -/- mice
Viability of pneumococci within the airways of iNOS-/- mice increased
immediately following infection with around a 1 log increase by 12h post
challenge (Figure 4.10). This trend was not evident in samples from
MFI/129 mice. Indeed, following 12h into the experiment MF1/129 mice
rapidly reduced the bacterial counts by around I log per mllavage fluid, with
levels remaining constant until the end of the experiment.
A similar, but delayed reduction in bacterial viability was observed within
airways of iNOS-/- mice, reducing viability to a level comparable with that
detected immediately following infection.
From 12h into the experiment, the enhanced ability of normal mice to
control pneumococcal viability resulted in significantly fewer pneumococci
cultured from their lungs than from lungs of iNOS-/- mice (P<O.Ol).
4.2.4.2.2Bacteriology in lung tissues of iNOS -/-mice
Bacterial viability within the lung tissues of both iNOS-/- and MF1/129 mice
increased initially during the experiment (Figure 4.11). Similar levels were
found in the two mouse strains at 6h and 12h post challenge although iNOS
-/- lung tissues contained slightly higher counts. Following 12h, viable
bacterial loads within iNOS-/-lungs continued to increase, albeit at a reduced
rate.
Whilst pneumococcal counts in iNOS-/- lung tissues were increasing, viable
counts within MF1/129 lungs increased to a lower level than iNOS-/- mice
(P<O.Ol)and then displayed a marked reduction. The decline in viability
displayed similar kinetics to those seen in MF1/129 air spaces, a reduction of
1 1/2 log magnitude occurring between 12h and 24h. This reduction
significantly lowered pneumococcal viability even further below that in
iNOS-/- mice at 24h post challenge (P<O.Ol).This effect was transient as by
24h the number of recoverable pneumococci had increased. This increase
continued until the end of the experiment, by which time the bacterial loads
in the two mouse strains were similarly elevated above Ohvalues (P<O.Ol).
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Mean Log Bacterial Load (CFU/ml)
Time post challenge (h) MFl/129 iNOS-I-
0 ND ND
6 ND ND
12 2.27 + 1- 0.21 2.42 + 1- 0.27
24 3.85 +10.55 3.91 + 1- 0.50
36 4.77 +1- 0.95 5.64 + 1- 0.60
48 4.82 + 1- 0.81 6.79 +1- 0.64
Table 4.6 Bacterial loads within the bloodstreams of iNOS-I-and control
MF1/129 mice following intranasal infection with 1.03 x 106 CFU S.
pneumoniae. n= 5-10. ND= below detection limit of viable count assay (clog
1.92 CFU Iml).
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4.2.4.2.3Systemic bacteriology in iNOS -/- mice
No blood-borne bacteria were found until 12h post challenge (Table 4.6). At
this time 7 iN05-/- mice and 3 MF1/129 had developed bacteraemia.
Kinetics of increasing bacterial viability within the bloodstream's of iNOS-/-
mice are similar to those in MF1/129 mice. Blood culture counts continued
to increase almost unchecked until the end of the infection in iNOS-/ - mice
so that they were almost a 210g higher than in MF1/129 mice.
4.2.4.3 Production of inflammatory mediators by iNOS -/- mice during
pneumococcal pneumonia
The ability of NO to interact with several other inflammatory mediators has
been widely studied (Chapter 1). In order to characterise such interactions
during this infection, TNF activity and IL-lOlevels were measured in iNOS-
/- mice.
Despite the inability to release high levels of NO via the Ca2+ independent
pathway, iNOS-/- mice retain the ability to release lower levels via the cNOS
pathway. The possibility that this occurred during pneumococcal
pneumonia was investigated by measuring levels of NO released in the
airways of both iNOS deficient and sufficient strains of mice.
NO is known to effect the integrity of endothelial barriers (Beckman et al.
1990). In order to determine whether this occurred to the alveolar/capillary
barrier during pneumococcal pneumonia, total protein levels within the
airways of mice unable to produce high levels of this mediator were recorded
and compared to NO sufficient controls.
4.2.4.3.1Production of inflammatory mediators in lungs of iNOS -/- mice
during pneumococcal pneumonia
TNF activity was undetectable within lavage fluid from all mice during early
infection (Figure 4.12A). 12h post challenge similar levels of activity were
found in iNOS-/- and MF1/129 mice. Throughout the remainder of the
experiment, no TNF activity was detected within MF1/129 samples. iNOS-/-
samples contained high levels of TNF activity at both 24h and 36h post
challenge which were significantly higher than those in MF1/129 samples
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Figure 4.12 Levels of inflammatory mediators within bronchoalveolar lavage
fluid from iNOS-/ - and MF1/ 129 mice following intranasal infection with 1.03
x 106 CFU S. pneumoniae. A= TNF activity, B= IL-10 levels, C= NO levels, and
D= total protein content. n=5-10, *, P<O.Ol, + P<0.05 higher for iNOS- / - when
compared to MF1/ 129 results.
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(P<O.Olat 24h and P<0.05 at 36h). By 48h such activity had returned to
undetectable levels.
The inability to synthesise NO via the iNOS pathway did not reduce the
capacity to release IL-IO(Figure 4.12B). Similar levels of IL-IOwere detected
within the lavage fluid from iNOS-I- and MF1/129 mice during the
infection. Both strains displayed a significant increase in IL-IOlevels by the
end of the experiment (P<O.Olfor MFl/129 and P<0.05 for iNOS-I-). Within
iNOS-1- mice, elevated cNOS activity may be responsible for the elevated IL-
10 production.
Very high levels of NO were detected within the lavage fluid from 1 iNOS-I-
mouse immediately following infection (Figure 4.12 C). The remaining 4
mice had similar levels to MFl/129 controls. NO production within the
airways of iNOS-I- mice increased slowly during the infection to peak at 5.5
JlM48h post challenge. Levels of NO within iNOS-1- mice were significantly
higher than those in MF1/129 airways at 36h post challenge (P<0.05). The
high variation in MF1/129 NO levels at l2h post challenge resulted in a
insignificant difference between the two mouse strains at this time post
challenge.
Low levels of NO were found in lavage fluid from MF1/129 mice during the
first 6h of infection. Production increased markedly in 4/10 mice at l2h to
peak at 9JlM, although the variation did not permit significance to be
reached. Increased production was transient with baseline values again
being detected from l2h post challenge until the end of the experiment.
Lavage fluid from 2/5 iNOS-I- mice contained high levels of total protein at
the time of infection (Figure 4.12 D). During the next 12h, low levels of
protein were found associated with the airways of iNOS-1- mice. Higher
levels were detected during the final 24h of the experiment indicating that
disruption to the alveolar1capillary barrier occurred around 24h into the
experiment despite the absence of NO.
Samples from MFl/129 mice contained similar levels of protein during the
initial 12h of the infection. From 24h post challenge, protein contents did
increase in MF1/129 mice, but not to the same extent as they did in iNOS-I-
mice. At 36h post challenge lavage fluid from iNOS-1- mice contained
significantly more protein than samples from MF1/129 mice (P<O.05).
These results show that airways of iNOS-1- mice have a greater
inflammatory stimulus due to elevated bacterial loads. This leads to
significantly more TNF, NO and total protein within pulmonary air spaces
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and perhaps the more severe signs of illness displayed by these animals
during infection.
Investigation of TNF activity within the lung tissues of mice sampled at the
time point of 24h post challenge revealed that mice unable to produce NO
via the iNOS pathway had lower levels in comparison to MF1/129 mice
(Table 4.7). Due to the small group size (n=5) this difference is not
significant.
At 24h post challenge iNOS-/ - mice released slightly higher (but not
significantly so) levels of this anti-inflammatory cytokine than did tissues
from MF1/129 mice.
Systemic TNF activity was found in only 3 mice in these studies. One iNOS-
/- and one MF1/129 serum sample at 24h and one MF1/129 sample at 36h.
4.2.4.4Systemic pneumococcal infection in iNOS-/- mice
There was no difference in levels of bacteraemia within iNOS-/- and
MF1/129 mice following intranasal infection with S. pneumoniae (Table
4.6). This suggests that any difference in bacterial survival within NO
sufficient and NO deficient infected animals is solely mediated by the lungs.
In order to investigate this hypothesis, groups of both strains of mice were
infected intravenously. If the hypothesis is correct, pneumococci would be
equally able to proliferate in the bloodstreams of iNOS-/- and MF1/129 mice.
4.2.4'.4.1Signs of illness and survival following systemic pneumococcal
infection in iNOS-I- mice
All of the mice displayed symptoms of illness during the experiment.
Development of symptoms in MF1/129mice was variable with 2 mice still
displaying normal appearance at 30h post challenge whilst another had
already succumbed to the infection. Once signs of illness became apparent,
mice rapidly developed full blown disease with 100%mortality by 72h post
challenge.
All iNOS-/- mice displayed clinical signs of illness by 30h post challenge. At
this time these were mild in nature with only a slightly hunched stance
evident. 2 mice progressed to succumb to the bacterial challenge whilst the
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Mouse strain Cytokine Level
TNF (U/ml) IL-IO (pg/ml)
MF1/129 53.84+/ -16.56 471.00+/ - 23.18
iNOS-/- 17.87+/- 5.61 588.50+/ - 45.54
Table 4.7 TNF and IL-10 levels within the lung tissues of MF1/ 129 and iNOS- t-
mice 24h post intranasal infection with 1.03 x 106CFU s. p ne u mo n ia e. n=5.
75
Percentage • iNOS-/-
Survival 50 • MFl/129(%)
25
o 48 96 144 192 240 288 336 384
Time post challenge (h)
Figure 4.13 Survival of iNOS-/ - and MF1/129 mice following intravenous
infection with 7 x 104 CFU S. p neu mo ni ae. n=5 group, +, P<0.05 shorter
survival times for MF1/129 mice than for iNOS-/ - mice.
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remaining 3 were again normal by 72h post challenge and remained so until
the end of the experiment.
Statistical analysis revealed that the survival times of MF1/129 mice were
significantly lower than those of iNOS-/- mice (P<0.05[Figure 4.13]).
4.2.4.4.2Bacteriology following systemic pneumococcal infection in iNOS-/-
mice
Similar numbers of pneumococci were recovered from the circulation
immediately following intravenous infection (Figure 4.14). During the
following 24h this number increased slowly in MFl/129 mice with greater
than 105CFU found in each ml of blood by 24h post challenge. iNOS-/ - mice
were better able to control the inoculated bacteria, with numbers of viable
pneumococci actually decreasing slightly in the 12h following challenge to a
level significantly lower than in MFI/129 mice (P<O.Ol). No further
significant alteration in pneumococcal viability was detected in the final 12h
of the experiment.
The survival data and bacteriology indicate that the ability to produce high
output NO via the iNOS pathway is detrimental during Gram-positive septic
shock.
4.2.5 Antibacterial effects of NO in vitro
The enhanced ability of NO sufficient mice to control bacterial loads wi thin
the lungs following intranasal infection with S. pneumoniae indicated that
NO could be directly bactericidal for pneumococci.
In order to investigate this, a NO donor (SNAP) was added to the growth
media of S. pneumoniae cultures. SNAP has previously been employed to
prove the direct effects of NO on other micro-organisms, for example
(Kaplan et al. 1996). The ability of NO to prevent or delay pneumococcal
proliferation was therefore investigated.
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Figure 4.14 Bacteraemia in iNOS-/ - and MF1/129 following intravenous
infection with 7.00 x 104CFU S. p neu mo n ia e. n=5, *,P<O.Ol higher for MFl/129
when compared to iNOS-/-.
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Figure 4.15 Effect of SNAP on growth of S. p neumo n iae in BHI n= 3 cultures/
group. Each point represents the mean, for simplicity SEM are left off.
Chapter 4 Results Modulation oj response
4.2.5.1Effect of SNAP on growth of S. pneumoniae
Incubation of S. pneumoniae in BHI plus 200llM of the NO donor SNAP has
no effect on the ability of bacteria to proliferate (as revealed by viable counts)
[Figure 4.15]. The peak absorbance in this group was slightly lower but this
difference was not significant. The negative control, D-penicillamine, did
delay the initiation of growth slightly but the overall growth of S.
pneumoniae was unaffected.
When statistical analysis was carried out there were no significant differences
in pneumococcal growth between any of the preparations either by optical
density or by viability counts.
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4.3 SUMMARY
The effects of surfactant, the ablation of TNF receptors, or of the enzyme,
iNOS, all on the induction of pneumococcal pneumonia in mice are
reported in this chapter.
Surfactant phospholipids were capable of reducing pneumococcal viability in
vivo if administered at the same time as the bacteria. This did not result in
an alteration in survival times.
The effect of ALECon pneumococci was not direct cytotoxicity as viability of
the organism was unaffected by incubation in the surfactant. In addition,
growth of D39was not altered in BHI and 5%ALEC, although viability at the
end of growth was.
TNFa was shown to be an important mediator of host defence in the setting
of pneumococcal pneumonia. Neutralisation of TNFa, either systemically
or locally, significantly altered bacterial loads in the lung airways and tissues.
Bacteraemia was also elevated in mice depleted in systemic TNFa.
Signalling through the p55 TNFa receptor was found to be important for
controlling bacterial levels and promoting survival during pneumococcal
pneumonia.
In addition to the beneficial effects of TNFa, signalling through the p55
receptor was involved in the disruption to lung integrity and development
of clinical symptoms during the infection.
Nitric oxide was not found to be directly bactericidal for pneumococci in
vitro, nor absolutely required for survival during pneumococcal
pneumonia. It was found to control bacterial viability within the lungs.
Mice unable to produce NO via the iNOS pathway were found to have
higher numbers of viable pneumococci within their pulmonary airways and
lung tissues.
Production of NO by the iNOS pathway was associated with reduced airway
TNFa levels and lowered disruption to the alveolar/capillary barrier
although IL-10production was unaffected.
During systemic infection the relationship was reversed. Mice unable to
utilise the iNOS pathway were significantly less susceptible to pneumococcal
infection. This indicates that production of high levels of NO during Gram-
positive sepsis is detrimental.
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5.1 INTRODUCTION
As mentioned in Chapter 1 (Section 1.4.3),host genetic factors are known to
affect the outcome during several infectious diseases and are believed to play
a role during pneumococcal pneumonia. At present the nature and effects of
these factors is not understood.
In order to better understand the host response to pneumococcal infection, a
detailed comparison of mouse strains was undertaken in this laboratory.
Initial studies (Gingles et al. manuscript in preparation) identified BALB/c
and CBA/Ca mouse strains as being resistant and susceptible, respectively, to
intranasal infection with S. pneumoniae.
Further experiments were undertaken to compare the nature of the
inflammatory response in these two mouse strains. The aim was to identify
differences in the inflammatory response mounted by CBA/Ca and BALB/c
mice that could account for the outcomes of infection.
Such link between the production of cytokines and outcome of disease has
been found in several other infection models. In a pulmonary model of
Cryptococcus neoformans infection, resistance correlates with elevated IFNy
and IL-2secretion (Hoag et al. 1995). During experimental leishmaniasis or
Listeria monocytogenes infection, insufficient production of TNFa. is
associated with death. High levels of INFo, have been correlated with severe
complications and death during malaria (Garcia et al. 1995). INFo, also plays
a role in determining resistance of mouse strains to pulmonary
Pseudomonas aeruginosa infection (Gosselin et al. 1995). Finally,
individuals with a low INFo, or high IL-10response (as determined by ex-
vivo endotoxin stimulation of whole-blood) are more likely to die from an
episode of meningococcal meningitis than are patients with a lower anti-
inflammatory response (Westendorp et al. 1997).
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5.2 RESULTS
5.2.1 Intranasal Infection
5.2.1.1Signs of illness following intranasal infection of BALB/c or CBA/Ca
mice
Following intranasal infection with 106 CFU S. pneumoniae, significantly
different signs of illness and survival times were displayed by CBA/Ca and
BALB/c mice (Figure 5.1). These results confirm the initial observations
from this laboratory (Gingles et al. Manuscript in Preparation). 4h into the
experiment all but one CBA/Ca mouse (out of 96 studied) displayed signs of
illness. The most common clinical symptoms at this time were a hunched
stance and a degree of piloerection, although 10 of the mice had already
passed through these signs of illness to become lethargic. Over the next l2h
all mice became so ill they were deemed moribund. The median survival
time for infected CBA/Ca mice was 36h post challenge. During time course
experiments it was necessary to finish experiments at 36h post challenge in
order to gather a full data set.
In comparison, although 24 of the 166BALB/c mice used in these studies
displayed some symptoms of infection, these tended to be of a milder nature
with hunched appearance and slight piloerection. Such signs of illness were
mainly recorded between 24h and 72h post challenge. Due to the nature of
these experiments, with each mouse sacrificed prior to sampling, it could not
be determined whether symptoms were transient in nature. Only 4 of the
166BALB/cmice passed through lethargy to become moribund by l44h. The
remaining BALB/ c mice were deemed to have survived the experiment and
were sacrificed at 336h post challenge. The median survival time for the
resistant mice was greater than 336h.
Comparison of the survival times for both strains of mice revealed that
those for non-implanted CBA/Ca were significantly lower than those
displayed by non-implanted BALB/cmice during pneumococcal pneumonia
(P<O.Ol).
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Figure 5.1 Survival of CBA/C and BALB/ c mice fol1owing intranasal infection
with either 9.75 x 105 (BALB/ c mice) or 9.82 x 105 (CBA/Ca mice) CFU S.
pneumoniae. n= 14 for CBA/Ca and n= 11 for BALB/ c, *, P< 0.01 shorter for
CBA/ Ca survival times compared to BALB/ c.
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Figure 5.2 Survival of implanted CBA/ C and BALB/ c mice following
intranasal infection with 1.01 x 106 (BALB/ c mice) or 9.95 x 105 (CBA/ Ca mice)
CFU S.pneumoniae. n=8, *, P<O.Ol shorter survival times for CBA/Ca mice
compared to BALB/ c.
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5.2.1.2 Telemetry following intranasal infection of BALB/c or CBAlCa mice
In order to better define the nature of symptoms in the two strains we used a
system of telemetry implants. The effect of chip implantation on the
response of the mice was first determined.
As with non implanted animals, implanted CBA/Ca mice displayed clinical
symptoms earlier than did BALB1c mice following intranasal infection with
S. pneumoniae. By 24h post challenge all CBA/Ca mice were hunched with
4/8 displaying piloerection. Signs of illness did not progress from this stage
until after 32h into the experiment. The mice then rapidly passed through
the range of symptoms so that there was only one survivor 48h post
challenge.
Two implanted BALBI c mice succumbed to the infection. These mice
displayed mild symptoms from mid infection (32h & 52h post challenge) and
survived until 79h post challenge. The remaining BALB1c animals showed
no signs of illness and survived the experiment.
Survival times displayed by implanted CBA/Ca mice were again significantly
shorter than BALB/c counterparts (P<O.OI).
Chip implantation did not significantly alter the survival time of BALB/c
mice following infection with S. pneumoniae (Figure 5.2), but survival times
of CBA/Ca mice were found to be significantly longer than those of non-
implanted animals. However the overall trend was the same, therefore in
subsequent experiments implanted and non-implanted mice were grouped
together.
Utilisation of the telemetry system made it possible to monitor the core body
temperature and activity of mice repeatedly during the infection in addition
to recording the development of clinical symptoms of disease. During early
infection, all but 1 (out of 15) CBA/Ca mouse displayed constant core body
temperatures (this mouse displayed transient hypothermia similar to that in
BALB/c mice [Figure 5.4]). In the final 7h of the experiment, body
temperature of all susceptible CBA/Ca mice began a continuous decline until
ambient room temperature was reached (Figure 5.3).
36/43 resistant BALB/c mice monitored for longer than 24h developed
transient hypothermia during early infection [around 20h post challenge]
(Figure 5.4). In 18 of the mice hypothermia was seen as a single episode but
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Figure 5.3 Core body temperature (OC)of a CBA/Ca mouse infected with 106 CFU
S. pneumoniae. Vertical line represents time of infection.
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in the other 18 there was one period, recovery and constant Teo for 1-2h and
then a second transient period of hypothermia.
During these periods of hypothermia (second drop if double episode), core
body temperature dropped to a mean of 31.5 °C for approximately 5h, a
significant drop in Teo (P<0.01). A further 8-12h were required before Tco
finally returned to baseline, where it remained until the end of the
experiment. The earlier period of hypothermia in double episode was less
marked (approximately 4°C) and lasted around Ih.
Periods of hypothermia appeared to occur as the normal circadian rhythm of
the mice was on a downwards trend. The subsequent increase in
temperature also corresponded in time frame to a shift in circadian rhythm
towards elevated temperature.
Two implanted BALB/c mice succumbed to pneumococcal pneumonia.
These mice still displayed the transient hypothermia during early infection
but also displayed the constant decline in Teo seen in CBA/Ca mice at the
end of the experiment
Corebody temperatures of PBS sham infected mice of both backgrounds did
not display hypothermia although a cyclical alteration in core body
temperature was evident (data not shown) as seen with MFI mice (Figure
3.5).
There was no correlation of hypothermia to signs of illness as only four
animals with a decreased Teo displayed symptoms whilst 2/7 animals not
displaying hypothermia still showed clinical symptoms.
There was also no correlation between hypothermia and survival as the
animals with constant Teo went on to survive the experiment.
Activity profiles were determined concurrently with core body temperature
and recorded on an arbitrary scale. Although CBA/Ca mice displayed
symptoms of infection as early as 24h post challenge, their activity score did
not alter until the final 2h of the experiment (Figure 5.5). The activity
profiles of infected resistant BALB/ c mice (Figure 5.6) and PBS sham infected
mice of both strains did not alter significantly during the experiment (data
not shown for sham infected BALB/c and CBA/Ca mice but similar to that
for sham infected MF1 mice Figure 3.6). In addition the activity counts
displayed for the representative mice show that the BALB/c animal was
generally more active than its CBA/Ca counterpart throughout the
experiment.
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5.2.1.3 Bacteriology in the pulmonary air spaces following intranasal
infection of BALB!c or CBAlCa mice
6
Inoculation of 10 CFU of pneumococci into the nose resulted in
5
approximately 10 CFU being recovered immediately in the airways of each
animal (Figure 5.7). Although higher numbers of viable pneumococci were
initially recovered in CBA/Ca mice than in the BALB/c mice (p<0.01), by 6h
into the experiment this relationship had reversed with significantly more
bacteria being found within airways of BALBI c mice (p<0.01). Following the
12h time point, the number of viable bacteria in both strains began a decline
that was sustained until the end of the experiment with BALB/c air spaces
containing significantly fewer pneumococci from 24h onwards (p<0.01). In
CBA/Ca mice this reduction was constant but in BALB/c mice there were
two stages. Between 12h and 48h there is a sharp decline in the viability of
pneumococci with the number of viable bacteria recovered reduced from
approximately 106CFUIlung to around 101CFUI lung. This was followed by
a more gradual reduction in bacterial viability so that by 336h post challenge
no viable bacteria could be detected within the airways.
5.2.1.4 Bacteriology in the lung tissues following intranasal infection of
BALB!c or CBAlCa mice
During the initial 6h of the infection, tissue associated pneumococci were
found to increase in both strains of mice (Figure 5.8). After this point, the
bacteria continued to multiply unchecked (mean doubling time of 3.00h)
within the lung tissues of CBA/Ca mice so that from 12h onwards
significantly higher numbers of pneumococci were associated with the lung
tissues of CBA/Ca mice than in BALB/c mice (P<O.Ol) By the time of death
107 CFU were associated with each ml of CBA/Ca lung tissue.
BALBIc mice were able to control tissue associated pneumococci after the 6h
time point with a levelling off of bacterial loads by 12h. This was followed by
a rapid decline in viable bacteria which occurred between 12h and 36h. A
slower, but steady reduction in bacterial viability resulted in around 102 CFU
being recovered at 2wks into the experiment.
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Figure S.7 Bacterial loads within lavage fluids from BALB/ c and CBA/ Ca mice
during infection with 9.91 x 105 (BALB/ c mice) or 9.02 x 105(CBA/ Ca mice) CFU
S. pneumoniae. n= 9-11, *, P<O.01 different for CBA/Ca and BALB/ c samples.
Red horizontal line represents detection limit of BALB/ c viable count assay.
No results for CBA/ Ca mice after 36h post challenge as there were no
survivors in this group past this time.
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Figure 5.8 Bacterial loads within lung homogenates from BALBI c and CBAI Ca
mice during infection with 9.91 x 105 (BALBI c mice) or 9.02 x 105 (CBA/Ca
mice) CFU S. pneumoniae. n=5, *, P<O.Ol higher for CBAICa when compared
to CBAI Ca. Red horizontal line represents detection limit of viable count
assay. No results for CBAI Ca mice after 36h post challenge as there were no
survivors in this group past this time.
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5.2.1.5 Systemic bacteriology following intranasal infection of BALB/c or
CBA/Ca mice
By culturing blood samples recovered from the same rruce during the
experiment it was possible to investigate the development of bacteraemia in
both resistant and susceptible mice during pneumococcal pneumonia (Table
5.1).
5 out of 12 CBA/Ca mice developed detectable bacteraemia by the first time
point investigated (6h after intranasal challenge), and all had by 12h (P<O.Ol).
Once in the bloodstream the bacteria multiplied exponentially (mean
doubling time 0.7h) until the end of the experiment when greater than 107
CFU were recovered per ml of blood (P<O.Olhigher than time Oh counts at
both 24h and 36h post challenge). From 12h onwards CBA/Ca mice had
significantly higher numbers of viable pneumococci within their circulation
than in the circulation of BALB/c mice (P<O.Ol).
Pneumococci were recorded within the circulation of only 5 BALB/c mice
during the experiments. The earliest cases of bacteraemia were discovered at
12h into the experiment and after 96h no further BALB/ c mice developed
bacteraemia. At no time were there significant numbers of pneumococci
within the circulation of BALB/c mice.
5.2.1.6 Production of inflammatory mediators following intranasal infection
of BALB/c or CBAlCa mice
The same range of pro- and anti- inflammatory mediators was investigated
within the lungs and circulation of BALB/c and CBA/Ca mice as were
studied in MFI mice (Section 3.2.3.9). An imbalance in the pro-
inflammatory / anti-inflammatory cytokine relationship was hypothesised to
explain the different outcomes to infection evident in this chapter.
5.2.1.6.1 Production of inflammatory mediators in pulmonary air spaces
following intranasal infection of BALB/c or CBAlCa mice
TNF activities increased within the airways of both BALB/c and CBA/Ca
mice during pneumococcal pneumonia (Figure 5.9 A). The peak of activity
in both mouse strains occurred at 6h post challenge with 75U of TNF activity
detected per lung in BALB/c mice but a significantly lower 5U/lung in
CBA/Ca mice (P<O.Ol). The activity level declined in both strains post 6h
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Mean Log Bacterial Load (CFU/ml)
Time post challenge BALBlc mice CBAICa mice
(h)
0 ND ND
6 ND 2.00 +/ - 0.06
12 2.06+/ - 0.11 5.07 +/- 0.18 *
24 ND 6.14 +/- 0.42 *
36 ND 7.79+/- 0.49 *
48 2.11+/-0.20 NS
72 2.16+/-0.20 NS
96 2.12+/- 0.21 NS
120 ND NS
144 ND NS
336 ND NS
Table 5.1 Bacterial loads within bloodstreams of BALB/c and CBA/Ca mice
during infection with 9.91 x 105(BALB/c mice) or 9.02 x 105(CBA/Ca mice) CFU
S. pneumoniae. n= 10-13 mice/group, ", P<O.Olhigher for CBA/Ca samples
than for BALB/C samples. ND= below detection limit of viable count assay «
log 1.92), NS=No survivors in this group at these times.
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Figure 5.9 Production of pro-inflammatory mediators within the
pulmonary airways of BALB/ c and CBA/Ca mice folJowing intranasal
infection with 9.91 x lOS(BALB/c mice) or 9.02 x 105(CBA/Ca mice) CFU S.
pneumoniae. A= TNF activity n=10, B= IL-1f3 level n=4-6, and C= IL-6
levels n=5. Values are corrected for volume differences and expressed per
lung. *, P<O.Ol, +, P<0.05 higher for BALB/ c vaJues when compared to
CBA/Ca values. No results for CBA/Ca mice after 36h post challenge as
there were no survivors in this group past this time.
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Figure 5.10 Production of inflammatory mediators within the pulmonary
airways of BALB/ c and CBA/Ca mice following intranasal with 9.91 x lOS
(BALB/c mice) or 9.02 x 105 (CBA/Ca mice) CFU S. pneumoniae. A= IL-IO
levels n=9-l0, B= NO levels n=8-11, and C= total protein levels n=lO. Values
are corrected for volume differences and expressed per lung. *, P<O.Ol, +,
P<O.OSfor BALB/ c values when compared to CBA/ Ca values. No results for
CBA/ Ca mice after 36h post challenge as there were no survivors in this group
past this time.
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and by 36h TNF activity was no longer detectable in the airways of CBA/Ca.
Significantly elevated TNF activity could not be detected in BALB/c mice
after 24h post challenge.
IL-1J3protein production within the airways was investigated by ELISA
(Figure 5.9 B). IL-1Pis up-regulated with similar kinetics in both strains of
mice with the highest levels also detected at the same time post challenge
(24h). This increased production occurred later than the increase in TNF
activity (Figure 5.9A). The levels of IL-1J3detected at this time in BALB/c
mice are more than three times that seen in CBA/Ca mice. Following this
peak, IL-1Pconcentrations declined until the end of the experiment in both
groups of mice and by 36h they had returned to baseline in CBA/Ca mice.
This did not occur in BALB/ c mice until 72h.
As with IL-1P,IL-6protein levels were determined by ELISA (Figure 5.9 C).
IL-6 levels of this cytokine within the airways of both BALB/c and CBA/Ca
mice were found to increase significantly above baseline by 6h into the
experiment (P<O.Ol).Maximum production was seen at 12h post challenge
in BALB/c mice and at 24h in CBA/Ca. The levels of IL-6detectable in both
strains of mice decreased towards the end of the experiment, in CBA/Ca mice
the concentration found at 36h was still significantly higher than baseline.
From 48h onwards significant levels of IL-6were not detected within the
airways of resistant BALB/cmice.
Investigation of the levels of the anti-inflammatory cytokine IL-10 within
the airways by ELISA revealed that high levels were detectable in BALB/c
mice throughout the infection (Figure 5.10A). Initial levels were increased
by 12h into the experiment and they remained elevated until the 96h post
challenge time point. By 120h, the level of IL-10detected was significantly
lower than that found at the beginning of this experiment (P<0.05). This
reduction continued for the next 24h with levels only returning to baseline
by 336h. The decline in IL-I0 levels during late infection are likely to be due
to IL-10 exerting a negative feedback mechanism on its own production
(Brown et al. 1996). Peak production of IL-10 occurred at the same time
points as TNFa, IL-IP and IL-6 levels were declining, suggesting a role for IL-
10 in regulation of these other cytokines.
Lavage fluid from infected CBA/Ca mice also contained detectable levels of
IL-10 throughout the experiment. At all times investigated, these levels
were significantly lower than those in BALB/c samples (P<O.Ol). Although
there was a slight increase in IL-I0 production within CBA/Ca airways at 24h
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post challenge, this was not significant. Indeed, the level of IL-IOdetected in
these samples did not alter significantly at any time during the experiment.
Nitrate was converted in to nitrite prior to carrying out a Greiss reaction.
This permitted the total levels of NO within the airways during
pneumococcal pneumonia in both strains of mice to be determined (Figure
5.10B).
Lavage fluids from CBA/Ca mice displayed higher concentrations of NO
than BALB/c samples from the initial time point until the end stages of
infection (P<O.Ol).There is a high level of variation within CBA/Ca lavage
fluids at the earlier time points resulting in no obvious trend. By 36h the
levels of NO detectable are higher than baseline, although this result is not
significant.
NO within the airways of BALB/c mice was only present at very low levels
during the infection. The highest level detected was actually at the time of
infection when 1.26JlMnitrite were found per ml of lavage fluid. Following
this, detection did not follow any discernible trend with no significant
alterations found.
Total protein analysis of bronchoalveolar lavage fluid by Bradford reagent
was carried out in order to monitor the integrity of the alveolar Icapillary
barrier during the infection using serum protein as a marker (Figure 5.10C).
Higher endogenous protein levels were present within the airways of
BALB/c mice than CBA/Ca mice (P<O.Ol). These protein levels increased
from very early post challenge indicating disruption of the barrier occurred
rapidly in both strains of mice. The disruption to BALBI c lungs appears to be
reversible, with protein levels only increasing during the mid stages of
infection (from 6h to 48h post challenge). By l20h into the experiment the
level of total protein associated with the lavage fluids has returned to
baseline as the lung parenchyma returns to normal and excess fluid is
removed by epithelial active transport (Chapter 6).
In the susceptible CBA/Ca mice the increase in total protein levels occurs
steadily throughout the experiment. Disruption occurred early during the
experiment and by the final time point the level had increased significantly
to 235Jlg/ml total protein (P<O.Ol). The relative disruption to lung integrity
was greater in susceptible CBA/Ca mice than in BALB/c mice (correlating
with higher NO levels).
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5.2.1.6.2 Production of inflammatory mediators in lung tissues following
intranasal infection of BALB/c or CBAlCa mice
With BALB/c mice, the lung tissue TNF activity profile again peaked at 6h
into the experiment with around IOU TNF activity/rnl lung homogenate
(Figure 5.11A) [P<0.05].Levels then decreased so that by 36h post challenge
no TNF activity could be detected in any mice.
In CBA/Ca lung homogenates there was a delayed but greater TNFa activity
peak at 24h into the experiment (P<O.Ol)with an activity level of almost 40
UIml reached per ml of lung tissue. This level had decreased slightly by 36h
when the experiment was ended.
The increased production of IL-l~ within lung tissues during the infection, is
similar in both strains (Figure 5.11B). At the height of production (around
l2h into the experiment) equal levels of IL-l~ were expressed by lung tissues
of both strains of mice. Following this peak, IL-l~ production declined until
the end of the experiment in both strains of mice. Levels were no longer
significantly increased in BALB/c samples 120h post challenge although
there was again significant release by 336hpost challenge (P<0.05).
IL-6 is detectable at similar levels within the lung homogenates of both
strains of mice at the time of infection (Figure 5.11C). This level increased
significantly by 24h into the infection in BALB/c mice (P<0.05),although this
change was not sustained After 24h there was a significant reduction in
levels at 120h& 144hpost challenge (Pctl.Ol compared to time Oh)with these
levels returning to baseline by 336h into the experiment.
In susceptible CBA/Ca mice, greatly elevated IL-6 concentrations were
detected within the lung tissues. From 12h post challenge until the end of
the experiment these were significantly higher than baseline (Pcfl.O'l) and
higher than those in BALBIc samples from the same times.
As with lung airways, BALB/c mice produced higher amounts of IL-IO in
their lung tissues than CBA/Ca mice at all times investigated (Figure 5.11D).
By l2h post challenge this level was significantly elevated when compared to
that originally found and remained significantly higher (P<0.05)until 144h.
By 336h, however the level had returned to being higher than baseline
(P<O.Ol).
IL-IO concentrations within CBA/Ca lung homogenates were increased
significantly from l2h into the experiment (P<O.05)until the final time
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Figure 5.11 Production of inflammatory mediators within the lung tissues of
BALB/ c and CBA/ Ca mice following intranasal infection with 9.91 x 105
(BALB/c mice) or 9.02 x 105 (CBA/Ca mice) CFU S. p neumo niae. A= TNF
activity n=5-7, B= IL-l~ levels n=4-5, C= IL-6 levels n=5, and D= IL-IO levels
n=5-7. *, P<O.Ol different for BALB/ c values when compared to CBA/ Ca
values. No results for CBA/Ca mice after 36h post challenge as there were no
survivors in this group past this time.
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point. This increase was not as marked as that in BALBI c lung tissues and
was followed by a slight decline by 36h after infection.
5.2.1.6.3Systemic TNFa activity following intranasal infection of BALB/c or
CBA/Ca mice
Serum samples from the same mice were also tested for TNF bioactivity
(Figure 5.12). Systemic TNF activity could not be detected within the serum
of BALBlc mice at any point during the experiment (detection limit of assay
was around 38U Iml for serum samples). This results correlates with the low
number of viable pneumococci present in these samples. Detection was
possible in serum from the susceptible CBA/Ca mice at 24h and 36h post
challenge. At these times serum from only 50% of mice displayed TNF
activity, but positive samples did contain very high levels (up to 440 U Iml).
All mice that had detectable systemic TNF activity had levels of bacteraemia
higher than log 6.46 (2.88 x 106) CFU/ml, indicating that there might also be a
threshold level of bacteraemia to initiate systemic inflammation in CBA/Ca
mice (as in MF1 mice Section 3.2.3.9.3). This threshold was not readily
identifiable as although 11 mice with bacteraemia greater than log 6.46 had
detectable TNF activity in their serum, 3 didn't.
In addition, the three CBA/Ca mice with highest levels of bacteraemia,
(above log 8.68 CFU /rnl, all at 36h post challenge) did not possess any
detectable systemic TNF activity. The short half life of TNF in the circulation
(around 6min (Aderka et al. 1992)) might indicate that TNF activity had
already peaked in these mice and had returned to being undetectable.
5.2.1.7 Histology following intranasal infection of BALB/c or CBAlCa mice
Lung sections from BALBIc mice sampled immediately after challenge did
not show marked signs of inflammation. This was altered by 6h into the
experiment when lungs had marked haemorrhage and oedema and a slight
cell influx in these same areas. Lungs sampled at 12h post challenge had a
similar histopathologic score as those at 6h but with most recruited cells
present within the airways. By 24h post challenge large numbers of
inflammatory cells were present within the airways causing significant
disruption to alveolar integrity (Figure 5.13 A) whilst perivascular areas
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Figure 5.12 TNF activity levels within serum from BALB/ c and CBA/Ca mice
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Mouse Time post challenge (h)
strain 0 6 12 24 36 48 72 96 120 336
BALB/c 1.50 4.00 4.50 7.50 7.00 5.50 5.50 5.00 5.50 4.00
CBA/Ca 1.50 2.50 4.50 6.50 6.00 NS NS NS NS NS
Table 5.2 Mean histopathologic score for lung sections from BALB/ c and
CBA/Ca mice following intranasal infection with either 9.75 x lOS (BALB/ c
mice) or 9.82 x 105(CBA/Ca mice) CFU S. p n eumo n iae. n= 2 mice per time
point. NS= no surviving CBA/ Ca animals after this time.
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remained less consolidated (Figure 5.13 B). Neutrophils were seen to
represent the majority of these cells with a few macrophages also present.
From 36h until the end of the experiment at 336h post challenge a similar
level of cell influx was noted although the ratio of neutrophils/macrophages
decreased with time, as did disruption to alveolar architecture and
haemorrhage.
Lungs from healthy, uninfected CBA/Ca mice and animals sacrificed
immediately following challenge contained marked areas of oedema around
airways. This histopathology did not alter greatly during the initial 12h.
From this time point onwards, haemorrhage was evident within alveoli and
a higher number of inflammatory cells were present. These cells were
mainly situated at the interface between bloodvessels and airways (Figure
5.13 D) with few present within the airways (Figure 5.13 C). These cells
displayed multi-lobed nuclei leading to their identification as neutrophils.
Table 5.2 displays the above results as histopathologic scores. It can be seen
that pathology occurs earlier in BALB/c mice than in CBA/Ca animals (due
to more rapid cell influx and haemorrhage in the former). Both strains have
similar peak levels of histopathology at 24h and 36h post challenge although
they differ in the location of this pathology. As mentioned above, BALB/c
pathology is situated within airways and in CBA/Ca lungs it is found in
perivascular areas of tissue.
5.2.1.8 Mast cell detection following intranasal infection of BALB/c or
CBA/Ca mice
By counting the number of cells containing positive staining granules it was
possible to quantify the number of mast cells within the lungs of BALBI c and
CBA/Ca mice during pneumococcal pneumonia. Table 5.3 shows that
immediately following infection with 106 CFU S. pneumoniae resistant
BALB/c mice have significantly more granular mast cells within their tissues
than do susceptible CBA/Ca animals (P<O.Ol). At the time mast cells were
generally found at the outer edges of the lung lobes or surrounding blood
vessels.
Following infection the number of granular mast cells decreased in BALBI c
lung sections until they were significantly lower by 12h post challenge
(P<0.01). This reduction was maintained until after 36h post challenge, with
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levels at 48h, 96h and 120h not significantly different from the numbers
detected at time Oh.
In contrast, the number of detectable mast cells within CBA/Ca lungs
increased during the infection. By 6h post challenge a significant increase of
the level (P<O.Ol)was obtained with P<0.05 found for the remaining time
points.
This data indicates that mast cells within the lungs of resistant BALB/c lungs
are normally primed with granular contents, an inflammatory stimulus
(such as S. pneumoniae) causes de-granulation of these cells. As they release
their granular contents they are no longer detectable by the stain, explaining
the reduction in numbers during infection. Mast cells within CBA/Ca lungs
do not endogenously contain high levels of granular contents and require
time in order to synthesise TNFo.with granular cells increasing during the
experiment, but still to a significantly reduced level in comparison to
BALB/c lungs at the time of infection (P<0.05lower for CBA/Ca lungs at 6h,
12h, 24h and 36h when compared to BALB/c sections at Oh).
5.2.2 In vitro stimulation of airway cells recovered from BALB/c or
CBA/Ca mice
Following the discovery that 15 fold higher TNFo. activity was associated
with BALB/c airways after infection with 106 CFU S. pneumoniae, the
possibility that BALB/cairway cells were better able to produce this cytokine
upon stimulation thus explaining the results gained in vivo. This was
investigated by in vitro stimulation of freshly recovered airway cells from
both mouse strains with various concentrations of LPS, heat killed S.
pneumoniae or recombinant pneumolysin (Figure 5.14).
Suspensions of 104and 105CFUheat killed S. pneumoniae were incapable of
stimulating the production of TNFo. protein by airway cells from either
mouse strain (Figure 5.14A). Increasing the stimulus to 106CFU did result
in the production of TNFa protein by cells from both BALB/c and CBA/Ca
mice. BALB/c cells released 126pg/ml whilst CBA/Ca supernatants
contained only 12pg/ml.
Although such levels of TNFa protein could be measured, these same
supernatant fluids did not possess and any TNF activity, as assessed by the
bioassay. The fact that heat killed pneumococci released lower amounts of
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TNF protein than did LPS (Figure 5.14 C & D) may have resulted in TNF
activity levels too low to be detected on the bioassay. Such a discrepancy
between ELISA and bioassay data has also been found for in vitro TNF
release from human monocytes stimulated with staphylococcal
peptidoglycans (Timmerman et al. 1993).
Airway cells incubated with 100ng/ml pneumolysin contained significant
amounts of TNFa protein (Figure 5.14B). BALB/c cells released the highest
level with 135pg/ml detected, CBA/Ca cells produced 54pg/ml. Thus there
was again a marked difference between mouse strains, in this case a
significant one (P<0.05).
TNF activity was not determined in these samples due to preliminary results
which indicate that pneumolysin is directly cytotoxic for the L929 indicator
cell line in the bioassay.
A combination of 106 CFU heat killed bacteria and 1ng/ml pneumolysin
resulted in significantly higher TNFa protein levels being released by cells
from BALB/c mice than from CBA/Ca cells (P<0.05)[data not shown]. This
stimulus resulted in the most marked difference between cells from mouse
strains (80 fold compared to 10 fold for heat killed bacteria alone). Such a
difference suggests that there might be synergy between pneumolysin and
pneumococci when acting on BALB/c cells but not on CBA/Ca.
TNFa total protein levels detected by ELISArevealed that this cytokine was
produced in vitro when airway cells were stimulated with LPS (Figure 5.14
C). As small an amount of LPSas Sng/ml was capable of inducing significant
amounts of TNFa in both cell populations. Lower concentrations of LPS
(O.05ng/ml and 0.0005ng/ml) were also tried but these did not stimulate the
production of any TNFa. At each level of stimulus airway cells from
BALB/c mice were capable of releasing higher amounts of TNFa than
CBA/Ca cells (p<0.05).
Analysis of the same LPS stimulated cell supernatants by TNF bioassay
revealed that not only was TNFa protein released, but this protein was active
(Figure S.14D). An LPSconcentration of at least SOOng/mlwas required to
induce significant TNF activity. This level of stimulation resulted in
significantly more TNF activity from BALB/c cells than from CBA/Ca cells
(P<0.05).Increasing the LPS stimulus to SO,OOOng/mlresulted in more TNF
activity detected in supernatant from cells of both mouse strains but did not
alter the relationship between strains. As with TNFa total protein, lower
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levels of LPS were used as stimuli but these were found ineffective at
stimulating any TNF activity.
Thus, although higher levels of TNFa protein were detected following
stimulation with LPS than with pneumococcal factors, the most striking
difference between the two mouse strains resulted from stimulation with the
latter.
5.2.3Role of lymphocytes in resistance to pneumococcal pneumonia
and cytokine production
In order to attempt to discover whether lymphocytes are required for the
resistance of BALB/ c mice to pneumococcal pneumonia, BALB/ c scid mice
were infected intranasally with 106 CFU S. pneumoniae. The Band T
lymphocytes . of these mice are incapable of expressing functional
immunoglobulin or T cell receptors on their surfaces, hence cell-mediated
and humoral defense mechanisms are impaired.
In these experiments scid mice were either culled at 24h and bacterial loads
and cytokine levels determined, or monitored for survival time.
5.2.3.1 Signs of illness and survival times following intranasal infection of
BALBlcor BALBlcscid mice
The control BALB/c data have already been described and showed the
increased resistance of BALB/ c mice to pneumococcal infection. BALB/ c scid
mice developed symptoms of illness by 20h into the experiment. At this
time a hunched stance was the predominant clinical manifestation. Mice
sampled for the 24h time point described below were all displaying mild
signs of illness, mainly a hunched stance with some mice exhibiting
piloerection. Female mice passed through the range of symptoms at a faster
rate than male mice, with most female mice had developing full symptoms
by 52h post challenge. Male mice did not do so until around 75h into the
experiment. By the end of the experiment all male mice had succumbed to
the infection and only one female mouse had survived (Figure 5.15).
Despite the differences in kinetics of symptom appearance, survival times
were not statistically different for female and male BALB/ c scid mice.
Comparison of survival times for BALB/ c and BALB/ c scid mice revealed
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Percentage
survival (%) 50
75
• BALB/C
• BALB/CSCID
25
o 48 96 144 192 240 288 336 384
Time post challenge (h)
Figure 5.15 Survival of BALBI c and BALBI c scid mice following challenge
with either 9.75 x lOS (BALBI c mice) or 1.01 x 106 (BALBI c scid mice) CFUS.
p neu moni ae. n= 21 for BALBlc and n=17 for BALBlc scid. *, P<O.Ol shorter
survival times of BALBI c scid mice when compared to BALBI c.
Mouse Strain Bacterial Load CFU/ml
Lavage Flui d Blood
BALBlc 3.63 + 1- 0.26 0.00
BALB/c scid 2.95 + 1- 0.39 6.11 +1- 0.24
*
Table 5.4 Bacterial loads within BALBI c scid mice lavage fluids and blood 24h
after intranasal infection with either 9.91 x 105 (BALBI c mice) or 9.75 x 105
(BALBI c scid mice) CFU S. p n eu mo n iae. n= SilO, *, P<O.Ol higher for BALBI c
bacteraemia than for BALBI c bacteraemia.
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that the immunodeficient mice (total of males and females) were
significantly more susceptible to intranasal infection with 106 CPU D39
(P<O.Ol).
5.2.3.2Bacteriology following intranasal infection of BALBlc or BALBlc scid
mice
There was no significant difference between the bacterial loads in BALB/c
and BALB/c scid airways at 24h post challenge. However there was a highly
significant difference between bacteraemia levels in the two strains at this
time (P<O.Ol). At this time BALB/c scid mice possessed comparable numbers
of viable pneumococci within their circulation as CBA/CA mice (Table 5.4)
5.2.3.3 Production of Inflammatory mediators by BALB/c or BALBlc scid
mice following intranasal infection
As the function of lymphocytes in BALB/c scid mice is impaired it was a
possibility that the production of inflammatory mediators might be
disregulated in these mice, explaining their increased susceptibility.
BALB/c scid mice were able to produce higher levels of TNF, IL-1~ and IL-6
within the lung airways (Table 5.5) and tissues (Table 5.6) during
pneumococcal pneumonia although none of these results were significant.
Production of NO was significantly higher in the airways of BALB/c scid
mice (P<O.Ol), as was the amount of total protein associated with the airways
(P<O.Ol).
Levels of the anti-inflammatory cytokine IL-IOwere significantly reduced in
the airways (to the level of P=O.028)and lung tissues (P<O.Ol)of BALB/c scid
mice with non functional lymphocytes.
Additionally, the BALB/c scid mice had detectable levels of TNFa activity
with their circulations (77.91 U Iml), although levels were highly variable.
The two BALBIc scid mice that possessed systemic TNF activity were those
that had the highest levels of bacteraemia log 6.53 and 6.55).
Overall these results indicate that BALB/c scid mice have heightened
inflammatory reactions within their lungs and circulation due to decreased
levels of IL-IO.
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5.2.4 Systemic susceptibility of BALB/c and CBA/Ca mice to S.
pneumoniae bacteraemia
5.2.4.1 Survival and signs of illness following intravenous infection of
BALB/c or CBA/Ca mice
In order to determine whether the resistance of BALBI c mice in comparison
to CBA/Ca mice was due to pulmonary defences alone, intravenous
infections were initiated with 2.40 x103 CFU or with 5.00 x 104 CFU S.
pneumoniae. The development of symptoms, bacteraemia and survival
times were recorded. These doses were chosen as 5.00x 104was similar to the
highest recorded level of bacteraemia in a BALBI c mouse following
intranasal infection (Table 5.1). The lower dose was selected in order to
determine whether CBA/Ca were able to resist pneumococcal infection if
very few bacteria gained access to the circulation from the lungs.
BALB/c mice display a heightened resistance to systemic challenge with S.
pneumoniae. CBA/Ca mice displayed symptoms from 24h into the
experiment at both doses used. At 24h post challenge they were hunched
and had a degree of piloerection. Rapidly after this point they passed
through a similar set of symptoms as with pulmonary challenge until all
mice had succumbed to the infection by 33h post challenge (Figure 5.16).
There was no difference between symptoms displayed on infection with 2.4 x
103 CFU than with 5.0 x 104 CFU S. pneumoniae.
BALB/c mice displayed mild symptoms in comparison, with a slight
hunched appearance being the worst symptom displayed during mid
infection (33h post challenge). By 49h all mice had returned to normal
behaviour and appearance. Furthermore, no BALBIc mice succumbed to
systemic infection with D39and when the experiment was actively finished
pneumococci could not be cultured from blood samples from any of the
mice.
Thus BALB/c mice displayed significantly longer survival times than
CBA/Ca mice following systemic challenge (P<O.Ol).
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Percentage •
Survival (%) 50-
25 -
.....- --
*
Time post challenge (h)
• CBA/Ca2.40 x 1<Y CFU
• BALB/C2.40 x 1<Y CFU
• CBA/Ca5.00 x 10l CFU
• BALB/C5.00x HfcFU
Figure 5.16 Survival of BALB/ c and CBA/ Ca mice after intravenous infection
with 2.40 x 103 or 5.00 x 104 CFUS. pneumoniae. n= 5 mice, *, P<O.Ol for
CBA/Ca when compared to BALBI c (both experiments).
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5.2.4.2 Systemic bacteriology following intravenous infection of BALB/c or
CBA/Ca mice
Serial tail-bleeds permitted the level of bacteraemia to be monitored for the
initial 24h following intravenous infection with two doses of S.
pneumoniae.
Similar levels of bacteraemia were found in all CBA/Ca and BALBI c mice
immediately following infection (Figure 5.17). Despite this fact, by 12h into
each experiment, the two mouse strains had significantly different numbers
of systemic bacteria (P<O.Ol). By 12h BALB/c mice showed a slight reduction
in bacterial numbers. This decrease was more marked by 24h into the
experiment when 4/5 BALB/c mice no longer had detectable levels of
bacteraemia.
In CBA/Ca mice, pneumococci had multiplied significantly by 12h post
challenge. This proliferation occurred unchecked until the end of the
experiment when around 108 CFU were present in each ml of blood. The
mean doubling time following infection with 5.00 x 104 was 2.0Bh and with
2.40 x 1031.BBh.
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8
Mean
Log 6
Bacterial
Load
(CFU/ml) 4
o 5 10 15 20
Time post challenge (h)
• CBA/Ca
2.40 x 1()3CFU
• BALB/C
2.40 x 1()3CFU
• CBA/Ca
5.00 x 1Q4CFU
• BALB/C
5.00 x 104 CFU
25
Figure 5.17 Mean +/- SEM level of bacteraemia in BALB/c and CBA/Ca mice
after intravenous infection with 2.40 x 103 or 5.00 x 104 CFU S. p neumo niae.
n=S, *, P<O.Ol higher for CBA/ Ca bacterial loads than for BALB/ c (both
experiments). Red horizontal line represents detection limit of viable count
assay.
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5.3 SUMMARY
It has long been recognised that there is a genetic component to susceptibility
to pneumococcal infections. Results in this chapter consolidate this
hypothesis with survival times and the inflammatory response produced by
two inbred mouse strains varying significantly following infection with 106
CFU type 2 S. pneumoniae.
CBA/Ca mice are highly susceptible and are unable to control the organisms
within the lungs and bloodstream and succumb around 36h post challenge.
These mice had developed bacteraemia by 6h post challenge (the first time
point studied, thus further experiments are required to establish how early
pneumococci can access the bloodstream in these mice following intranasal
infection). As low a number of pneumococci as 2000CFU was capable of
instigating a fatal infection in these mice.
In contrast BALB/c mice are able to reduce the viability of pneumococci
within their lungs and prevent access to the bloodstream. Even if
pneumococci entered the circulation, protective systemic immunity was
capable of removing 5.00x 104 CFU, indicating that a constant shedding of
larger numbers of these organisms from the lungs would be required for fatal
infection in this mouse strain.
Infection of the two strains results in alteration in Teo. Resistant BALB/e
animals display transient hypothermia during early infection lasting
approximately 6h. Susceptible CBA/Ca mice become severely hypothermic
during end stage disease with temperature dropping to ambient room
temperature.
Inflammation is rapidly instigated within the lungs of both strains of mice.
In BALB/e mice this is predominantly contained within the airways (as are
the pneumococci) and is manifested mainly by TNF. In CBA/Ca mice
inflammation spills over into the lung tissues where TNF and IL-6 are
released in very high levels and into the bloodstream where TNF activity
could be detected as a marker of inflammation.
Airway cells of BALB/c mice are capable of releasing significantly higher
levels of TNF than those from CBA/Ca. This appears to be especially
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relevant to Gram-positive infections and explains the ability of BALB/c mice
to mount a significant inflammatory response rapidly following infection.
The location of cytokine production is directly related to the site of
inflammatory cell influx. In infected BALB/c animals neutrophils arrive in
the air spaces approximately 12h post challenge and it is within the airways
that most inflammatory cytokines (especially TNF) are released in these
animals. Maximum pro-inflammatory cytokine release in infected CBA/Ca
mice is within the tissues themselves, supported by the location of recruited
cells. Inflammatory cell influx into these lungs predominantly occurs in
perivascular areas, with minimal recruitment to the airways. The rapidity
with which these animals develop bacteraemia is likely to cause cells
surrounding blood vessels to secrete cytokines and chemokines early during
infection, explaining this pattern of cell influx.
Lymphocytes, previously not thought to play a role in pneumococcal
pneumonia, are important in this model. Mice with incompletely
functioning T and B lymphocytes display elevated susceptibility to S.
pneumoniae infection. This may be due to a disregulation of inflammation
on the behalf of IL-10 permitting an overzealous response.
135
Chapter 6
General Discussion
Chapter 6 Discussion
The results presented in this thesis demonstrate the characterisation of the
inflammatory response occurring during pneumococcal pneumonia caused
by a frequently studied isolate of S. pneumoniae. Effects on bacterial loads,
lung histology, inflammatory mediators and core body temperature are
reported.
Although the viability of pneumococci is reduced immediately following
resuspension in PBS (Figure 3.2), no such drop in viability was seen
following inoculation into pulmonary airways. Constant numbers of S.
pneumoniae were cultured from the lavage fluid of MF1 mice from
immediately after intranasal inoculation of 106CFU D39until the end of the
experiment (Figure 3.9). Thus the pulmonary air spaces are more suitable for
pneumococcal survival than is PBS.
Viability of the inoculum does drop immediately following intranasal
challenge when bacterial counts are performed on the lungs as a whole (un-
lavaged lung homogenates) (Kadioglu et al. 2000). Therefore the different
environments that exist within the lungs vary in their suitability for
survival of S. pneumoniae, possibly connected to the immune cell types and
numbers that the organisms encounter in each.
The ability of pneumococci to survive within the airways also varied with
mouse strains. An elevation in viability occurred immediately after
intranasal challenge of either BALB/c or CBA/Ca mice (Figure 5.7). This
indicates that S. pneumoniae readily adapts to airways in these mouse
strains. It is possible that BALB/c and CBA/Ca mice express higher levels of
the pulmonary receptors utilised by pneumococci (Section 1.4.2)than do MF1
mice. From 12h onwards viability declined in both mouse strains. Separate
causes may be responsible for these reductions in the two mouse strains. In
the resistant mice it is probable that the reduction in bacterial viability is a
real reflection of pneumococcal kill. In CBA/Ca mice lavage fluid counts
may decrease as the bacteria become more tightly associated with the lung
tissues from mid infection onwards. They would therefore be recovered and
counted within the lung homogenates. Indeed bacterial counts wi thin
CBA/Ca lung tissues at the same time points do increase. If it were a simple
matter of a reduction in bacterial viability a corresponding reduction within
the CBA/Ca lung tissues would also be expected.
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The ability of BALB/c airway defences to control pneumococci occurs in two
stages (Figure 5.7). The earlier reduction in viability is more effective with a
6 fold difference resulting over a matter of 24h. The second stage is a more
gradual decline with complete removal of viable organisms not detected
until a further 312h.
In addition to there being several mechanisms of pneumococcal kill acting
within the airways of resistant BALB/c mice, there may also be separate
methods of bacterial kill occurring within the environment of the lungs as a
whole. At the same time as the airway counts are reduced 6 fold, only a 2
fold reduction is evident within the tissues (Figure 5.8). It is possible that the
mechanism responsible within BALB/ c airways for the initial rapid kill is
not present within the lung tissues whilst the second mechanism active
within the airways is also found in the tissues.
Although there was complete clearance of bacteria from the airways of
BALB/cmice, there were still viable pneumococci associated with the lung
tissues at 336h into the experiment. A more chronic infection was therefore
established in these mice. Indeed the slight increase in certain cytokine
levels (IL-6,IL-1& IL-10-see below) in the lung homogenates (but not lavage
fluid) by the end of the infection indicates that an inflammatory stimulus
remains within these tissues.
In contrast to the ability of resistant BALB/c mice to control pulmonary S.
pneumoniae viability, lung homogenate counts from susceptible mouse
strains increased throughout the experiment (Figures 3.10& 5.8). Infections
in MF1 mice revealed a significant correlation between lung homogenate
and blood pneumococcal viable counts. The possibility that bloodborne
bacteria were responsible for the increase in lung homogenate bacterial loads
was therefore tested by lung perfusion. Removal of blood from the
pulmonary vasculature did not significantly reduce lung homogenate
bacterial loads (Figure 3.11), a result that has since been repeated by
collaborators. This experiment does not exclude the possibility that the
bacteria are adherent within the bloodvessels and not readily removed by
perfusion. However, Harrow et al have previously shown that the number
of bacteria present within the blood of the lung does not meaningfully
contribute to the total number of lung associated bacteria (Harrow et al. 1975).
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This model therefore stands as one of bacteraemia following pneumococcal
pneumonia and not pneumococcal bacteraemia alone.
The bacteria are readily recognised by the immune system of the host and an
inflammatory response occurs rapidly following their inoculation. This
response is primed for action in healthy individuals with low levels of TNF,
IL-1and IL-6mRNA constitutively expressed in the spleen, liver, kidney and
peripheral blood of healthy individuals (the lungs were not examined)
(Tovey et al. 1988).
The pulmonary inflammatory response within both resistant and susceptible
mice was initially characterised by an increase in TNFa protein and activity.
Such elevated TNFa levels are found within the lungs of patients with
bacterial pneumonia (Dehoux et al. 1994). Similar results been found in a
range of animal models of pulmonary infection including those caused by
extracellular bacteria; S. pneumoniae (Takashima et al. 1997),(Bergeron et al.
1998)& (van der Poll et al. 1997a),Klebsiella pneumoniae (Laichalk et al.
1996)and Pseudomonas aeruginosa (Gosselin et al. 1995); the intracellular
bacterium Legionella pneumophila (Brieland et al. 1995) and the fungus
Pneumocystis carinii (Chen et al. 1992a).
TNF activity within MF1 airways and tissues increased in 2 waves (Figure
3.13). The number of levels of variation in the MF1 experiment prevent
statistical analysis to determine whether the dual peaks of TNF activity were
real or experimental artefacts. If repeat experiments support the dual peak
hypothesis, separate cell populations may be responsible for these kinetics.
Resident cells such as mast cells (secreting both pre-formed and newly
synthesised TNF) and alveolar macrophages could have caused the 18h post
challenge peak in TNF activity. The 30h post challenge activity peak may
have been released by newly recruited neutrophils and additional
macrophages. Histological examination revealed no significant cell influx
until 24h post challenge (Figure 3.12),supporting this separate population
hypothesis. Mast cell staining revealed their degranulation (or efflux of the
cells themselves) by 12h post challenge, the time point immediately
preceding the earlier peak in TNF activity. Mast cell release of TNF has
previously been implicated in host resistance to infectious disease (Malaviya
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et al. 1996)& (Abraham and Malaviya 1997). It is therefore probable that
these cells are responsible for early TNF production, initiating the host
inflammatory response during pneumococcal pneumonia. Further work is
planned to investigate this hypothesis both by investigation of mast cell
protease levels (Wastling et al. 1997) and through the use of mast cell
deficient mice (Malaviya et al. 1996).
A reduced capacity of recruited cells to produce TNF (in comparison to
resident cells) would explain the reduced magnitude of the second peak in
TNF activity at 30h. The recruited cells may be of a different phenotype
(neutrophils are less capable of releasing cytokines than are cells of the
monocyte lineage (Cassatella 1995). Alternatively, higher levels of anti-
inflammatory mediators (IL-10and soluble TNF receptors) at 30h may be
antagonising TNF activity. Further proof of action of an antagonist is found
in the ability to detect sustained levels of TNFa by ELISA and
immunohistochemistry at 36h post challenge whilst activity is reduced
(Figures 3.13& 3.17).
Only single waves of TNF activity were evident within the lungs of all other
strains sampled in this study; perhaps a reflection of the longer sampling
interval.
A marked difference was detected in the levels of TNF activity associated
with lung airways from susceptible CBA/Ca and resistant BALB/c mice
(Figure 5.9). At peak production airways of BALB/cmice contained 15 fold
higher levels of this inflammatory cytokine than CBA/Ca airways although
kinetics of TNF production are similar in both strains of mice. TNF is
therefore a prime candidate for a factor that might be responsible for
mediating the susceptibility to pneumococcal pneumonia. Significantly
elevated production of TNF within the airways of BALB/c mice during P.
aeruginosa infection when compared to susceptible C57Bl/6 mice, has also
been suggested to play a role in resistance (Sapru et al. 1999)& (Gosselin et al.
1995). Elevated TNF levels in BALB/c airways may playa role in chemotaxis
of phagocytic cells which arrive earlier and in greater numbers than in
CBA/Ca. TNF can cause up regulation of V-CAM and E-selectin in lung
tissue in vivo as little as 4 h after stimulation (Neumann et al. 1996). A
correlation between location of TNFa and neutrophil recruitment has also
139
C!tapter 6 Discussion
been discovered (Nelson et al. 1989). In addition to recruiting neutrophils
into the air spaces, TNF will activate these cells so that they are primed for
anti-microbial activity on arrival at the site of infection (Dusi et al. 1996),
(Klebanoff et al. 1986)& (Shalaby et al. 1985).
It is not clear whether the amount of TNF released during infection in the
two mouse strains is regulated by different levels of transcription of the gene
or by other post transcription/translation events. For example it could be
that the secretion of active TNF is reduced in susceptible CBA/Ca mice.
TNFa has two active forms, one is a surface bound 26kDa protein and the
other is a 17kDasecreted protein released from cell surfaces by cleavage of the
26kDa form. This cleavage is regulated by TNFa converting enzyme (Black
et al. 1997)& (Moss et al. 1997). A disruption to the activities of this enzyme
in CBA/Ca mice would result in lower levels of secreted TNFa, leading to
impaired host defences within the airways whilst lung tissue levels would be
elevated (Figures 5.9& 5.11).
Variations in the cell type and number at lung airways in BALB/c and
CBA/Ca mice would also explain the difference in TNF activities. A
candidate cell type would be the mast cell. Significantly elevated numbers of
mast cells were found in the lungs of BALB/c mice immediately following
infection with S. pneumoniae than were found in the lungs of CBA/Ca
mice. These BALB/cmast cells were primed for release of granule contents
within hours of infection, perhaps explaining the rapid nature of TNF
response. In contrast, the lower number of granule containing cells within
lungs of CBA/Ca animals required longer to synthesise and secrete TNF
which they continued to do throughout the experiment (as granule
containing cells did not decrease in number once elevated). This continual
release of TNFa is more likely to be involved in pathology than protection.
A striking finding of these studies was the significantly reduced numbers of
granule containing cells in BALB/c and CBA/Ca mice when compared to
MF1 animals (Table 3.3 and 5.3). As BALB/ c mice displayed the most rapid
TNF activity kinetics these mice might have been expected to have more
mast cells than MF1mice. Although mast cells from MF1 mice have more
granule contents, the TNFa content might be reduced in comparison to the
histamine or serotonin content. In comparison, BALB/c granules may
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contain a significantly greater proportion of pre-synthesised TNFa, primed
for release on inoculation of the pneumococci.
Epithelial cells may also contribute to the cytokine profile by release of
cytokines on interaction with bacteria (Khair and Davies 1996). Previously
epithelial cells were thought of as bystander cells with no real role to play in
inflammatory responses. More recent research indicates that interaction of
pneumococci with BALB/ c airway epithelial cells could be responsible for the
high TNF activity levels seen during pneumococcal pneumonia.
Staphylococcus aureus has been shown to induce cytokine expression by
epithelial cells (IL-8 release from canine tracheal epithelial cells in vitro)
(Massion et al. 1995). This cytokine release was also shown to mediate
neutrophil recruitment Although this field of research is in its infancy, it is
possible that the ability of BALB/c airway epithelial cells but not CBA/Ca
cells to respond in this manner explains the marked difference in TNF
levels.
Ongoing studies are being carried out to investigate the cell populations
within BALB/c and CBA/Ca mice both before and during pneumococcal
pneumonia.
Thus a deficiency in TNF activity in CBA/Ca mice is likely to be involved in
the heightened susceptibility of these mice to intranasal infection with S.
pneumoniae. In order to investigate whether the reduced lavage fluid TNF
activities from CBA/Ca mice was the result of airway cells from CBA/Ca
being less able to respond to stimuli by the production of TNF than BALB/c
mice, in vitro stimulation of airway cells recovered from BALB/c and
CBA/Ca mice was carried out (Figure 5.14).
When low concentrations of pneumolysin were utilised as a stimulus, a
complete lack of TNFa protein production was evident. This is in contrast to
findings previously published by this laboratory (Houldsworth et al. 1994).
The disagreement is likely to be explained by the different cell types used,
that is rodent airway cells in place of human monocytes. Increasing the
stimulus to 100pg/ml resulted in significant TNFa release from BALB/c cells
but not from CBA/Ca cells, giving a statistically significant difference
between the cell types.
Similar results were found with another pneumococcal stimulus.
Incubating airway cells with numbers of heat killed pneumococci utilised in
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vivo resulted In BALB/c cells releasing high levels of the cytokine. In
contrast, CBA/Ca cells still only released minimal levels. This result is
supported by the ability of other investigators to induce the production of
TNFa by macrophages in vitro with heat killed S. pneumoniae (Simpson et
al. 1994).
The most significant difference in TNF levels between cells from the two
strains was achieved by stimulating with a combination of pneumolysin and
heat killed S. pneumoniae. Such a result suggests that pneumolysin may act
in synergy with cell wall products to induce inflammation in BALB/c cells
but not in CBA/Ca cells. This synergy has previously been shown to occur
following stimulation of human monocytes with the alpha toxin of
Staphylococcus aureus (Bhakdi et al. 1989).
The least significant difference in TNFa levels between cell from the two
mouse strains was evident following stimulation with the Gram-negative
factor, LPS. Although cells from BALB/c mice stimulated with LPS were
capable of producing higher levels of TNF protein and activity, the difference
in the two strains was lower than the 15 fold difference seen in vitro. This
result indicates that the difference between cell responses is most significant
during Gram-positive infections.
The recognition of a pathogen involves receptors that bind molecular
structures (pathogen-associated molecular patterns (PAMPS) which are
shared by large groups of micro-organisms (Medzhitov and Janeway Jr 1997).
These receptors are referred to as pattern-recognition receptors (PRRS). One
such group of receptors are the recently identified Toll-like receptors which
are believed to mediate innate responses against foreign bacteria via
interaction with the transcription factor NF-kB (Kopp and Medzhitov 1999).
Toll-like receptor 4 (TLR4)is believed to be the major receptor involved in
recognition of Gram-negative bacteria whilst TLR2is implicated in responses
to Gram-positive organisms (Yoshimura et al. 1999).
If CBA/Ca airway cells express a high percentage of TLR4 they would be
expected to respond best to Gram-negative bacteria. Alternatively, if BALB/c
cells expressed more TLR 2 they would be better able to respond to S.
pneumoniae cell wall (Yoshimura et al. 1999).
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The relationship between BALB/c and CBA/Ca TNF activities within the
airways is reversed in the rest of the lungs, with CBA/Ca mice displaying the
highest TNF activities (Figure 5.11). This result has also been documented in
the Toxoplasma gondii encephalitis model which utilises BALB/c animals as
resistant mice whilst CBA/Ca mice are susceptible. In that model, equal peak
levels of TNFa. and IFNy were found within mesenteric lymph nodes but
elevated TNF levels persisted for longer in CBA/Ca mice (Hunter et al. 1994).
A difference in location of the inflammatory stimuli might explain this
finding in our model of pneumococcal pneumonia. Compartmentalised
TNFa. production does occur following either intravenous or intratracheal
administration of LPS (Nelson et al. 1989),suggesting that TNF production
only occurs where there is a direct stimulus. Pneumococci do not leave the
airways in BALB/ c mice but they readily gain access to the lung tissues of
CBA/Ca mice. However, bacterial loads within the airways and lung tissues
of the two mouse strains are similar at 6 and 12h post challenge indicating
that a difference in bacterial loads is not responsible for the difference in
cytokine production. Therefore the elevated BALB/c airway TNF levels are
involved in reducing bacterial loads within the tissues and not vice versa.
TNFwithin the lungs of BALB/cmice appears to be present at levels that are
sufficient to carry out its functions and are contained within the airways but
are not great enough to cause overwhelming pathology. In CBA/Ca mice the
TNF production is not contained to the airways but is mainly found within
the lung tissues. This could play a role in pathology due to overzealous
production of this mediator too late to have a beneficial effect but rather
leading to further disruption to lung integrity.
If the total level of TNF activity per lung is calculated for both mouse strains
the values obtained are approximately the same. This indicates that the role
playedby TNF in determining the outcome of pneumococcal pneumonia IS
mediated by the location and timing not the absolute level.
Further investigation of the role played by TNFa. during pneumococcal
pneumonia in the MF1model was carried out via utilisation of anti- TNFo.
neutralising antibodies (Section 4.2.2).
An effect of systemic anti-TNFa treatment on bacterial loads within the
lungs has previously been controversial. We have shown that with type 2
pneumococci systemic neutralisation of TNF activity is associated with
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impaired bacterial clearance both within the lungs and bloodstream (Table
4.1). van der Poll et al found a similar result (van der Poll et al. 1997a),whilst
Takashima et al could only detect a difference in pneumococcal viability
within the bloodstream (Takashima et al. 1997). In all published results this
treatment was associated with reduced survival. Therefore, although the
effect of anti-TNFa treatment on survival time was not assessed in this
model, data from other models (and that for TNFa p55 receptor deficient
mice (Figure 4.5) indicate that survival times would have been shortened
following anti-TNFa treatment and therefore that systemic TNFa is required
for an effective host response during pneumococcal pneumonia.
There have been no previous reports testing the effects of local TNFa within
the lungs during pneumococcal pneumonia. We therefore neutralised
pulmonary TNF activity via intranasal administration of the anti- TNFa
antibody.
Elevated pulmonary bacterial loads following local neutralisation of TNFa
revealed that pulmonary TNFa activity does playa protective role during
the infection. This role is only sufficient to alter S. pneumoniae viability
within the lungs and does not prevent the bacteria gaining access to the
circulation (Table 4.3). Thus during bacteraemic pneumococcal pneumonia
systemic TNFa production plays a more critical role in controlling S.
pneumoniae than does locally produced TNFa.
In an attempt to identify which TNF receptor mediated the protective
responses of TNFa during pneumococcal pneumonia receptor deficient mice
were infected. As described in chapter 3, mice infected with S. pneumoniae
pass through a range of symptoms. The first to appear is a hunched stance,
they then develop piloerection before becoming lethargic. The final
symptom is the unwillingness to move (moribund). On infecting TNFa p55
knockout mice 8/10 did not display the normal range of signs of illness,
rather they rapidly progressed from being slightly hunched to becoming
moribund. This group of mice were susceptible to the infection, with very
high bacterial loads and 100%mortality by 89h into the experiment. TNFa
therefore mediates the development and progression of symptoms during
pneumococcal infection. Indeed animals infused with TNFa display
biochemical and physiological changes similar to those seen in animals with
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Gram-positive or Gram-negative bacteraemia, that is hypotension, oedema
of lung interstitium and intravascular thrombosis that is fatal within
minutes to hours (Traceyet al. 1987). Furthermore, these alterations can be
inhibited by administration of anti-TNFa antibodies (Tracey et al. 1986).
p55-/- mice were unable to control pneumococci either within the lungs or
within the bloodstream. Whether TNFa is directly responsible for reducing
pneumococcal viability within lungs (e.g. by activating phagocytes) or
whether p55 is involved in the up-regulation of a separate mediator is
currently unknown.
Despite high levels of bacteraemia at 12h post challenge pneumococcal
viability did not increase as rapidly in these mice as it did in MF1, MF1/129,
iNOS-/ - or CBA/Ca mice. This indicates that the heightened susceptibility of
p55 mice is due to the lack of TNFa in the lungs not bloodstream (this could
be proven by infection via the intravenous route). Indeed mice unable to
signal through the p55 TNF receptor are more resistant to septic shock than
are animals capable of signalling via p55 (see below & (Garcia et al. 1995)).
This increased susceptibility of p55-/- mice to pneumococcal pneumonia is
supported by a previous report on these mice in S. pneumoniae infection
(O'Brien et al. 1999). p55-/- mice infected intraperitoneally with
pneumococci have a LD50 10,000fold lower than that of controls with no
detectable defect in neutrophil migration or acute phase response. The p55
receptor may thus act to up-regulate the anti-pneumococcal activity of those
phagocytic cells already present without altering their recruitment.
Only preliminary histological examination has been carried out in our
model of pneumococcal pneumonia in TNFa receptor deficient mice.
Results support those of O'Brien in that there was no difference in cell
recruitment at 24h post challenge. However this time point may be too early
for any difference to be apparent.
Therefore it is likely that TNFa's protective role in pneumococcal
pneumonia is to upregulate phagocyte antibacterial activity, signalling via
the p55 receptor.
Infections of TNFa receptor deficient mice also provided evidence that TNF
interacts with NO during pneumococcal pneumonia. Airways of p55-/- mice
145
Chapter 6 Discussion
contained significantly reduced NO levels than did p75-/- and C57B/6 mice
(Table 4.5). Such a result agrees with reduced NO levels within lungs from
p55-/- and p55 and p75 double deficient mice during Toxoplasma gondii
infection (Deckert-Schluter et al. 1998). These mice were unable to elevate
NO levels despite elevated IFNy, TNFa and IL-1Blevels. Decreased NO
levels were ultimately responsible for death in these experiments. Such an
NO deficiency is unlikely to be the cause of death during pneumococcal
pneumonia as iNOS-/- mice are not significantly more susceptible to S.
pneumoniae infection than are iNOS sufficient animals (see below).
NO is not the only inflammatory mediator that TNFa interacts with. The
production of TNF during pneumococcal pneumonia initiates a cascade of
further mediators which act together in an attempt to control the foreign
bacteria (Bergeron et al. 1998). In our MF1 model, increased pulmonary
production of IL-1Bwas initiated with similar kinetics to that of TNF (Figure
3.13). By 18h post challenge production appeared to be at its peak with levels
decreasing towards the end of the experiment.
Higher IL-1Blevels expressed in vivo during pneumococcal pneumonia
were detected within the airways of BALB/c mice than in CBA/Ca mice,
although the difference was not of the magnitude seen with TNF activity
(Figure 5.9).
TNFa and IL-Bare likely to be involved in the induction of the other
inflammatory mediators studied in these experiments. As with TNF
activity, there appeared to be two peaks in IL-6 levels within MFI lavage
fluid, suggesting rapid induction of IL-6by TNF (Figure 3.13).
Comparative levels of IL-6 were recovered within the airways of both
BALB/c and CBA/Ca mouse strains (Figure 5.9). Thus BALB/c mice do not
simply possess a greatly elevated intrinsic ability to produce pro-
inflammatory cytokines within their airways. Within lung tissues, however,
CBA/Ca mice were capable of releasing far higher levels of IL-6 than BALB/c
mice (Figure 5.11).
It is currently unknown whether IL-6was playing an inflammatory or anti-
inflammatory role within the lungs during these infections. A previous
investigation of the role of IL-6 in pneumococcal pneumonia using IL-6
deficient mice indicated that within the lungs the latter was true. These mice
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displayed higher levels of TNFa and IL-I0 levels within lung tissues than
did control mice. However it was impossible to determine whether the
significantly elevated bacterial loads were directly responsible for inducing
higher levels of cytokines (van der Poll et al. 1997b).
Thus the two mouse strains display different pro-inflammatory cytokine
profiles during pneumococcal pneumonia. To summarise, airways from
resistant BALB/c animals contain higher TNF activities and similar IL-l and
IL-6when compared to CBA/Ca animals. Samples from BALB/c lung tissues
possess less TNF activity, similar IL-1 and less IL-6 than samples from
CBA/Ca animals.
Results of the MFl and BALB/ c mice studies indicate that NO release is not
up-regulated in murine lungs as part of the normal host response to clear an
infectious challenge with S. pneumoniae (Figures 3.14 & 5.10). A similar lack
of effect for NO was found in a mouse model of pulmonary P. carinn
infection (Shellito et al. 1996).
The possibility remains that these mice do not induce high levels of NO
during pneumococcal pneumonia as the lower levels are optimal for
bacterial control without playing a role in pathology. Indeed, those effects of
NO that occur prior to high levels of detectable NO may be more important
than later effects. That is, cNOS may be more important than iNOS. For
example, moderate levels of NO are more effective inducers of TNF than are
very high levels (Eigler et al. 1993). Alternatively the higher levels of other
inflammatory mediators may make NO redundant, perhaps the case with
TNF in BALB/c airways.
These facts do not prove that NO is redundant within the setting of this
model of pneumococcal pneumonia. NO may be mediating more subtle
actions during the infection that were being masked by other factors in the
previous experiments. Indeed results from infections of iNOS-/- mice reveal
that NO is capable of controlling pneumococcal viability within the lungs
during the initial stages of infection.
iNOS sufficient MF1/129 mice are able to prevent the initial increase in
bacterial viability evident within airways of iNOS-/- animals (Figure 4.10).
This is followed by MF1/129 significantly reducing bacterial viability
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associated with the lung airways following the 12h time point. A similar
reduction does occur in iNOS-/- air spaces but not until12h later.
Such kinetics indicate that it is unlikely to be a direct antibacterial activity of
NO and its breakdown products that is responsible for pneumococcal control.
More probable is that NO up-regulates the effects of other mediators such as
pro-inflammatory cytokines (Eigler et al. 1993)or relaxes vascular smooth
muscle (Palmer et al. 1987),increasing blood flow to the site of infection,
increasing cell recruitment.
Although iNOS -/- mice are deficient in RNI they retain the ability to release
RO!. Interaction between RNI and ROI has been shown to augment
cytotoxicity of the mediators (Beckman et al. 1990). Perhaps this interaction
to increase cytotoxicity is required to control pneumococci and occurs later in
iNOS-/- mice as they depend upon cNOSwhereas MF1/129 mice will be able
to initiate this method of kill earlier via iNOS.
A similar reduction in pneumococcal viability within MF1/129 lung tissues
occurs at the same time post challenge (between 12h And 24h) [Figure 4.11].
This indicates that the same mechanisms is likely to be responsible, i.e. a
factor capable of acting both within the lung tissues and airways.
Pneumococci associated with MF1/129 lung tissues are not permanently
controlled despite the availability of NO. The mechanism that they utilise in
order to overcome this control is not clear. The protective levels of NO may
be reduced by some factor following the 24h time point e.g. IL-10 (Cunha et
al. 1992)or NO itself (Assreuy et al. 1993). The balance between NO and other
inflammatory mediators may alter NO's role from pro- to anti-
inflammatory. In addition, higher levels of NO may inhibit production of
certain cytokines (MacMickinget al. 1997),whilst low levels actually promote
their release. It is possible that during early infection the low levels of NO
induce high TNF thereby reducing bacterial viability (van der Poll et al. 1996),
whilst later on higher NO leads to low TNF and in turn higher bacterial
loads.
Alternatively, the pneumococci may produce a factor that enables the
bacteria to resist NO's anti-bacterial effects. S. pneumoniae is known to
release an inhibitor of the oxidative response (Perry et al. 1993). As this
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inhibitor is believed to be released in high levels by autolysis, its presence
would increase at later time points (perhaps also released by neutrophil-
mediated killing of pneumococci) thus explaining the delay in action until
late infection (Perry et al. 1994). As mentioned in Section 1.3.2,pneumolysin
is also capable interfering with the neutrophil respiratory burst. In addition,
pneumococcal extracts prepared by sonication or lysis with deoxycholate
have been found to inhibit elastase activity (Vered et al. 1984). Elastase in a
enzyme contained in neutrophil granules that is capable of degrading
proteins in bacterial cell walls. Thus an elastase inhibitor may protect the
bacteria against recruited neutrophils.
An inability to produce high output NO via the iNOS pathway resulted in an
upregulated inflammatory response within the lungs (Figure 4.12).
Significantly elevated TNF activity was evident in bronchoalveolar lavage
fluid from iNOS-/ - mice at 24h and 36h post challenge when compared to
MF1/129 samples. As these elevated TNF activities were associated with
elevated levels of total protein within lungs of iNOS-/-, TNF is implicated in
mediating disruption to alveolar/capillary barrier in iNOS-/- mice. If NO
was directly responsible for this disruption, NO depletion would be expected
to prevent disruption. Instead removal of NO caused higher levels of TNFa
and this in turn affected lung integrity.
There are several possible explanations for this elevated inflammatory
response. NO may routinely act in an anti-inflammatory capacity within
lungs during pneumococcal pneumonia (Kageyama et al. 1997). The low
levels of NO produced by cNOS may be more capable of elevating pro-
inflammatory cytokines than are higher levels induced by iNOS (Eigler et al.
1993). Finally, the higher pneumococcal viability within airways of iNOS
mice is likely to act as a more potent stimulus of inflammation.
Thus during a localised infection NO production is beneficial in that it
reduces bacterial loads and controls inflammatory response. This is in
contrast to the role of the same mediator during systemic infection (see
below).
In vitro culture of S. pneumoniae in the presence of the NO donor SNAP
did not alter growth of the organism thus indicating that NO does not exert a
direct anti-bacterial activity on S. pneumoniae (Figure 4.15). However, at
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pHS but not pH7 (these experiments were carried out at the latter) the N02-
anion is converted into nitrous acid, a compound with bactericidal activity
that can generate addition RNI species such as ·NO (Kaplan et al. 1996). Thus
at a lower pH a significant antibacterial activity may have been recorded.
Such an effect has previously been documented for against M. bovis at pHS
but not pH7 (O'Brien et al. 1994). However, SNAP has been shown to exert
an anti-bacterial effect against S. aureus (Kaplan et al. 1996)at pH7. The
possibility that SNAP (and thus NO) is anti-bacterial for S. pneumoniae at
lower pH could easily be investigated in the future.
Production kinetics of the anti-inflammatory cytokine IL-I0 within the lungs
were delayed in comparison to those of the pro-inflammatory mediators
(Figures 3.14 & 5.10). Therefore an elevated inflammatory stimulus is
required before IL-I0 production is increased. Within lung airways and
tissues maximum levels of this IL-10were detected concurrently with the
decline in pro-inflammatory cytokine levels. Such kinetics implicate IL-I0 in
the control of TNFa and IL-l (and likely a range of other inflammatory
mediators) during pneumococcal pneumonia (van der Poll et al. 1996).
Down-regulation of inflammatory cytokines during late infection in all
strains of mice might also be explained by the fact that alveolar macrophages
become hyporesponsive during pneumococcal pneumonia (Dehoux et al.
1994). Such cells release lower levels of pro-inflammatory cytokines than
either circulating monocytes from the same individual or alveolar
macrophages from healthy controls. In addition, pulmonary defence against
P. aeruginosa is significantly reduced during sepsis, an effect recently
attributed to over production of IL-I0 (Steinhauser et al. 1999). Thus
pulmonary defences in CBA/Ca mice would be impaired further on the
development of bacteraemia, serving to perpetuate pneumococcal survival.
BALB/c lavage fluid IL-10 levels increased during mid infection but then
dropped dramatically during late infection, with a significant reduction by
120hpost challenge. This decrease in IL-10is likely to be due to the ability of
IL-10to negatively feedback upon its own production (Brown et al. 1996)via
the destabilisation of mRNA over a period of hours. However, it is also
possible that a pneumococcal product is playing a role in the down-
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regulation of IL-10 levels. Cytokines have previously been shown to be
susceptible to degradation by bacterial proteases. For example, the
bioactivities of recombinant TNFa and IFNI' are significantly reduced by
incubation with proteases from Pseudomonas aeruginosa (Parmely et al.
1990). If this is the case during pneumococcal pneumonia, it suggests that
pneumococci are gaining an advantage by perpetuating the inflammation,
perhaps aiding their spread out of the lungs.
IL-10 levels were higher within the lung tissues and airways of BALB/c than
in the susceptible mouse strains from the initiation until the end of the
infection. Elevated production of "Th2" cytokines by BALB/c mice has been
recognised in other infections such as pulmonary infection with
Pseudomonas aeruginosa (Moser et al. 1999). The higher tissue IL-10 levels
may explain lowered TNF activities in these mice Le. due to tighter anti-
inflammatory regulation. This is the reciprocal finding from that in
susceptible BALB/ c scid mice.
This inflammatory response was accompanied by a rapid increase in the
level of total protein within pulmonary airways (Figures 3.14& 5.10). Such
an increase is believed to be an indication that the integrity of the
alveolar / capillary barrier has been affected permitting serum proteins to
cross the barrier (the majority of which is albumin) (Rubins et al. 1995). The
bacteria may be able to utilise some of these proteins as energy sources at the
site of infection. The rapid kinetics of lung disruption have previously been
demonstrated via electron microscopy in another model of pneumococcal
pneumonia (Yoneda and Coonrod 1980).
This disruption was evident until the end of the experiment in susceptible
mice. The relative lung disruption in these animals was greater than that in
resistant BALB/c mice. Furthermore, disruption in resistant BALB/c mice
was transient, only occurring until mid infection, protein levels then
reached a plateau before declining again toward the end of the experiment as
resolution occurred.
Cells of the immune system may be responsible for this disruption to the
alveolar/capillary barrier. Increased demand for neutrophils during
pneumococcal pneumonia results in release of immature cells from the bone
marrow. Such cells have reduced deformability in comparison to mature
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neutrophils and are less able to migrate into the alveoli (Lawrence et al.
1996). However the immature neutrophils do have an elevated capacity to
produce oxygen radicals and proteolytic enzymes than mature cells. Partial
activation of neutrophils before they migrate out of the pulmonary
capillaries can result in damage occurring to healthy tissues (Hogg 1994),
causing disruption to the alveolar capillary membrane and protein and fluid
leakage from the vascular space into the lung interstitium and air spaces
(Flick et al. 1981).
However, the presence of early epithelial and vascular changes in the
absence of significant numbers of inflammatory cells suggests that these cells
are not required for the initial disruption. A bacterial factor or early response
cytokines (e.g. TNF and IL-1)are more likely candidates.
Cell wall constituents have been found to be responsible for accumulation of
protein with lavage fluid. They are capable of binding to epithelia and
endothelia in vitro, leading to separation of cells from each other, removing
the endothelium's barrier (Tuomanen et al. 1987). The direct pore forming
action of pneumolysin, may alter the integrity of the alveolar/capillary
barrier permitting influx of protein. Formation of pores leads to ionic
disequilibrium which in turn creates gaps in the endothelium between cells
(Suttrop et al. 1988). In addition, pneumolysin is capable of direct interaction
with the inflammatory response (for example complement, Section 1.5.3.4),
perhaps initiating damage to lung integrity. In vitro pneumolysin is also
capable of inducing the production of TNFa and IL-1by monocyte cell lines.
These cytokines have been implicated in disruption to the alveolar/capillary
barrier as their in vivo administration results in damage to pulmonary
vascular endothelium (Okusawa et al. 1988) & (Stephens et al. 1987).
Furthermore, release of TNFa and IL-1 from endothelial cells occurs in
response to pneumococcal adherence. These cytokines were shown to cause
separation of tight junctions and eventual disruption of monolayers. This
effect was not mediated by NO as the NO inhibitor N-monomethylarginine
did not inhibit the cytopathic effects (Geelen et al. 1993).
Further evidence for TNFa's involvement in this disruption is found in the
lower levels of protein associated with lavage fluids from p55-/- mice than
half those in C57Bl/6 or p75-/- mice. This fact implicates the p55 TNFa
receptor in disruption to the alveolar/capillary barrier during pneumococcal
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pneumonia, either directly or via induction of NO (as NO levels were
significantly reduced in p55-/- mice). TNFo. and IL-1may also playa role in
the instigation of tissue damage via production of iNOS. This enzyme then
leads to release of free radicals and oxidants via one of the two pathways
described in Figure 1.4. Such products of iNOS are known to mediate
epithelial/endothelial damage. The elevated NO levels within airways of
CBA/Ca animals (Figure 5.10)may therefore be involved in disruption to
pulmonary integrity during end-stage disease.
Alveolar epithelial cells are capable of active transport of salt and water from
the airspace to the interstitial compartment (Cott et al. 1986). Indeed removal
of excess fluid from the alveoli occurs in part by active transport mechanisms
(Sakuma et al. 1994). Resolution of inflammation within BALB/c lungs is
likely to be aided by these transport mechanisms.
Initiation of this disruption to lung integrity was quickly followed by
recruitment of phagocytic cells, a characteristic of inflammatory responses
initiated by cells resident at the site of infection. The cell influx to infected
MF1 lungs was evident from 12h post challenge as oedematous areas with
few associated cells (Figure 3.12). This was followed by a rapid increase in cell
numbers through 24h and 36h until by 48h post challenge large areas of the
lungs were consolidated with recruited cells. Utilisation of
immunohistochemistry identified the majority of cells associated with this
bronchopneumonia as neutrophils, a finding confirmed by previous work of
this laboratory (Kadioglu et al. 2000) & (Canvin et al. 1995) and others
(Bergeron et al. 1998). A similar cell influx was evident within infected
CBA/Ca lungs (Figure 5.13).
Rapid neutrophil recruitment was also evident within the lungs of BALB/c
mice. In these mice cell influx mainly occurred within the airways and
occurred by 12h post challenge (Figure 5.13). Additional macrophages begin
to arrive inside inflamed bronchioles and in perivascular tissue areas
surrounding such bronchioles 24-48hpost challenge (Kadioglu et al. 2000)&
(Bergeron et al. 1998). These cells are responsible for a longer lived but
slower anti-microbial effect and resolution of the disease.
Resident macrophages within the alveoli and interstitium of all strains of
mice are ideally situated to act as primary defences against the inoculated
153
Chapter 6 Discussion
bacteria (Jonsson et al. 1985)and are capable of recruiting additional cells as
required. These cells constitute the vast majority of cells recovered within
bronchoalveolar lavage fluid from healthy mice whilst neutrophils
constitute less than 0.15% of total cells (Vial et al. 1984). Activation of
resident macrophages may be responsible for recruitment of neutrophils via
production of pro-inflammatory cytokines or chemokines or via activation
of the complement pathway (Section 1.5.3.4). Neutrophils are highly
efficient phagocytes capable of arriving in significant numbers within the
airways and tissues by as little as 4h after instillation of pneumococci (Vial et
al. 1984),(Doerschuk et al. 1994)& (Pierce et al. 1977)with migration finished
by around 24h post challenge (Haslett 1992), fitting with the kinetics of
reduced pneumococcal viability evident in Figures 4.10& 4.11.
A defect in the ability of CBA/Ca neutrophils to reach the lung airways as
early as those in BALB/ c mice would playa role in determining the outcome
to infection. Potential reasons for different neutrophil recruitment in the
two mouse strains include the original chemotactic signal or a different
intrinsic response on behalf of the neutrophils themselves.
Observations in this laboratory (Gingles et al. manuscript in preparation)
have found that BALB/c mice have statistically higher numbers of
neutrophils within their lungs (whole lungs only, airway cell influx was not
measured) than CBA/Ca mice at both 12h and 24h post challenge with 106
CFU D39. Maximal neutrophil recruitment occurred between 6h and 12h
post infection. BALB/c mice also develop a higher level of pathology during
Toxoplasma gondii encephalitis but go on to survive whilst CBA/Ca mice
develop less of an inflammation and are susceptible (Hunter et al. 1994).
Additionally, Morissette et al (Morissette et al. 1995) have shown that
BALB/c mice, resistant to Pseudomonas aeruginosa infection, have a
heightened neutrophil influx during early infection. Cellular recruitment
correlated to the ability of BALB/c mice to control the growth of bacteria
within the lungs.
Neutrophils could conceivably be responsible for the initial, rapid
pneumococcal kill evident within BALB/ c airways and tissues whilst other
cell types e.g. additional macrophages are responsible for the more gradual
reduction in pneumococcal viability.
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Pulmonary lymphocyte numbers are also known to change during
pneumococcal pneumonia. By 24h post challenge significantly elevated
numbers of these cells surround inflamed bronchiole walls. During end
stage disease lymphocytes migrate further into the tissue surrounding these
bronchioles and into the perivascular tissues (Kadioglu et al. 2000).
Lymphocytes have previously not been implicated in the host response
during pneumococcal pneumonia (Winkelstein and Swift 1975). This influx
to and migration around the lungs led us to investigate their role via
infections of BALB/ c scid mice.
Systemic bacterial loads are significantly higher in the immunocompromised
mice than in control BALB/c animals (Table 5.3) indicating that lymphocytes
are required for protective immunity against S. pneumoniae.
Pro-inflammatory cytokine production was not impaired (Tables 5.4 & 5.5),
so lymphocytes are not responsible for the production of TNFa., IL-1 and IL-6
during pneumococcal pneumonia. Engwerda et al have shown that scid
mice infected with Leishmania donovani have a much lower pro-
inflammatory response than BALB/c mice (Engwerda et al. 1996). This
suggests that the elevated bacterial loads with S. pneumoniae infected mice
do act as a stronger stimulus of cytokines in this model. Lymphocytes are
likely to be major producers of the anti-inflammatory cytokine IL-10during
pneumococcal pneumonia since levels of this cytokine were significantly
reduced in BALB/c scid mice.
In order to validate these findings it would have been useful to adoptively
transfer some Band T cells from BALB/c mice into BALB/c scid mice and
then infect them as previously. Such treatment has previously been shown
to prevent movement of E. coli out of the gastrointestinal tract in mice
depleted of T cells by thymectomy and administration of anti-T cell antibody
(Gautreaux et al. 1995). A resistant phenotype would indicate that Band T
cells are required for protection in pneumococcal pneumonia whilst a
susceptible phenotype would indicate that the difference documented in
these experiments are due to other factors for example defects in other
myeloid cells such as y8 T cells.
The classic use of scid mice in infection studies is to investigate innate
defence mechanisms as specific responses are depleted. The classic
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hypothermia increasing survival times (Eiseman et al. 1956). Thus the early
induction of hypothermia in BALB/cmice may be beneficial. Pneumococci
cannot multiply as quickly at hypothermic temperatures as at 3TC (both in
vivo and in vitro (Eiseman et al. 1956)& (Eiseman et al. 1964),indicating that
reducing core body temperature may be the hosts attempt to halt bacterial
proliferation.
Additionally the immune response may be affected. Low temperatures
(-30°C) down-regulate cytokines levels and activities released by helper T
cells (Hanson 1997),phagocytic index is reduced during hypothermia and
leukopenia is present (Eiseman, et al. 1956)& (Eiseman et al. 1964). Taken
together these results suggest that hypothermia is associated with a down-
regulation of the inflammatory response. Timing of this effect in BALB/c
mice suggests that lowered Tco regulates inflammation before it can have a
detrimental effect. The delayed onset of this response in CBA/Ca and MF1
mice occurs too late to have a beneficial effect as overwhelming
inflammation has already been initiated.
The initiation of hypothermia in these mouse strains occurred rapidly after
peak pulmonary inflammation. Such kinetics suggest that one or more of
the inflammatory mediators may be playing a role in the development of
hypothermia displayed by infected mice.
Each of the mediators studied have been implicated in Teo alteration.
Injection of TNFa alone in to mice induces a period of hypothermia (Kozak
et al. 1995)whilst the same treatment in rabbits induces a febrile response
(Dinarello et al. 1986). Neutralisation of TNFa activity in vivo results in
elevated febrile responses following LPS injection whilst injection of
recombinant TNFa prolongs the fall in Teo evident following LPS treatment.
It has recently been found that systemic TNF is more likely to be detected and
at higher levels within the circulation of hypothermic patients than in
hyperthermic patients (>80%vs.<20%) (Arons et al. 1999). It has also become
clear that lower levels of TNFa induce febrile responses whilst higher levels
induce hypothermia (Kettlehut et al. 1987).
As IL-6 is known to induce febrile responses (Leon et al. 1998)& (Helle et al.
1989), it may also be able to prevent the development of hypothermia.
Therefore the elevated IL-6 levels within the lungs of CBA/Ca and MF1 mice
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in comparison to BALB/ c mice may prevent the decline in Tco that is
evident in BALB/ c mice during early infection.
The ability of these mediators to induce hypothermia during pneumococcal
pneumonia could be tested by the neutralisation of TNFa or IL-6 with
antibodies (as in Section 4.2.2)prior to infection of implanted animals. If
these mediators are responsible, their neutralisation would be expected to
block the development of hypothermia. Conversely, the administration of
recombinant TNFa or IL-6would be expected to cause a decline in Teo, also
readily examinable in this model.
The classic model of temperature alteration states that production of pro-
inflammatory cytokines such as IL-l~, TNFa and IL-6in the circulation acts
as an inducer of Teo change (Netea et al. 1999). On reaching the brain these
cytokines induce the release of prostaglandins which are responsible for the
actual response. More recently, the possibility that cytokines can alter core
body temperature without being detectable in the circulation has been
suggested (Netea et al. 1999). The highly labile nature of pro-inflammatory
cytokines within the bloodstream makes this a likely possibility.
Alternative methods that pulmonary cytokines may employ to alter core
body temperature include the induction of mediators such as phospholipase
2 (Rintala and Nevalainen 1993). This in turn stimulates prostaglandin
release and temperature change. Alternatively the cytokines may remain
membrane-bound and therefore undetectable in serum. The cell association
would not prevent them activating endothelial cells within the brain and
stimulating temperature change. Indeed Munoz et al have shown that cell-
associated TNFa, IL-la and IL-l~ are more frequently identified in the
circulations of febrile individuals than are the soluble forms (Munoz et al.
1991).
It has previously been shown that instillation of lower numbers of bacteria
into the lungs causes a reduced inflammation to that seen with higher doses.
This indicates that resident pulmonary cells are capable of containing low
levels of inflammation, only recruiting additional cells once they are
overcome (Toews et al. 1979). In addition, the number of inflammatory cells
recruited to the lung depends on the size of the bacterial inoculum (Vial et
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al. 1984}. Taken together these data indicates that there is a threshold
number of bacteria required to initiate the pulmonary inflammatory
response during pneumococcal pneumonia. Infections were thus carried out
with lower doses of S. pneumoniae in order to investigate whether the
inflammatory response would be reduced following intranasal infection
with reduced doses of S. pneumoniae.
Decreasing the number of bacteria inoculated permitted the innate defences
of most mice to successfully counter the bacteria. However, reducing the
infectious dose 100 fold still resulted in some of the MF1 population
succumbing to the infection (Figure 3.18). Those mice challenged with the
105 CFU dose of S. pneumoniae that succumbed to the infection mainly
responded in a similar manner as those infected with 106 CFU but with
slightly delayed kinetics. However, reducing the dose 10 fold further did
significantly reduce the inflammatory response.
The majority of mice in the 104 or 105CFU groups did not have TNF activity
within their airways, nor did these mice have high numbers of viable
bacteria in their airways. 11/54 in the 104CFU group had less than log 3.00
CFU/ml with only 4/56 animals in the 105CFU group possessing higher than
log 4.00 CFU/ml throughout these experiments. Such low levels of bacteria
were only found in association with lavage fluid TNF activity in the 106 CFU
dose when a long "incubation time" had occurred e.g. 24h or 30h post
challenge. Therefore, pneumococci instilled into the lungs of mice at
reduced doses require a lengthened incubation period on order to induce
detectable TNF activity. This hypothesis would explain the slightly slower
kinetics of inflammation and death seen following infection with 105and 104
CFU S. pneumoniae. This possibility could be investigated by varying
incubation periods of pneumococci during the in vitro stimulation assay
reported in Chapter 5.
As MF1 mice are an outbred population, a group of these mice would
contain a range of genotypes. Some mice will be more similar to CBA/Ca
mice with others similar to BALB/c. This explains the ability of some mice
to resist infection with lower numbers of pneumococci whilst others remain
susceptible.
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Previous reports indicate that inflammatory responses are altered in elderly
populations (Bruunsgaard et al. 1999). It is therefore possible that an altered
inflammatory response during pneumococcal pneumonia is responsible for
the elevated susceptibility of elderly humans to pneumococcal pneumonia
(Burman et al. 1985). This possibility was investigated in the MF1 mouse
model of the disease.
1yr old MF1 mice displayed slightly lower survival times than young MF1
mice but there was no significant alteration suggesting that 1yr old MF1 mice
were not elderly enough (Figure 3.23). A previous report found that this age
of mice were no different from 2 month old mice in respect of cytokine and
NO production during endotoxic shock (Chorinchath et al. 1996). However,
studies with these MF1 mice could not have been postponed for a further
year as they were already displaying mortality due to natural causes.
Time course experiments for bacterial loads and cytokine levels in aged mice
were ended at 30h post challenge in contrast to the normal 36h in young
mice due to several of the aged mice displaying high levels of bacteraemia
(which also developed earlier) and appearing moribund. These mice were
found to possess elevated pro-inflammatory cytokine production within
their lungs. Aged animals are known to produce heightened levels of TNF
within their serum during endotoxic shock (Chorinchath et al. 1996).
Significantly earlier and elevated TNF responses within airways of aged mice
in this model of pneumococcal pneumonia support this hypothesis (Figure
3.27). TNF is not the only pro-inflammatory cytokine that is upregulated
with age. Following LPS injection, elevated TNF and IL-6 levels are
displayed in the serum of aged Fischer rats when compared to young animals
(Foster et al. 1992).
Aged mice constitutively released significantly lower levels of NO than
younger mice. However, aged animals were capable of rapidly and
significantly increasing this NO production whilst young mice did not. This
indicates that iNOS activity is elevated during ageing whilst cNOS activity
may decline. Previous research has also indicated that NO production
following endotoxin treatment of mice increases with age (Chorinchath et al.
1996).
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The literature in this field and results presented here show that elderly mice
and humans have an upregulated and prolonged inflammatory response
during infection. Rather than providing protection, this response is likely to
be involved in lung pathology. These facts explain the earlier progression to
systemic infection during pneumococcal pneumonia evident in aged mice.
Upregulated inflammation may cause more pulmonary disruption earlier
following infection, permitting S. pneumoniae earlier access to the
circula tion.
In addition to aged MF1 rruce, BALB/c mice have an upregulated early
inflammatory response within their lungs, but in this case it is controlled
and protective. The elevated TNF activities within BALB/c airways may not
be the only factor involved in the resistant phenotype of BALB/c mice
during pneumococcal pneumonia.
The presence of increased endogenous protein levels in the lungs of BALB/c
mice may result in increased availability of proteins related to inn ate
immunity. These could include antibodies, complement or surfactant.
Alternatively a protein that possess direct bactericidal properties (such as
lysozyme) may account for the elevated protein levels.
The role played by surfactant in this model of pneumococcal infection was
further investigated in these studies. Surfactant phospholipids did not alter
viability of pneumococci in vitro indicating a lack of direct bactericidal action
(Figure 4.1). A similar lack of effect has been gathered for incubation of S.
pneumoniae in human alveolar lining material (Jonsson et al. 1986).
However, Coonrod et al have previously found that rat pulmonary
surfactant will accelerate the decline in viability of S. pneumoniae over
several hours, an effect attributed to a detergent-like action of long-chain free
fatty acids (Coonrod et al. 1984). ALECmight have exerted a similar effect in
these experiments if the incubation time had been extended. It is a possibility
that this is the effect that ALECexerted when it was co-administered with S.
pneumoniae into the lungs of mice (Figure 4.2). The viability of the bacteria
may not have been affected immediately following inoculation into the
lungs but with time it could have declined until the levels detected at 24h
were reached.
In addition to a possible direct bactericidal action of ALEC, pneumococcal
viability may have been reduced by virtue of the ability of surfactant material
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to enhance alveolar macrophage recruitment in vitro (Schwartz and
Christman 1979) or to increase phagocytosis of Gram-positive bacteria (5.
aureus) by rat alveolar macrophages in vitro (O'Neill et al. 1984).
However, bacterial loads within lungs 24h post challenge with co-
administration of ALEC are similar to those normally recovered
immediately following infection. This suggests that ALECdoes not exert its
effect by decreasing pneumococcal viability within the lungs but rather by
preventing the increase. ALECmay be in some way capable of preventing S.
pneumoniae from gaining access to nutrients. Indeed a modified natural
surfactant preparation containing 99% lipids and 1% protein (no SP-A or SP-
D) instilled into the lungs of pre-term rabbits was shown to reduce
proliferation of B streptococci in comparison to streptococci within untreated
lungs (Herting et al. 1997). As with the in vivo ALEC experiments this
treatment did not significantly alter survival times.
Whatever the action, some pneumococci were obviously resistant since
administering the infectious dose in ALEC did not significantly alter
survival times. Perhaps 106 CFU was too high a dose to be affected
completely by surfactant (Figure 4.4). These pneumococci were capable of
proceeding to cause the infection and subsequent death of the animals.
ALEC was unable to alter in vitro growth of S. pneumoniae in optimal
growth conditions (BHIgrowth media plus 5% ALEC,Figure 4.3). In similar
investigation by Rubins et al (Rubins et al. 1996), incubation in 20%
pulmonary surfactant was found to inhibit growth and then cause a rapid
decline in bacterial viability. As little as 2.5% pulmonary surfactant was
found to have a bactericidal effect on pneumococci, with 5% causing a
significant reduction in bacterial survival in vitro. Such a discrepancy
indicates that some other constituent of surfactant rather than phospholipid
is responsible for this effects, for example the protein constituent (Schagat et
al. 1999).
Although surfactant can enhance immunity as stated above, it can also
suppress some aspects of it. Surfactant has been shown to prevent the
activation and proliferation of lymphocytes exposed to various stimuli.
Surfactant lipids (from humans, pigs or rabbits) are capable of significant
suppression of the proliferative response of a mixed lymphocyte population
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from human blood following phytohaemagglutinin treatment (Wilsher et
al. 1988). By fractionating human amniotic fluid surfactant Catanzaro et a 1
have shown that the surfactant associated lipids phosphatidylcholine,
phosphatidylglycerol and phosphatidylinositol (Le.constituents of ALEC)are
responsible for the inhibition of lymphocyte effector functions such as NK
cell mediated lysis of human myeloid target cells (Catanzaro et al. 1988). This
result indicates that surfactant does not inhibit lymphocyte activity by simply
preventing proliferation. Artificial surfactants are also known to act in an
anti-inflammatory manner, capable of reducing TNF, IL-1 and IL-6
production by human alveolar macrophages stimulated with endotoxin
(Thomassen et al. 1992). Neutrophil and macrophage functions can also be
inhibited by surfactant preparations. A reduced capacity to adhere in vitro, to
respond to chemotaxis and to produce superoxide have all been recorded in
the past (Suzuki et al. 1992) as has a reduction in pulmonary macrophage
bactericidal activity (Sherman et al. 1988).
It is possible that ALEC may initially confer resistance to the host by
preventing pneumococcal proliferation. The anti-inflammatory activities of
surfactant phospholipids would then have the opposite effect, phagocytes
would not be recruited due to the lack of cytokine and chemokine
expression. This would permit pneumococci to proliferate, reaching
comparable levels to those in mice not treated with ALECand causing the
subsequent death of the animals.
A separate mechanism of resistance against S. pneumoniae that may be
employed by BALB/ c mice is the endogenous possession of type-specific
antibodies. The ability of BALB/c mice to clear approximately 106 CFU S.
pneumoniae from the lungs has previously been described (Vial et al. 1984),
in this case capsular type 3 pneumococci were used. Resistance therefore
does not appear to be dependent upon capsular type of the pneumococcus
and it is unlikely to be due to endogenous anti-capsule antibodies (unless the
mice possess antibodies against a range of capsular types). Indeed the
possibility that BALB/ c mice possess antibodies against type 2 pneumococci
has previously been investigated by this laboratory. No such antibodies
could be detected in unchallenged mice (Gingles et al. manuscript in
preparation).
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The protective effects of type specific anti-capsule antibody in the circulation
during pneumococcal pneumonia are well known (MacLeod et al. 1945)&
(Wood [r 1940). These effects have not previously been investigated within
the local environment of the lungs. Results presented in this thesis show
that anti-capsule anti serum mainly exerts its effects in the bloodstream.
Systemic administration resulted in reduced pneumococcal viability within
each body site investigated but intranasal administration did not exert
significant effect. The larger population of phagocytes located within the
spleen and liver than in the lungs is likely to be involved in this
observation. Indeed studies in both animals and humans have revealed the
spleen and liver as the major organs involved in clearing bloodborne
bacteria (Bruyn et al. 1992). As in the lungs, effective clearance of
pneumococci by the liver is dependent on opsonisation by type-specific
antibodies or complement (Friedman and Moon 1980). The spleen does not
require this process to have taken place (Brown et al. 1981) due to its
anatomical arrangement which allows prolonged contact between the
phagocyte and the blood borne pathogen (Wara 1981)although opsonisation
will still improve phagocytosis.
Although possession of anti-capsule antibodies is unlikely to be involved in
BALB/c resistance to the infection it may be that these mice possess higher
levels of some other protective antibodies, e.g. anti-phosphocholine
antibodies. Such antibodies have been detected in the serum from normal
mice (Briles et al. 1981)and were shown to be protective against intravenous
challenge with type 3 pneumococci.
McDaniel et al have shown that these antibodies do increase blood clearance
of the organisms (McDanielet al. 1984). The most likely explanation for the
mechanism of protection is that these antibodies act by mediating
phagocytosis.
Another opsonin that may be responsible for increasing pneumococcal
clearance from the circulation of BALBIc mice is C-reactive protein (CRP). A
major role of CRP in infection is to opsonise bacteria by initiating the early
complement pathway which leads to deposition of C3b on the bacterial
surface (Kaplan and Volanakis 1974). This promotes phagocytosis of the
bacteria and therefore clearance from the host. Additional relevant effects of
CRP on the immune response include its ability to induce monocytes to
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release monocyte chemottractant protein-1 (MCP-l) thereby recruiting
addition cells to a site of infection (Zhou et al. 1995)and up-regulation of
microbicidal activities of monocytes and neutrophils by increasing O2-. and
H202 levels (Zeller and Sullivan 1992).
Complement has also previously been shown to play an important role in
the clearance of pneumococci from the bloodstream (Hosea and Frank 1978).
Treatment of guinea pigs with cobra venom factor significantly impaired
their ability to clear pneumococci administered intravenously. In contrast C4
deficient animals were able to control the bacteraemia, indicating that the
alternative complement pathway was most important for host defense in
this setting.
The presence of higher levels of anti-phosphocholine antibodies, CRP or
complement within the circulation of BALB/c mice could also account for
some of the non-specific immunity to S. pneumoniae and may act to control
the infection until protective levels of anti-capsular antibodies can be
induced around 5 to 6 days following challenge (Brileset al. 1981).
One cytokine that has also been implicated in systemic host response during
pneumococcal pneumonia is IFNy, known to be protective against
intracellular organisms. Rubins and Pomeroy have shown that IFNy
deficient mice have a 20-fold lower LDsodose following intranasal infection
with virulent S. pneumoniae than do wild type animals (Rubins and
Pomeroy 1997). Investigation of IFNyproduction in wild type mice revealed
that systemic levels increased significantly during the infection whilst
pulmonary levels were unchanged. These results thus indicate that IFNy is
an important mediator of the host defense against S. pneumoniae in the
bloodstream but may be less effective in the lungs.
An additional range of cytokines have been shown to be involved in host
defence against pneumococcal bacteraemia caused by less virulent strains of
S. pneumoniae. In this setting intravenous inoculation of D39 leads to
exponential growth of the bacteria until death of the mice 24-36h post
challenge when the level of bacteraemia reaches approximately 109CFUIml
(Benton et al. 1998). In contrast, infection with pneumolysin deficient
bacteria results in bacteraemia that does not pass the 106/107 CFU Iml level
with mice not succumbing to the infection for several days. A subsequent
inoculation of pneumolysin sufficient D39 into these same mice is no longer
as rapidly fatal, indicating that immunity is conferred to the host by infection
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with pneumolysin-deficient bacteria. Cytokines have now been implicated
in this protective response. Mice infected with pneumococci unable to
produce pneumolysin release lower levels of TNFa within their circulation
than do animals infected with D39. These low levels of TNFa are in some
way protective as their neutralisation significantly reduces survival during
bacteraemia caused by pneumolysin deficient bacteria. A similar effect on
survival was observed following IL-1~neutralisation (Benton et al. 1998).
Taken together these data indicate that low systemic levels of TNFa and IL-
1~ are implicated in the protective host response and immunity evident
following infection with less virulent S. pneumoniae strains. These
cytokines may exert their effects locally within the spleen (by increasing
phagocytosis of pneumococci) and thus would not be found in high levels
within the circulation. Therefore low levels of pro-inflammatory cytokines
within the circulation result in protection without pathology.
Utilisation of the intravenous route of infection permitted investigation of
the hypothesis that the resistant phenotype of BALB/c was mediated solely
by the lungs. Systemic infection resulted in the same clinical signs of
infection as in pulmonary model within a similar time frame. CBA/Ca mice
rapidly progressed through piloerection and lethargy to become moribund by
around 30h post challenge. Similar numbers of pneumococci were detected
within the circulation of intravenously challenged CBA/Ca as at the end of
pulmonary infection (Table 5.1 & Figure 5.17). Thus there is a threshold
number of bacteria responsible for initiating the lethal event within this
model of pneumococcal infection (see below).
The nature of the intranasal infection experiments precluded us from
determining whether any BALB/ c mice that displayed bacteraemia would
progress to develop the disease or survive. However, the ability of BALB/c
mice to resist intravenous infection with 7.00 x104CFU S. pneumoniae
shows that a level of bacteraemia lower than this would not prove fatal for
BALB/c mice. In a situation where pneumococci were constantly being shed
from the lungs into the bloodstream, they may no longer be able to contain
the infection, explaining why four mice did die during these experiments. In
addition, Briles et al have previously shown that BALB/c mice are
susceptible to intravenous infection with D39but the LD50was greater than
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106CFU (Briles et al. 1986). Therefore, with low numbers of pneumococci,
BALB/c mice can control the infection and survive, but with larger
inoculations of the micro-organisms, the defence mechanisms are overcome
and the infection becomes fatal.
In contrast to pulmonary inflammation, systemic inflammation is likely to
be detrimental during infection, contributing to septic shock (Sriskandan and
Cohen 1995).
Systemic TNF activity was only detected during the end stages of infection in
all of these experiments. This fact can be explained by the low levels of
viable bacteria within bloodstreams until this time. During all experiments
with young MF1 mice, detectable TNF was only found in serum from one
mouse with fewer than 2.88 x 107CFU/ml, whilst all mice with more severe
bacteraemia had detectable TNF activity. In addition, all CBA/Ca mice with
detectable systemic TNF activity possessed levels of bacteraemia higher than
log 6.46(2.88x 106CFU/ml) whilst BALB/c mice did not have high levels of
bacteraemia nor circulating TNF activity.
This threshold level is in agreement with data presented by Benton et a 1
(Benton et al. 1998). In this study, mice infected intravenously with 5 x 104
CPU of S. pneumoniae deficient in pneumolysin did not produce TNFa in
significant levels whereas D39 infected mice did. It was not until levels of
bacteraemia in D39 infected mice reached approximately 5x107/ml that
detectable levels of TNF protein were induced. Such high numbers of
bloodborne bacteria were not seen in mice infected with pneumolysin
deficient bacteria, perhaps explaining the lack of systemic TNF in these mice.
The threshold hypothesis also fits with the data from the in vitro
stimulation experiments reported earlier. Stimulation of airway cells with
heat killed pneumococci only resulting in TNF activity when the highest
dose of bacteria (106CFU)was employed (Figure 5.14).
The exact mechanism of death during bacteraemic pneumococcal
pneumonia remains unknown. Even days after initiation of antibiotic
treatment, when the site of infection has returned to being sterile, patients
can still die (Austrian and Gold 1964). The general belief is that an
overzealous host response to infection is the main culprit with antibiotics
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releasing increased levels of pneumolysin and cell wall products to increase
the inflammation.
During severe sepsis overwhelming inflammation is believed to lead to
death. In less severe sepsis higher levels of anti-inflammatory cytokines are
able to control the inflammation and promote survival (Walley et al. 1996).
Similar results have also been reported in a model of pneumococcal
pneumonia (Mohler et al. 1998) where infection with virulent S.
pneumoniae resulted in delayed and increased expression of pro-
inflammatory cytokines compared to an avirulent strain. Thus, the fine
balance between survival and death in infectious disease depends on the
balance between pro-inflammatory and anti-inflammatory cytokines.
During the studies reported in this thesis, production of a range of
inflammatory mediators has been characterised. All of these have been
implicated in the pathology and even lethality following infection or
endotoxin shock. Although TNF levels were the only marker of systemic
inflammation investigated, comparison to other models of Gram-positive
bacteraemia can help identify production kinetics of other cytokines in this
model. Yao et al discovered that IL-l levels increased concurrently with
TNF, peaking early after bacterial introduction with IL-6 production not
maximal until 72h post stimulus (Yoa et al. 1997). Thus TNFa is implicated
in the initiation of inflammation.
Levels of detectable TNF activity were highly variable in all of the mouse
strains used in these studies. Such variability is also associated with human
disease, Marks et al were able to measure TNF in only 12 of 32 patients
suffering from Gram-positive sepsis (Marks et al. 1990). It is thus a possibility
that the variability seen in human models is also dependant on the level of
bacteraemia.
Despite these highly variable reports of systemic TNFa detection during
Gram-positive bacteraemia, one factor that is reproducible in human models
of bacteraemia is the positive correlation between circulating TNF and
mortality (Hindshaw et al. 1992)& (Marks et al. 1990). TNF is implicated in
pathogenesis of septic shock as administration of antibodies directed against
TNFa has been shown to be protective in mice (Tracey et al. 1986). However,
investigations of the role of TNF during pneumococcal pneumonia have
attributed this cytokine a protective role (Section 4.2.2, (Takashima et al. 1997)
& (van der Poll et al. 1997a», up-regulating recruitment of phagocytes and
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preventing bacteraemia. Such a dual effect of TNFa has been demonstrated
in other models of infectious disease. For example, in Listeria infection
excessive production of TNFa may be associated with dramatic shock and
organ failure, while neutralisation of TNFa activity resulted in increased
bacterial loads and decreased circulating granulocytes (van Furth et al. 1994).
Therefore the role of TNF is likely to be dependent on the location, timing
and magnitude of the response.
The slower disease progression In p55-/- mice than in MFl (or CBA/Ca)
animals indicates that TNFa does initiate the lethal event during Gram-
positive bacteraemia. However, as mice unable to signal via p55 are resistant
to septic shock (Garcia et al. 1995) it is unlikely to be TNFa that is directly
responsible, however. A similar prolonged infection occurred in BALB/c
scid mice. Despite these animals having very high bacteraemia levels and
detectable TNF activity at 30h post challenge the median survival time was
63h. Furthermore, the CBA/Ca mice with highest levels of bacteraemia did
not have detectable systemic TNF activity at the time of their death (Section
5.2.1.6.3).
IL-1 production is a likely candidate for mediator of lethal event in the
absence of high levels of TNFa. In vivo administration of IL-1~ results in
hypotension, elevated heart rate and leukopenia (as does TNFa
administration), all symptoms of a shock-like state which might be fatal
(Okusawa et al. 1988). Plasma levels of both TNFa and IL-1~ correlate well
with severity of shock and mortality (Crudlund, et al. 1995).
IL-1~may act independently or it can induce production of IL-6,also capable
of mediating pathological events. High levels of IL-6have been observed in
patients and animals with Gram-positive and Gram-negative sepsis
(Calandra et al. 1991). In comparison to other inflammatory cytokines, levels
of IL-6 detected in serum from patients during sepsis correlate well with
outcome. Excessive production of this cytokine is considered a good marker
of an elevated inflammatory response and poor prognosis both in humans
and in rodents (Damas et al. 1992). In a porcine model of pneumococcal
septicaemia over production of IL-6was associated with mortality (Ziegler-
heitbrock et al. 1992). Furthermore, treatment of sepsis with anti- TNF
antibody reduces IL-6 levels and leads to 100% survival (from 0%)
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(Hindshaw et al. 1992). A similar improvement in survival in a mouse
model where lethal intraperitoneal doses of E. coli were inhibited with anti-
IL-6 antibodies, has been reported (Starnes et al. 1990). Conversely a
protective role has been ascribed to IL-6in a model of septic shock initiated by
LPS-galactosamine. Neutralisation of IL-6in this setting enhance mortality
(Barton and Jackson 1996). Thus the balance of IL-6 and other mediators is
likely to determine the role played by this cytokine during disease.
TNFu, IL-1and IFNy can act synergistically to induce production of NO in
vascular smooth muscle cells (Sriskandan and Cohen 1995). Indeed, serum
levels of this mediator are elevated during sepsis (Evans et al. 1993).
Furthermore, inhibition of iNOS in endotoxin treated animals prevents the
development of shock (Evans et al. 1994). Despite this fact, inhibition of
nitric oxide synthase has not been conclusively demonstrated to promote
survival in models of live bacterial sepsis. We therefore investigated the
role played by iNOS in pneumococcal bacteraemia via intravenously
infecting iNOS-/ - mice.
MF1/129 mice succumbed significantly earlier (and in higher numbers)
following intravenous infection than did iNOS-/- mice, with significantly
elevated pneumococcal viability associated with their circulations (Figures
4.13& 4.14). Results suggest that the low dose of pneumococci used in this
experiment was around the threshold number of bacteria required to initial a
fatal bacteraemia in mice on the MF1/129 background (as 3/5 iNOS-/- cleared
the bacteraemia and survived). However, this dose of S. pneumoniae was
sufficient to initiate a fatal Gram-positive septic shock via an. NO mediated
pathway. NO is known to cause relaxation of vascular smooth muscle
(Palmer et al. 1987),contributing to hypotension. NO is also implicated in
the reduced myocardial contractility evident during sepsis. It was shown that
TNFu, and IL-6 could prevent contractions of hamster heart muscles in vitro
and that these contractions were blocked by NO inhibition (Finkel et al. 1992).
The development of hypotension and hypoxaemia due to vasodilation and
cardiac dysfunction leads to acidosis and hypoperfusion of tissues and
eventually leads to death (Sriskandan and Cohen 1995). Further
investigation of the interactions of NO with other inflammatory mediators
during Gram-positive septic shock may be possible with this model. Results
may prove particularly relevant as the lung represents the source of infection
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in the majority of cases of septic shock in humans (Sriskandan and Cohen
1995).
IL-10 is known to regulate the levels of all of these inflammatory mediators
implicated in systemic inflammation. Indeed repeated injection of mice
from birth with anti-IL-10 antibody renders them highly susceptible to
endotoxic shock (Ishida et al. 1993). Thus during overwhelming sepsis the
levels of IL-10 released into the bloodstream, along with other anti-
inflammatory mediators (such as soluble TNF receptors and IL-1Ra) are
insufficient to control the inflammation and shock results.
The overall body of evidence presented in this thesis and in other literature
suggests that the "inflammatory balancing act" that occurs during bacterial
infection depends on whether the infection is localised or systemic. During
localised lung infections, a pro-inflammatory response is required to rapidly
and effectively clear the bacteria before dissemination can occur. In the
setting of systemic infection, an overwhelming pro-inflammatory response
will result in shock and death.
In the case of this model of pneumococcal pneumonia the balance must tip
in favour of an inflammatory response during the early stages of disease thus
elevated TNF activity (mediated by the p55 receptor) and the ability to express
iNOS is beneficial. If and when systemic infection occurs the balance must
tip in the opposite direction with tight regulation of inflammatory mediators
by IL-10. Data from this model and others implicates TNFa as the initial
mediator in the shock-like response during bacteraemic pneumococcal
pneumonia. TNF induces other factors such as NO which is implicated in
the shock like end-stages of disease. However, the inflammatory mediators
studied in this thesis are by no means the only repertoire that the host
produces to combat S. pneumoniae. It is highly likely that a range of other
host factors such as other interleukins, chemokines and metabolites of the
arachidonic acid pathways, which were beyond the scope of this study, are
involved in both the protection and pathology of bacteraemic pneumococcal
pneumonia.
A detailed description of the initiation and regulation of the alveolar
inflammatory response by mediators investigated in this thesis is given in
Figure 6.1.
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Appendix
PHOSPHATE BUFFERED SALINE
80.0gNaCI
1l.6g Na2HP04
2.0gKH2P04
2.0gKCL
Make up to 10L;pH to 7.0
In all experiments directly involving mice, PBS was made from tablets
(Oxoid) by addition of 1 tablet to 100ml dH20
FORMAL SALINE
3.06g
6.70g
lOamI
9g
NaH2P04 Anhydrous
Na2HP04 Anhydrous
Formaldehyde
NaCl (Sigma)
Made up to 1 litre with distilled water.
TOLUIDINE BLUE STAIN FOR MAST CELLS
0.5% Toluidine blue in O.5MHCI; pH to 0.3
MAST CELL COUNTER STAIN
0.5% Safranine 0 in 0.125M HCI
IL-6 ELISA COATING BUFFER
O.lM Na2HP04 adjust pH to 9.0 with 0.1M NaH2P04
IL-6 BLOCKING BUFFER
PBSwith 10% FCS (vIv) and 0.25%Tween 20.
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IL-6 AND IL-lO ELISA SUBSTRATE
Sufficient substrate for 1 plate is obtained by mixing 10ml solution A with
100111solution B and adding 4111H202
(A) 1.36g sodium acetate in 100ml dH20, pH adjusted to 5.5 with
citric acid
(B) 6mg Tetramethylbenzidine (TMB) in 1ml DMSO
IL-lO ELISA COATING BUFFER
Citrate coating buffer, is obtained by mixing 33ml of solution A with 17ml
solution B, making up the volume to 50ml and adjusting the pH to 4.0.
(A) O.lM citric acid
(B) O.lM sodium citrate
IL-lO ELISA BLOCKING BUFFER
PBS with 1.0% BSA and 0.25% Tween 20.
IL-lO ELISA STANDARD DILUENT
PBS with 1% BSA, 0.25% Tween 20 and 25% heat inactivated FCS
GREISS REAGENT
The Greiss reagent is obtained by mixing In equal volumes, the two
following solutions:
(A) 0.1% alpha-naphtyl-amine in distilled water.
(B) 1% sulphanilamide in phosphoric acid.
Both solutions were stored in the dark at 4°C. Fresh Greiss reagent was
prepared every time.
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NITRATE CONVERSION BUFFER
Stock Reagents
NADPH
FAD
5mg/ml in distilled water. Aliquots
of 500Jll stored at -20oe.
41.5 mg/ml in distilled water.
Nitrate reductase
Aliquots of 500Jll stored at -20oe.
34mg/ml in distilled water. Aliquots of
50Jll stored at -70°C
O.5M, pH 7.5
Buffer
For 50 samples and standards in duplicate:
500Jll NADPH
500Jll FAD
500Jll KH2P04
SOOJlldistilled water
SOJllnitrate reductase freshly diluted in 4S0Jll distilled water.
TISSUE CULTURE GROWTH MEDIA
RPMI 1640 media with 300mg/L L-Glutamine (Life Technologies,) plus 10%
heat inactivated FeS (Life Technologies) and 100IU/ml penicillin and
100llg/ml streptomycin (Life Technologies).
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